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ABSTRACT (ITALIANO) 
PP2A (Protein Fosfatasi 2A) è una serin/treonin fosfatasi espressa in maniera ubiquitaria e altamente 
conservata tra le specie (eucarioti in primis). Essa è coinvolta in delicati pathway di segnalazione 
cellulare, ed ha come effetto complessivo quello di promuovere eventi pro-apoptotici ed anti-proliferativi; 
una sua diminuita attività comporta un aumento di segnali anti-apoptotici e proliferativi. La sua attività, 
come quella di ogni fosfatasi, è controbilanciata dalle protein chinasi; mentre queste ultime sono state 
ampiamente indagate nel corso degli anni, il ruolo di PP2A è stato preso in considerazione solo molto più 
di recente, e insieme ad esso è stata esplorata la possibilità di considerare l’enzima un target per farmaci. 
Infatti, è stato dimostrato che l’attività di PP2A è ridotta in svariate forme tumorali, in particolare 
leucemie e ancor più nel dettaglio nei casi di B-CLL (leucemia linfatica cronica a cellule B). Al momento, 
la principale ipotesi per spiegare questo fenomeno è che PP2A sia inattivata non tanto in maniera diretta, 
quanto piuttosto per aumentata espressione della proteina SET, suo inibitore endogeno. In questi casi, la 
capacità della cellula di entrare in apoptosi è fortemente compromessa, quindi la possibilità di ripristino 
dell’attività di PP2A è attualmente presa in considerazione come nuova, possibile terapia anti tumorale. 
Fingolimod (nome IUPAC 2-ammino-2-[2-(4-ottilfenil)etil]propan-1,3-diolo) è stato approvato nel 2010 
per il trattamento della sclerosi multipla in forma recidivante-remitente. La sua attività è legata al fatto 
che, una volta internalizzato dalla cellula, esso viene fosforilato e diventa strutturalmente simile alla 
sfingosina-1-fosfato (S1P), mimandone l’azione sui linfociti T: sovrastimolando i recettori per S1P, 
infatti, Fingolimod può portare alla loro degradazione, evitando che i linfociti T possano uscire dai 
linfonodi e perpetrare il danneggiamento degli assoni neuronali. Più di recente, è stato dimostrato che 
Fingolimod può, come effetto collaterale, ristabilire nei tumori l’attività di PP2A; il meccanismo 
sottostante a questa attività non è stato ancora del tutto chiarito, ma sembra legato all’interazione tra 
Fingolimod e il complesso PP2A/SET. Curiosamente, questa funzione richiede che Fingolimod non sia 
fosforilato. 
Questo lavoro di tesi presenta la sintesi e la caratterizzazione di una libreria di analoghi di Fingolimod che 
vogliono isolare l’effetto pro-apoptotico da quello immunosoppressivo. Tenendo a mente che Fingolimod 
agisce su PP2A solo se non fosforilato, ciò significa progettare e creare molecole con caratteristiche 
strutturali modulate rispetto al composto preso a modello, ma con un’attenzione particolare alla loro 
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capacità di subire fosforilazione. Questo approccio ha lo scopo di ottenere nuove, potenziali drug entities 
anti-cancro che possano ripristinare la capacità delle cellule interessate di subire apoptosi. I composti 
sono stati testati nel laboratorio della Prof. Brunati (Dipartimento di Medicina Molecolare, Università di 
Padova) per valutare la loro attività verso PP2A in cellule di B-CLL. In questo senso, sono stati ottenuti 
alcuni composti meritevoli di interesse e vengono qui riportati i risultati dei saggi biologici sul composto 
più attivo.  
Inoltre, è stato perseguito lo scopo di produrre le proteine PP2A (subunità catalitica) e SET tramite 
tecnica del DNA ricombinante al fine di ottenere dettagli strutturali sull’interazione tra proteine, e sulla 
eventuale modalità di legame tra queste e i composti sintetizzati; questa parte del progetto è stata svolta 
presso Diamond Light Source (UK). Il lavoro svolto getta le basi per un approfondito studio strutturale 
dell’interazione tra PP2A e SET (che, ad oggi, è piuttosto lacunosa), sia alla razionalizzazione delle 
relazioni struttura-attività tra le proteine di interesse e composti anti-neoplastici; questo potrà aiutare a 
chiarire le caratteristiche strutturali di cui necessitano le molecole per essere attive, e di conseguenza a 
progettare in modo razionalizzato analoghi di Fingolimod nuovi e migliorati. 
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ABSTRACT (ENGLISH) 
PP2A (Protein Phosphatase 2A) is a Ser/Thr phosphatase ubiquitously expressed and highly conserved 
among the species (especially eukariotes). It is involved in delicate signaling pathways, and overall it has 
the effect to enhance pro-apoptotic and anti-proliferative events; a decrease of its activity makes anti-
apoptotic and proliferative signals prevail. Its activity, as the activity of any other phosphatase, is 
counterbalanced by protein kinases; while the latter have been widely studied through the years, the role 
of PP2A was taken into account much more recently, and together with that the possibility to consider it 
as a drug target has been exploited. Indeed, PP2A is demonstrated to be down-regulated in several forms 
of tumors, in particular leukemias with a peculiar focus on B-CLL (B cell chronic lymphocytic leukemia). 
To date, the main hypothesis to explain this is that PP2A is inactivated not directly, but because of the 
over-expression of the protein SET, its endogenous inhibitor. In these cases, the capability of the cell to 
die is strongly impaired, so trying to restore PP2A activity is nowadays being exploited as a new, possible 
anti-cancer therapy. 
Fingolimod (IUPAC name 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol) has been approved in 
2010 for the treatment of relapsing-remitting forms of multiple sclerosis. Its activity is due to the fact that, 
once internalized by the cell, it gets phosphorylated and reaches a structural similarity with sphingosine-
1-phosphate (S1P), mimicking it on T cells: by overstimulating S1P receptors, indeed, Fingolimod can 
lead to their degradation, avoiding the possibility for T cells to egress secondary lymphoid organs and to 
keep on damaging neural axons. In more recent years, it has been shown that Fingolimod can restore 
PP2A activity in tumors as a side effect; the mechanism underlying this event is still not clear, but it is 
probably due to the interaction Fingolimod has with the PP2A/SET complex. Curiously, this activity 
needs Fingolimod not to be phosphorylated. 
This thesis work presents the synthesis and characterization of a library of Fingolimod analogs which are 
meant to isolate the pro-apoptotic effect from the immunosuppressive one. Keeping in mind that 
Fingolimod acts on PP2A only if unphosphorylated, this means designing and synthesizing molecules 
with modulated structural characteristics, but with a peculiar focus on their phosphorylatability. This 
approach is meant to obtain new potential anti-cancer drug entities that could restore the capability of the 
involved cells to die for apoptosis. The compounds were assayed in the laboratory of Prof. Brunati 
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(Department of Molecular Medicine, University of Padova) for their capability to restore PP2A activity in 
B-CLL cells. In this sense, some promising compounds were obtained and the results of the biochemical 
assays on the most performing compound have been here reported.  
In addition to this, the aim of producing PP2A (catalytic subunit) and SET proteins through recombinant 
DNA technique was pursued in order to obtain more details about the structural features involved in the 
interactions between the proteins themselves, and also the eventual ones between the proteins and the 
synthesized compounds; this part of the project was performed at Diamond Light Source (UK). 
Combining all the pieces of information obtained from these aims will lead both to an enhanced 
knowledge about the structural interactions between PP2A and SET (which to date is lacking) and to the 
possibility of rationalize eventual structure-activity relationships between the proteins of interest and anti-
cancer compounds; this will help in elucidating the structural characteristics which are needed for the 
molecules to be active, and as a consequence in designing more, improved, rationalized Fingolimod 
analogs.  
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1.1 CELLULAR SIGNALING 
 
Signaling is a complex and delicate ensemble of processes within the cell and among cells; the robustness 
of the signaling pathway performances and their repeatability are mandatory in order to elicit the 
appropriate physiological response to given stimuli. Cells use signaling pathways for obtaining a series of 
effects such as modulation of enzyme activity, regulation of proteolysis, assembly of macro-molecular 
machines, intracellular localization, creation of protein docking sites, cell division, proliferation, 
differentiation and apoptosis, in order to modulate all the aspects of cell life. Because of this, each 
signaling pathway needs to be submitted to a fast and fine regulation through proper effectors and a 
proper control on the effectors themselves1. 
Effectors are often represented by molecules subject to phosphorylation and dephosphorylation events 
which control their activation or inactivation. Reversible phosphorylation represents for a cell a fast and 
easy way to transmit and amplify signals of various types; because of this, it is easy to understand the fact 
that it plays key roles in several physiological processes. Phosphorylation state unbalances can be 
dangerous because they can affect the normal life of the cell in many ways, and indeed they have often 
been found in pathological conditions (among the others, hematological malignancies)1,2.  
It is well known that, while phosphorylation of nucleophilic aminoacid side-chains in protein is catalyzed 
by protein kinases (PKs), dephosphorylation is controlled by protein phosphatases (PPs). The role of PKs 
has been widely investigated, and it has been proved that the dysregulation of the relative oncogenes is 
responsible for cancer initiation and maintenance2,3; by counterbalancing the activity of kinases, 
phosphatases started in recent years to be considered as tumor suppressors3,4 as demonstrated by the fact 
that the loss of function of various phosphatases has been detected in many cancers5. 
The human genome encodes for 518 protein-kinases; among them, 428 are Ser/Thr kinases and 90 are Tyr 
kinases. Actually, PPs are not so abundant: the human genome encodes for 107 Tyr phosphatases and 
only 40 Ser/Thr phosphatases, for a total amount which is around one fifth of total one of the kinases. 
Apart from this discrepancy, Ser and Thr account together for 98% of the phosphoprotein targets (86% 
and 12% respectively), but the total amount of PKs and PPs specific for these residues is much lower than 
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the number of Tyr specific kinases and phosphatases6.  
Probably due to their abundance, PKs have been much studied through the years, and now they represent 
one of the main drug targets for pharmaceutical industry; imatinib mesylate, the first commercial Bcr-
Abl1 Tyr kinase inhibitor developed for the treatment of chronic myeloid leukemia (CML), was 
commercialized starting from 19987. The appreciation of the potential role of PPs was made only much 
later and only a few phosphatases were characterized until recent years, because of their small amount (at 
least when compared to kinases) and of the objective limitations of the available tools for targeting – and, 
as a consequence, analyzing - them (above all, the lack of specificity of PPs inhibitors)8. 
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1.1.1 PROTEIN PHOSPHATASES 
 
Several classifications have been made for PPs through the years, but the most recent one divides these 
phosphoproteins in three main classes basing on sequence, structure and catalytic mechanism8: 
- Ser/Thr phosphatases, which are divided between 
· Phosphoprotein phosphatases or PPPs (PP1, PP2A, PP2B, PP4, PP5, PP6 and PP7) 
· Mg2+ or Mn2+ dependent phosphatases or PPMs (PP2C). 
Most of the Ser/Thr phosphatase in vivo activity is performed by PP1, PP2A, PP2B and PP2C. 
The heterogeneity of this family has to be addressed to the way the subunits assemble, since 
these phosphatases are usually composed of hetero-oligomeric complexes made up by relatively 
simple subunits, that can interact with a number of regulators affecting targets and activity6;  
- Tyr phosphatases (PTPs), which are divided in classes I, II and III. PTPs are multidomain 
proteins presenting the peculiar feature of having the catalytic and regulatory domains combined 
in one single chain. They are responsible for a variety of signals: cell adhesion, insulin signaling, 
immune response, cell cycle control9. Among them, a relevant role is played by SHP1 (Src-
homology 1 domain phosphatase), a PTP which is shown to dephosphorylate Bcr–Abl 
oncoprotein: its activity, also due to the downstream signals that involve other phosphatases and 
kinases as PP2A and Lyn, leads to the production of pro-apoptotic factors and because of this it 
is often down-regulated in imatinib-resistant CML forms10; 
- Asp-based protein phosphatases, less abundant and less known; they use a peculiar mechanism 
for the dephosphorylation which involves an Asp residue, and comprise 
· Dual specificity phosphatases (DUSPs), that can act on all of the three mentioned aa 
residues 
· FCP (TFIIF-associating C-terminal domain phosphatase)/SCP (Small C-terminal 
domain phosphatase) family 
· HAD (haloacid dehalogenase) family. 
18 
 
To date, the Asp-based PP category is the less investigated and known one, and also the 
classification here reported is not univocally recognized (e.g., some authors consider DUSPs to 
be belonging to PTPs)3,6,8,11. 
In recent years, because of its role and its cellular abundance, one of the most pharmaceutically promising 
phosphatases has been considered to be PP2A (Protein Phosphatase 2A). 
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1.2 PROTEIN PHOSPHATASE 2A 
 
Protein Phosphatase 2A (PP2A) is a term that comprises a family of Ser/Thr phosphatases, which are 
ubiquitously expressed and highly conserved among the species (mostly eukariotes)1; this family makes 
up 1% of all cellular proteins and together with PP1 realizes over 90% of all Ser/Thr phosphatase activity 
in the cell12. PP2A is involved in many cellular functions: cell metabolism, cell cycle, DNA replication, 
transcription and translation, cell proliferation, cell mobility and, above all the others, apoptosis13. Its 
importance in oncogenesis was shown first when okadaic acid (OA), an already known carcinogen, was 
demonstrated to be able to selectively inhibit PP2A. This evidence was followed by others, for example 
that PP2A can also be inhibited by the oncogenic simian vacuolating virus 40 (SV40) small T-antigen 
(which probably displaces one of the subunits from the complex PP2A is formed by). Furthermore, 
different components of the PP2A holoenzyme were shown to be mutated in various tumor forms, e.g. the 
already cited CML, acute myeloid leukemia (AML) or lung cancer; the restoration of a normal PP2A 
activity induces instead cell death in cancer cells (both in vitro and in vivo) and counteracts uncontrolled 
proliferation12,14. 
 
1.2.1 PROTEIN PHOSPHATASE 2A: STRUCTURE 
 
 
Figure 1. PP2A structure; modified from PDB ID: 2NYM. 
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Subunit Gene Isoform Other name 
Catalytic (C) PPP2CA α PPP2Cα 
Catalytic (C) PPP2CB β PPP2Acβ 
Structural (A) PPP2R1A α PR65α, PP2A-Aα 
Structural (A) PPP2R1B β PR65β, PP2A-Aβ 
Regulatory (B) PPP2R2A α B55α, PR55α, PP2ABα 
Regulatory (B) PPP2R2B β B55β, PR55β, PP2ABβ 
Regulatory (B) PPP2R2C γ B55γ, PR55γ, PP2ABγ 
Regulatory (B) PPP2R2D δ B55δ, PR55δ, PP2ABδ 
Regulatory (B’) PPP2R5A α B56α, PR56/61α, PP2AB’α 
Regulatory (B’) PPP2R5B β B56β, PR56/61β, PP2AB’β 
Regulatory (B’) PPP2R5C γ1,2,3 B56γ, PR56/61γ, PP2AB’γ 
Regulatory (B’) PPP2R5D δ B56δ, PR56/61δ, PP2AB’δ 
Regulatory (B’) PPP2R5E ε B56ε, PR56/61ε, PP2AB’ε 
Regulatory (B’’) PPP2R3A α PR130, B’’α1 
Regulatory (B’’) PPP2R3A α PR72, B’’α2 
Regulatory (B’’) PPP2R3B β PR70, PR48, B’’β 
Regulatory (B’’) PPP2R3C γ G5PR, G4-1 
Regulatory (B’’) PPP2R3D δ PR59, B’’δ 
Regulatory (B’’’) STRN  Striatin, PR110 
Regulatory (B’’’) STRN3  SGN2A 
Regulatory (B’’’) STRN4   
Regulatory (B’’’) PPP2R4  PTPA, PRS3 
Table 1.Possible isoforms of PP2A subunits15. 
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Active PP2A holoenzyme is composed of three main subunits, which can all exist in various isoforms (as 
shown in the previous table): 
- PP2AC, the catalytic subunit (coloured with bright azure in figure 1) 
- PP2AA, the structural subunit (coloured with dark blue in figure 1) 
- PP2AB, the regulatory subunit (coloured with light blue in figure 1). 
The core of the enzyme (PP2AD) is constituted by PP2AC and PP2AA, and can exist as it is in a dimeric 
form (one third of the total cellular PP2A) or can be associated to one of the types of B subunits. The 
numerous types of genes and isoforms which are responsible for PP2A subunits, together with their 
genetic redundancy (at least two genes encoding for each subunit), lead to a large heterogeneity of PP2A 
holoenzymes16. Taking into account all the possible dimers and trimers, nearly 100 PP2A holoenzymes 
can be found in the cell.17  
 
C subunit 
The catalytic subunit of PP2A, also called PP2AC, hosts the dephopshorylative activity of the whole 
enzyme. PP2AC has a MW of 36 kDa and it is encoded by two genes (both made up by seven exons and 
six introns) that produce two isoforms, Cα and Cβ, with 97% identity in their primary sequence13,18. This 
high similarity, however, does not lead to redundancy in the roles of the two isoforms; it has been shown 
that loss in PP2ACα activity cannot be replaced by PP2ACβ in yeast and mice, and this loss leads to cell 
death12,17. These two isoforms are ubiquitously expressed (with peaks in brain and the heart), being Cα 
predominant in the plasma membrane and Cβ in the cytoplasm and nucleus; their expression levels are 
different, since Cα is 10 times more abundant than Cβ. This is probably due to some differences which 
involve the activities of the promoters and the turnover of the corresponding mRNAs18.  
Molecular cloning and overexpression of PP2AC has been achieved in lower organisms as insects thanks 
to baculovirus technology, and here it showed to have had its structure conserved through the evolution, 
being maybe the most conserved among the known enzymes; unluckily, until now it was not possible to 
clone it in mammal cells18. 
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Figure 2. C subunit; isolated from PDB ID 2NYM. 
 
Apart from the fundamental catalytic role it has, this subunit also shows another peculiarity since it results 
to be the mainly involved one in enzyme regulation; so, in PP2AC reside both the dephosphorylative 
activity and the regulation of the activity itself. It has been demonstrated that this subunit can be subject 
to post-translational modifications as well as to the modulation from a series of interactors, which can 
either promote or inactivate the enzyme itself19. This point will be better elucidated in the “Protein 
phosphatase 2A: regulation” section. 
 
A subunit 
A subunit, also known as PR65 or structural subunit, is the structural docking platform for subunits B and 
C; in the absence of a B subunit, it can alter the substrate specificity of PP2AC. The structure of PP2AA is 
made by 15 tandem repeats of a 39 aa sequence, termed HEAT (huntingtin/elongation/A subunit/TOR, 
where TOR is target of rapamycin) motif18. The reported crystal structure of PR65 (PDB ID: 1B3U) 
shows that each repeat is virtually the same, i.e. two superimposed α-helices stacked in a stable, elongated 
unit20. 
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Figure 3. Crystal structure of A subunit. PDB ID: 1B3U. 
 
As already seen for PP2AC, also PP2AA is encoded by two genes which lead to the production of two 
protein isoforms, Aα and Aβ, which share around 87% of sequence identity and the MW of 65 kDa. Once 
again, however, this does not mean that they are interchangeable: it has been shown that loss of Aα 
activity in mice cannot be replaced by Aβ. In addition to this, 90% of PP2A holoenzymes contain the Aα 
isoform and 10% the Aβ, so it is reasonable to think that they do have different roles in the cell; it has 
been discovered that Aβ has an higher abundance in testis when compared to other tissues, suggesting a 
role for Aβ in spermatogenesis15,21. 
 
B subunit 
The group of B subunits is the most heterogeneous, and the scaffolds belonging to it are coded by genes 
(15 were identified until now) that totally lack structural similarity12,18. The presence of this subunit 
results to be of extreme importance, since the subtype of B subunit is related both to the tissue it is 
expressed in, and to the substrate specificity it is meant to mediate; this distinction lead to the 
classification of four distinct families, which share almost no structural similarity12. 
 
B family (PR55) 
This first family comprises four distinct subunits (called α, β, γ, δ) with a MW of 55 kDa each; while α 
and δ are present in all tissues in comparable amounts, β and γ are highly enriched in brain. One of the 
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most interesting features of this family is the presence of five degenerate Trp/Asp-40 (or WD-40) repeats, 
i.e. sequences composed by 40 aa (conserved just in a minimal part) and ending with Trp-Asp. These 
portions are thought to mediate the protein-protein interaction, for example the one with TGF- β 
receptors18. 
B’ family (PR61) 
These subunits have a MW of 61 kDa and are encoded by five genes which, thanks to their splicing 
variants, lead to the production of seven subunits. They show to have a peculiar and precise distribution in 
the cell: α, β, ɛ are mostly found in the cytoplasm and γ1, γ2 and γ3 are mostly found in the nucleus, 
while δ is expressed in both the nucleus and the cytoplasm12. All the PR61s have similar structure in the 
central part (80% of sequence identity), while they are different at N- and C- termini; this leads to 
different expression levels in tissues13.  It has been shown that this type of subunits exposes a highly 
acidic surface, which is believed to be responsible of further protein recruitment12; the structure is mostly 
α helical and it is a potential substrate for phosphorylation13. 
B’’ family (PR72) 
The pieces of information about this family are not really abundant and also the number of members is 
uncertain: some authors claim it exists in five forms, while others believe they are four18. PR72 is found 
exclusively in heart and skeletal muscle, PR130 is ubiquitous (with highest levels in heart and muscle), 
PR59 in testis, kidney, liver, brain, heart and lung; PR48 and G5PR are still matter of discussion13,18. 
B’’’ family 
Like the previous one, also this family is not extremely well known. These subunits have been shown to 
share a conserved structure which is the same as B’ subunits, and also the WD-40 repeats which are 
typical for B family. They are supposed to be somehow involved in Ca2+-dependent signaling18. 
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1.2.2 PROTEIN PHOSPHATASE 2A: ROLE 
 
Being a phosphate, PP2A has of course the main role of dephosphorylating substrates; however, it is 
worth considering the very final effects of this dephosphorylative activity. Since there are so many 
possible subunit combinations, it is reasonable to imagine that PP2A has an impressive number of 
functions: so it is, and they mainly depend on the specific assembly and localization of the subunit 
themselves, and of course on the specific substrates. Because of its profusion of roles, PP2A has been 
defined as a “social butterfly”22. Overall, it can mainly affect signal transduction, with influence in cell 
proliferation, differentiation, adhesion, migration, metabolism and, most of all, survival16,17. 
The following image shows only some of the signaling pathways regulated by PP2A. 
 
 
Figure 4. Biochemical pathways in which PP2A is involved2. 
 
PP2A and the cell cycle 
As mentioned above, PP2A has a deep role concerning cell cycle: indeed, it can inhibit the phase 
transitions that characterize cell life. When duplicating, eukaryotic cells leave their latent phase (G0) to go 
through a four stages cycle, tightly controlled by a number of checkpoint mechanisms: 
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- G1 phase (gap 1), corresponding to the time gap between mitosis and initiation of DNA 
replication; 
- S phase, where the S stands for synthesis: at this point DNA is replicated replicated to provide a 
copy of the genetic material to each of the daughter cells; 
- G2 phase (gap 2), where the cell grows and produces proteins in preparation of mitosis; 
- M phase, and so mitosis (when the mother cell divides into two genetically and functionally 
equivalent cells), which is usually followed by cytokinesis23. 
 
Figure 5. Schematic representation of the cell cycle24. 
 
Depending on its specific structural composition, PP2A is capable of controlling some of the phase 
transitions in the cell cycle, i.e. G1-S and especially G2-M11; the latter occurs thanks to the inhibition of 
some maturation-promoting factors (CDK1 and cyclin B) and it is more likely in the presence of a B55α-
containing PP2A form. In the presence of B56δ, instead of B55α, PP2A catalyses the exit from mitosis 
thanks to the inactivation of CDC25 (Cell division cycle 25 phosphatase). 
The activity of this enzyme is also exerted through the inactivation of MEK (Mitogen-activated protein 
kinase kinase) and ERK (Extracellular signal-regulated kinase): this leads to the decrease of the 
functionality of transcription factors as c-MYC and STAT5, leading to the inhibition of their mitogenic 
and antiapoptotic effects and to an overall negative regulation of the so-called MAPK (Mitogen activated 
protein kinase) signaling pathway 5. 
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PP2A and apoptosis 
Apart from the effects on the inhibition of the cell cycle PP2A can act on many biochemical pathways, 
mainly exerting its effects on the promotion of the apoptosis. Apoptosis – or programmed cell death - is a 
crucial event for cellular turnover; a lacking or an excessive apoptotic signaling is a common hallmark of 
pathologies as neurodegenerative diseases, ischemia, autoimmune disorders and cancer. The capability of 
modulating cell life and death is an extremely desirable pharmaceutical aim because of its huge 
therapeutic potential25. 
The influence of PP2A on apoptotic pathways can be seen on many sides; one of them is the inhibitory 
effect it has on Jak2 (Janus kinase 2) Tyr kinase. PP2A and Jak2 have opposite effects, so the activation 
of PP2A induces inactivation of Jak2, resulting on the suppression of pro-survival signals1. 
β-catenin is a protein subunit belonging to the cadherin, and it is the central focus of  Wnt (Wingless-type 
MMTV integration site)/β-catenin pathway. β-catenin activates growth and anti-apoptotic mechanisms 
thanks to the activation of c-MYC genes, and it has been shown that its levels are often increased in 
colorectal cancer. PP2A can inactivate this pathway and block these pro-survival signals, and also stem 
cells self renewal and embryonic development5,14. 
PP2A is also involved in one of the main apoptosis-modulating signaling cascades: the PI3K 
(phosphoinositide 3-kinase)/AKT (Protein kinase B) pathway. PP2A suppresses the signals coming from 
this pathway by directly dephosphorylating and inactivating AKT and by suppressing Akt-activation 
signals2. This is extremely important because AKT is a well-known kinase, involved in the regulation of 
cell survival and proliferation: it promotes key features as cell cycle progression, cell survival, growth, 
proliferation, angiogenesis, and self-renewal of stem cells1. The pro-survival activity of AKT is exploited 
in two main ways: the inactivation of pro-apoptotic signals and the parallel activation of anti-apoptotic 
signals. For example, part of its effects is due to the fact it inhibits the release of cytochrome C from 
mitochondria through phosphorylation (i.e. inactivation) of pro-apoptotic factor caspase-95. The same 
pathway partly also involves the inactivation of Bcl-2 (B-cell lymphoma 2), an anti-apoptotic factor, and 
the activation of BAD (Bcl-2-associated death promoter) and Bim (Bcl-2-like protein 11). This is the 
result of the direct inactivation of AKT and the activation of BAD performed by PP2A which leads to the 
activation and translocation of BAD to the membrane of mitochondria, where it binds and inhibits Bcl-
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226. For being active, however, AKT needs to be phosphorylated; this can occur on a Tyr or a Ser residue. 
The activation leads to its translocation to various subcellular compartments, where it can phosphorylate 
its substrates and interfere with the activation of apoptotic signals. As a consequence, it is not surprising 
that it is considered to be a protooncoprotein and that aberrant Akt activity has been found in diseases as 
cancer or neurodegenerative disorders1. Having it dephosphorylated by PP2A means inactivating it, 
favouring cell death.  
 
PP2A as a tumor suppressor 
Many evidences support the idea that PP2A can be considered to be a tumor suppressor; the very first one 
was the demonstration it is inhibited by okadaic acid (OA), which is both a tumor promoter and a specific 
PP2A inhibitor27. However, the strongest evidence arose with the studies on eukaryotic cells, that showed 
how the alteration of balance in one or more of the subunits cause severe misregulation in normal cell 
life; in particular, 
- overexpression of Aα subunit leads to the inhibition of cytokinesis; indeed, this event can lead to 
the disruption of the protein complexes that lead to cytokinesis and/or the sequestration of the 
catalytic subunit. As a result, it is possible to have inefficient dephosphorylation and activation 
of myosin light chain kinase, issue that leads at the very end to the inhibition of the contractile 
force in the cleavage furrow28. In addition to this, overexpression of Aα subunit can enhance the 
formation of bi- or multi-nucleated cells28; 
- truncation of PR61 leads to radio-resistance and metastasis; PP2A is in fact involved in the 
regulation of paxillin and Mdm2 (an inhibitor of p53 tumor suppressor). The dephosphorylation 
of the latter permits to Mdm2 itself to bind p53 and block its pro-transcription activity29. In 
addition to this, the decreased dephosphorylation of paxillin (a multidomain-containing adaptor 
molecule involved in cell migration), enhances cell motility promoting metastasis in case of 
cancer30; 
- mutations in the A subunit have been demonstrated to be present in a variety of human cancers, 
specially lung tumors, lung-derived tumors and colon tumors31, while mutations of PPP2R1B 
gene are involved in the onset of almost all types of colorectal cancers32; 
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- subversion of PP2A activity performed by SV40 ST (Small t antigen, a viral protein involved in 
the onset of cancer), which mainly targets B56γ-containing holoenzymes, contributes to 
malignant cell transformation33; in fact, suppressing the expression of the PP2A B56γ subunit in 
human embryonic kidney (HEK) epithelial cells expressing SV40 large T antigen, hTERT, and 
H-RAS lead to the inhibition of PP2A-specific phosphatase activity, to an anchorage-
independent cell growth and to the formation of tumors. On the other hand, overexpression of 
PP2A B56γ3 in tumorigenic HEK cells expressing ST partially inverted the tendency towards 
tumorigenicity of these cells33; 
- deletion of PR55 in eukaryotes (mainly Drosophila) leads the activation of MAPK signaling, 
responsible for cell overgrowth, in a very short amount of time (5-15 min)34. The deletion of 
either A or C subunits provokes the disappearance of all PP2A subunits; ablation of total PP2A 
by using dsRNA against either A or C subunit enhances ERK activation, affecting as a 
consequence the MAPK cascade34. 
Taken together, all these pieces of information can lead to the reasonable statement that PP2A can be 
considered to be as a tumor suppressor22. As a direct consequence, a deep comprehension of the 
properties and the regulation of this enzyme could lead to a new approach in cancer treatment 
strategies. 
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1.2.3 PROTEIN PHOSPHATASE 2A: REGULATION 
 
Given the important roles PP2A has, it is necessary to know how it can be regulated in order to 
understand where misregulations can occur and how to correct them. Because of the many possible 
isoform combinations, the modes of regulation of PP2A are quite heterogeneous, and can be divided 
mainly between post-translational modifications and interactors-mediated modulation. 
 
Post-translational modifications 
The main post-translational events that can affect PP2A activity are two: phosphorylation and 
methylation, both occurring on the catalytic subunit.  
Plenty of kinases can phosphorylate PP2AC, and this event is enhanced by the presence of OA19. 
Phosphorylation can occur on Tyr307 or Thr304 residues, and in both the cases this leads to the inactivation 
of the whole enzyme but in different ways: indeed, the phosphorylation of Thr304 gives enough hindrance 
for avoiding the recruitment of other subunits, while P-Tyr307 adds to this function the lack of possibility 
for the subunit to undergo methylation5. However, there is the chance for the enzyme to auto-
dephosphorylate itself, thanks to its Tyr auto-dephosphorylative activity, and being restored19. 
At the C-terminal of PP2AC, also resides the methylation substrate: it is represented by Leu309, which can 
be methylated by a specific enzyme, called Leu-carboxyl methyltransferase of type I (LCMT1)5,19. So, in 
contrast to the previous case in which the post-translational modification could be performed by many 
kinases, here there is only one enzyme; its action can be reverted only trough a specific phosphatase 
methylesterase. The addition of a methyl residue to the Leu leads to the recruitment of B subunits in a 
preferential way than B’ and B’’, which instead prefer non-methylated PP2AC19. 
 
Physiological modulators 
Another level of PP2A regulation is represented by the interaction that can occur between the phosphatase 
and its endogenous inhibitors or enhancers. 
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Inhibitors 
The inhibitor category comprises various macromolecules. Among them there is CIP2A (Cancerous 
inhibitor of PP2A), which prevents the PP2A-mediated c-Myc degradation; it is significantly up-regulated 
in some tumor cells, e.g. head, neck and breast cancer35. It is supposed to directly bind PP2AC, but 
structural information is still lacking. Another one which is worthy to consider is ANP32A (acidic nuclear 
phosphoprotein 32 kDa A) or I1PP2A (PP2A inhibitor 1): it has been found that this type of protein can 
bind sphingosine and inhibit PP2A as a consequence36. From a functional point of view, this can affect 
cell proliferation, but striking evidences are still lacking and the protein is still a matter of study. 
Among the inhibitors of PP2A, probably the best known – and more widely studied – is SET (Suvar3-9, 
enhancer of zeste, trithorax), sometimes named after I2PP2A or TAF-Iβ5. 
 
Figure 6. Crystal structure of SET protein, monomer (modified from PDB ID 2E50). 
 
This potent and specific protooncoprotein exists in two splice variants (α and β, 290 and 277 aa 
respectively), and both of them can inhibit PP2A. In its active form, SET has an average MW of around 
28 kDa, and a calculated pI around 4; the N-terminal globular domain is the part of the macromolecule 
responsible for PP2A interaction37, while the C-terminal elongated α-helical domain is extremely acidic 
and seems to be responsible for histone binding14. SET can be located both in the cytoplasm and the 
nucleus17, and has been shown to have several functions: it is involved in the promotion of chromatin 
remodeling19,37 and histone acetylation14. Apart from these functions, which are not PP2A-inhibition-
dependent, SET is believed to inhibit PP2A by the direct binding to PP2AC; notwithstanding, the precise 
mechanism by which this happens has still to be cleared out14. In fact, the surfaces which are involved on 
this interaction are not well characerized, since to date there is only one crystal structure for a truncated 
dimer form of SET on the PDB protein structure databank (ID: 2E50), while no co-crystallized structures 
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between SET and PP2A are available. What is structurally known is that SET, for being active towards 
PP2A, has to be phosphorylated on two Ser residues, probably by PKC18. Given the binding to PP2A 
leads to phosphatase inactivation, it should not surprise that SET is found overexpressed in a plethora of 
tumors: CML and Ph1-ALL (both BCR/ABL driven leukemias), Wilms tumors, lung cancers, AML, B-
cell non-Hodgkin lymphoma, B-CLL. SET gene was also found to be fused with the nucleoporin NU214 
(CAN) in t(6;9) acute undiﬀerentiated non-lymphocytic leukaemia, probably as a consequence of a 
chromosomal translocation5,14,19. Moreover, ectopic SET expression demonstrated the role it has in 
primary human NK (Natural Killer) cells, since it leads to the production of interferon-γ and to an 
increased cytotoxicity5. An indirect way in which SET can be upregulated is the overexpression of 
SETBP1 (SET binding protein 1), a regulator that prevents the inactivation of SET by protecting it from 
proteases, as found in the case of AML5. 
 
Activators 
The category of PP2A activity enhancers has its main representing element in ceramide (1), a 
sphingolipid metabolite and a structural component of the cell membrane furnished with potent signaling 
properties35. Ceramide has been shown to activate PP2A and to restore its pro-apoptotic activity, but the 
mechanism by which this happens is poorly understood: indeed, it has been hypothesized to directly bind 
PP2A holoenzymes containing the PR61/B’ subunit, in vitro and ex vivo35. More recently, however, the 
most acknowledged theory is that ceramide activates PP2A because it binds SET38 and prevents its 
inhibiting function towards the phosphatase. . The mechanism by which ceramide can induce apoptosis in 
prostate-cancer cells involves the suppression of Akt signaling pathway, since the reactivation of PP2A it 
performs leads to a subsequent AKT dephosphorylation5. 
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Non-physiological modulators 
 
Inhibitors 
PP2A has also plenty of non-physiological modulators, which were discovered through the years. The 
very first one, as already explained, was okadaic acid (OA, 2), the toxin that brought to consider PP2A as 
a tumor suppressor for the first time. OA is a carboxylic acid derived from common black sponges, and 
which in the late 1980s was demonstrated to be a non competitive/mixed inhibitor for PP2A, even if the 
mechanism which underlies its activity is not totally clear. The inhibition it provides has been shown to 
be reversible on myosin light chain phosphorylation, so it has been used for a long time as an analysis 
tool for phosphorylation regulated systems27. 
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In more recent years, cantharidin (which origins from  Lytta vesicatoria beetles) derivatives LB100 (3)39 
and LB102 (4)40 have shown PP2A inhibiting activity as well. Both of these molecules displayed 
significant effects when co-administered to classical anti-tumor drugs in several forms of cancer (LB100 
showed its effects on hepatocellular carcinoma, while LB102 on glioblastoma, neuroblastoma, and stem 
cell–derived aggressive sarcoma); indeed, their inhibitor activity towards PP2A alters cancer cell 
signaling leading them to avoid cell cycle checkpoints, fact that makes the cell more vulnerable towards 
external factors as anti-tumor drugs39,40. 
O
N
O
N
O
O
OH
O
                       
O
N
O
N
OH
O
 
                                                                       3                                                                   4 
 
34 
 
Another inhibitor coming from natural source is calyculin A (5), a spiro ketal skeletal molecule derived 
from a marine sponge (Discodermia calyx). Actually, this compound was first studied in comparison with 
OA: the two molecules displayed comparable results for what concerning the inhibitory activity on 
PP2A41. However, calyculin A has been shown  not to be selective for PP2A, but rather a broad spectrum 
inhibitor of phosphatases42. 
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Activators 
Given the role the activity of PP2A has in the correct apoptosis of the cells, and keeping in mind the fact 
that many tumor forms have PP2A activity impaired, it is not surprising that restoring the activity of 
PP2A has recently been considered as a potential new therapeutic approach against cancerous diseases. In 
this context, many compounds are currently being investigated, especially in the field of small molecules. 
As previously described, ceramides are good PP2A enhancers; however, they cannot be considered as 
potential drugs because, if administered, they can be easily metabolized. A possible way to increase 
ceramide levels could be the treatment with ceramide biosynthesis activators; this would increase the 
physiologically produced quantity of ceramide itself and can be obtained through molecules of very 
different nature, for example vitamin D3 (6) and anthraquinones (daunorubicin, 7; mitoxantrone, 8)43. 
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Apart from this approach, PP2A activation can be obtained thanks to compounds as dithiolethiones. 
These are known as chemopreventive molecules, and their activity has been attributed to their antioxidant 
responsive elements (AREs); however, it has been shown that some of them (for example ACS-1, 9)  
target PP2A, activating it independently from de novo phosphatase synthesis and restoring its inhibitory 
activity towards the Akt pathway44. 
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Forskolin (10) is mostly known for its activity of increasing cAMP levels; however, it has also been 
shown that it can restore PP2A activity in leukemic cells when administered in vivo. The involved 
mechanism has still to be clared out, but it does not seem to reside in a direct interaction with the 
phosphatase or with one of its inhibitors. Curiously, the capability of forskolin to activate PP2A does not 
involve cAMP19. 
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Growing interest was gained by OP449, a peptide which comes from Apolipoprotein E (ApoE), known 
for being responsible for the transport of cholesterol. The residues 133-149 of ApoE (called COG133) 
fused with the cell-penetrating antennapedia peptide, form a dimeric peptide which is the final 
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OP4495,45,46. Its activatory activity towards PP2A is believed to be caused by its binding to SET, which 
prevents it from sequestering PP2A; it has been shown to exert antineoplastic effects in some forms of 
leukemia45. 
Anyway, the compound that recalled more attention in this sense is Fingolimod (11). 
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1.3 FINGOLIMOD 
 
Fingolimod (FTY720), or 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol, is commercially known as 
GilenyaTM (Novartis); it was approved by FDA (Food and Drug Administration) in 2010 for the treatment 
of relapsing-remitting forms of Multiple sclerosis (MS)47. 
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MS is a chronic disease of the central nervous system which has its main effect in the demyelination of 
nerves; it is believed to be driven by two main pathogenetic mechanisms, i.e. inflammation and 
degeneration. In this context, inflammation is related to the occurrence of acute episodes of neurologic 
dysfunction (relapses) and the formation of focal demyelinating lesions in the brain and the spine, while 
the degenerative effect would be responsible for progression of disability48.  
From the physio-pathological point of view, in MS central memory T cells become self-reactive, and they 
expand following low-intensity cross-reaction on self antigens in lymph nodes that drain the antigen from 
the central nervous system49. This provides axonal damages by progressively destroying the myelin 
coating axons in the central nervous system47. 
The disease occurs in different clinical forms, likely related to the varying interplay of the pathogenetic 
mechanisms: 
- relapsing-remitting MS (85% of patients) is characterized by relapses followed by total or partial 
recovery; 
- primary progressive MS (10% of patients), characterized by the progression of the degenerative 
mechanism but not of the inflammatory one; 
- secondary progressive MS (30%–40% of patients), which usually follows the relapsing-remitting 
form after 10-15 years. It is characterized by the progression of degeneration with or without 
superimposed relapses, and it can be considered to be the overt form of the pathology; 
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- progressive-relapsing MS (5% of patients), characterized from a progressive onset with 
superimposed relapses, followed by partial/total recovery48. 
Fingolimod represented an innovation in the field of MS treatments because it was the first drug suitable 
for oral administration; indeed, until 2010 the only available treatments were injective, with the main part 
played by interferon β, a cytokine, and natalizumab, a monoclonal antibody. This kind of therapies was 
not lacking of adverse effects as liver and thyroid dysfunctions, leucopenia, leucoencephalopathy or mood 
disorders48. 
The structure of Fingolimod was first described in 1995 and was inspired to myriocin (12), a fungal 
metabolite coming from Isaria sinclarii50. 
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Myriocin, traditionally used in Chinese medicine as a drug for “eternal youth”, was shown to have 
immunosuppressant activity. Its potent and selective inhibitory effects on SPT (Serine 
palmitoyltransferase) were determined in mammalian cells in vitro at a nanomolar range50. SPT is 
responsible for the first step of sphingolipid biosynthesis, and its inhibition through myriocin suppresses 
T cell proliferation thanks to the interference with sphingolipid metabolism. However, due to its severe 
gastrointestinal effects, it was not suitable as a drug51. Nonetheless, its scaffold was used for deriving less 
toxic analogs: among them, Fingolimod was found to be the best performing one, but its mechanism of 
action is completely different from that of its parent compound. 
 
1.3.1 Fingolimod: immunosuppressive action 
The mechanism of action that makes Fingolimod an immunosuppressive drug resides in its structural 
similarity with sphingosine (13, see next page). 
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Once internalized, Fingolimod can be phosphorylated in vivo by Sphingosine kinase 2 (SK2) to S-
Fingolimod-P (14), and because of this it reaches a structural similarity with sphingosine-1-P (S1P, 15), 
the product of phosphorylation of sphingosine performed by SK1 (mainly) and SK249. 
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S1P is extremely important in MS; central memory T cells egress from lymph nodes and recirculate to 
blood in a S1P-dependent manner, and they invade the central nervous system following restimulation by 
self antigen presented on phagocytes. Here, this type of reactivated T cells causes proliferation and local 
differentiation of effector T cells49. 
The structural similarity between S-FTY720-P and S1P leads the phosphorylated form of Fingolimod to 
mimic the action of S1P itself on the same receptors49; S1P can interfere with several signaling pathways 
thanks to the interactions with plasma membrane localized GPCRs (G-protein coupled receptors), called 
S1PRs (sphingosine-1-phosphate receptors) 52. Five receptors, named S1PR1-5, are currently known. 
S1PR1, S1PR2 and S1PR3 are ubiquitous (they are present in the immune, cardiovascular and central 
nervous systems), S1PR4 is selectively expressed in lymphoid tissues and lung, while S1PR5 in spleen 
and white matter. The expression of S1PR1 in CD4+ T cells is much higher than the other S1PRs, making 
of S1PR1 the main receptor on lymphocytes53. Indeed, the S1PR1 receptor plays a crucial role in 
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lymphocyte mobility, by selectively arresting the trafficking of naïve and central memory T and B 
lymphocytes in peripheral lymphoid organs without affecting the trafficking of effector memory 
populations54. 
Fingolimod-P (but not parent Fingolimod) can work as an agonist for S1PR1, 4 and 5 (EC50 ~0.3–0.6 nM) 
and for S1PR3 at higher concentrations (EC50 ~3 nM) in vitro, but not for S1PR249. However, after the 
the initial stimulation of the receptors, the drug can work as a “functional antagonist” since S-FTY720-P 
bound to S1PR inhibits their function inducing the internalization of the receptors themselves when these 
are overstimulated48,49. As a consequence also the migration of T-cells, which is mediated by S1PR1 
expressed on the membrane surface, is blocked and the blood lymphocyte count decreases49.  
Fingolimod has the great advantage, over other MS drugs, of being orally administrable, which is ideal 
for the long-term treatment a chronic disease requires; the classical injective therapy for MS lacks this 
compliance requirement. In addition to this, side effects of Fingolimod are limited to those typical for 
immunosuppressant drugs: leucopenia and increased risk of infections. In addition to this, however, since 
S1PRs are also expressed in the cardiac tissue, Fingolimod also leads to the increased risk of 
bradycardia48. 
 
1.3.2 Fingolimod and PP2A: why? 
The interconnection between PP2A and Fingolimod is not trivial, because it means combining the 
properties of a pro-apoptotic enzyme with a molecule which is known to be immunosuppressive. After its 
discovery, Fingolimod showed unexpected anti-cancer functions in CML and Ph1 ALL as a side effect; 
this was verified in vitro and in vivo using model systems, but also ex vivo on cultured human cells. In  
these assays FTY720 showed to induce apoptosis in imatinib/dasatinib-sensitive and –resistant leukemia 
cells, leaving the healthy ones unaffected55. In lymphoid cell lines, FTY720 restores Bcl-2 
dephosphorylation and apoptosis; primary CLL cell lines treated with FTY720 displayed down-regulation 
of Mcl-1 but not of Bcl-2, and concurrent activation of the dephosphorylation of ERK1/22; these 
combined mechanisms are a way to promote apoptosis. Actually, these are not the only cases in which 
FTY720 showed pro-apoptotic effects, since similar tests were performed also on a number of solid 
tumors with comparable results. The detailed mechanism of action of Fingolimod is not clear yet; 
however, in this case for providing this sort of effect it has been shown that Fingolimod does not have to 
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be phosphorylated55. This implies the presence of another mechanism of action, alternative to the S1PRs-
related one. Several in vitro studies were performed in order to elucidate this point, suggesting the 
effectiveness of FTY720 on tumor forms like multiple myeloma, hepatocellular, bladder, breast and 
prostate carcinomas: its pro-apoptotic activity and its ability to suppress mitogenic and survival signals 
resulted from the inhibition of ERK  and  PI3K/AKT  pathways5. Since PP2A is involved in the 
inactivation of these pathways, pro-apoptotic effect of unphosphorylated FTY720 is thought to be due to 
the activation of PP2A, at least in leukemias2,5. 
Structural data that could elucidate the mechanism of action at a molecular level are still missing. The 
most exhaustive study (performed by Saddoughi et al.)38 assessed the occurrence of a direct interaction 
between Fingolimod and SET, rather than PP2A; the activation of the phosphatase is supposed to be 
indirect, and mediated by the inhibitory action of Finoglimod on its physiological inhibitor. As already 
mentioned, SET is overexpressed in several forms of tumor, especially leukemia (considering, however, 
that the studies are still at a preclinical stage2), so the capability of FTY720 of restoring PP2A activity 
through the interaction with SET could represent a valuable tool in the treatment of leukemia.  
Experimental data were obtained through SPR (Surface Plasmon Resonance) performed between SET 
and, alternatively, ceramide C18 (the most performing of the ceramides, when considering their binding 
to SET), FTY720 and S-FTY720-P. The response curve for unphosphorylated FTY720 is comparable to 
that of ceramide, while S-FTY720-P seems to bind quite inefficiently to SET38. This confirms that the 
phosphorylated form of Fingolimod does not bind to SET, while unphosphorylated Fingolimod does. 
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1.4 LEUKEMIA: AN OVERVIEW 
Leukemia represents a group of heterogeneous blood cancers that belong to the group of hematologic 
disorders; they occur when immature or mature white blood cells multiply without control within the 
bone marrow56. This type of tumor affects men more than women (almost 2:1 ratio) and exists in a 
number of peculiar forms, which differ for the biological alterations occurring in the cell and, as a 
consequence, for their main morphological and molecular characteristics57. Types of leukemias are 
traditionally classified on the bases of:  
- progression of the disease: 
· acute: fast growing cancer that affects mainly immature cells;  
· chronic: cancer with a slow growth and that affects mature cells; 
- type of affected cells: 
· myeloid (involving cells of the innate immune system); 
· lymphocytic (involving cells of the adaptive immune system)56,57.  
The graphs in Figure 7 and 8 indicate the incidence and the mortality of leukemias are shown for the US 
in a period of 20 years. 
 
  
 
Figure 7. US leukemia incidence/100000 inhabitants 58. 
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Figure 8.US leukemia mortality/100000 inhabitants58. 
 
During the considered period of time, the trend of the curves does not seem to change during the 
considered two decades. Ethnic origins differentiate the incidence of the disease, with Whites being the 
most affected, while the number of African Americans, Hispanics, Asians and Native Americans is 
sensibly lower. This could be linked to genetic and congenital factors, which are thought to be the key 
factor to the onset of the pathology (together with ionizing radiations or exposition to mutagenic 
chemicals); the details of this ethnical diversification, however, are still not clear 56. 
 
1.4.1 B-CLL 
Among the blood tumors, the most outstanding is B-CLL (B cell chronic lymphocytic leukemia), the 
most common type of leukemia in the Western world, and also the one with the most heterogeneous 
clinical course among patients2; the American Cancer Society estimates the diagnosis of about 14,620 
new cases in the USA in 201559. The incidence is higher in male population, with an average age of 65; it 
is diagnosed to 1 person/year/100000 inhabitants in the 40-50 years age range, and this number increases 
to 20 cases/year/100000 inhabitants in the 70-80 range. More than 40% of B-CLLs are diagnosed at 75 
years old, while the diagnosis before 50 years old accounts for 10% of the whole60. 
B-CLL is a chronic blood disease characterized by the accumulation of monoclonal, mature, neoplastic B 
lymphocytes co-expressing CD5, CD23 and CD19 antigens61. In this kind of leukemia, the signaling 
pathway of BCR (B cell receptor) is impaired, which leads to the unusual expression of cell surface 
receptors on the disease-affected B cells. BCR-mediated stimulation has an important role in the 
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development of the disease, as confirmed by the impairment of the signal transmission they perform in 
CLL62. These abnormal B lymphocytes are found in the peripheral blood, bone marrow, lymph nodes and 
spleen, and as a consequence normal immunocompetent cells are reduced in their number and impaired in 
their function62. The affected subjects have a high prevalence of autoimmune phenomena, characterized 
by the production of polyclonal autoantibodies (autoAb) against autoantigenes (autoAg) which are 
expressed exclusively in blood cells63. 
Nowadays, the main hypothesis about the pathogenesis of B-CLL is that the cells involved in the disease 
might be selected by some sort of antigenic pressure resulting in a restricted gene repertoire for 
immunoglobulin heavy chain variable region (IGHV) gene repertoire compared to that found in normal 
adult B-cells64.. 
 
1.4.2 PP2A and Leukemia: why? 
Even if the precise pathogenesis of leukemia is not completely clear, many considerations about typical 
pathogenic features can be made; in particular, in this section results of experimental evidences that 
correlate various forms of leukemia with PP2A activity alterations are reviewed.  
In myeloid leukemia, even if genes encoding PP2A subunits are most of the times intact, the enzyme is 
inhibited in its pro-apoptotic activity because of two main reasons: post-translational modiﬁcations of C 
the subunit, and/or interactions with negative modulators on B and A subunits16. Focusing peculiarly on 
AML, PP2A dysregulation is characterized by the silencing of A subunit and the overexpression of B 
subunit16; in addition to this, SET was demonstrated to be expressed in a markedly increased manner65. 
AML can also result from genetic translocations leading to the overexpression of SETBP1; by protecting 
SET from protease cleavage, SETBP1 indirectly inhibits PP2A and leads to an enhanced proliferation of 
leukemic cells66. Another study examinated hematopoietic stem cells (HSCs) from CML patients and 
revealed that PP2A activity was suppressed in CML compared with normal HSCs67.  
As for B-CLL, the most common type of leukemia, several considerations can be made on the role of 
PP2A. Indeed, some CLL result from 11q gene deletion, and as a consequence reduced PP2AAβ subunit 
transcript levels can be observed. On the other hand, the expression of alternative splicing of PP2AAβ 
(PP2R1B) transcripts (skipping of exons 2/3, 3, 9) was associated with a reduced activity of PP2A68.  
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In order to evaluate PP2A most classical counterpart, also SET expression and activity were assessed in 
B-CLL. Basically, SET (both α and β isoforms) is found to be overexpressed in CLL cells when 
compared with healthy B cells. As a confirmation of this, elevated SET levels in patients were associated 
with the already acknowledged prognostic factors, like IGVH mutational status. To determine whether 
SET levels are indicative of more rapid CLL disease progression, cell extracts coming from 285 patients 
were evaluated; as a result, patients with high SETα, high total SET (α+β), and a high α/β ratio showed 
earlier need for therapeutic intervention, indicating that SET expression levels correlate with the 
progression of the pathology. In parallel to this, it was demonstrated that, in CLL cells, increased levels of 
SET correlated signiﬁcantly with disease severity and a poorer outcome69.  
This effect can also be enhanced through the stabilization of PP2A/SET complex, which is shown to 
happen in CLL due to an aberrant activity of the Tyr kinase Lyn; this kinase is one of the most relevant 
enzymes in the onset of B-CLL, and it has been shown to exert its activity in phosphorylating Tyr307 of 
PP2AC, stabilizing the interaction between PP2A and SET70. 
All of these data confirm a link between PP2A inactivation and the pathogenesis of leukemia, especially 
B-CLL; this feature can be extremely useful for a tumor cell, which has in immortalization one of its main 
developmental characteristics. 
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1.5 AIM 
B-CLL is the most common type of leukemia in the Western world, and the American Cancer Society 
estimatd the diagnosis of about 14,620 new cases in the USA in 201559. Since unphosphorylated FTY720 
can affect leukemia by the inhibition/disruption of the interaction between PP2A and SET38, it would be 
worth considering it as a lead compound for the development of new potential drugs against B-CLL. This 
project aims to develop new Fingolimod analogs that could reactivate PP2A in tumors, avoiding 
immunosuppressive effects. As already mentioned, these two activities are discriminated by the 
phosphorylation state of FTY720: the compound does not have to be phosphorylated for acting as a tumor 
suppressor, while it has immunosuppressive activity in its phosphorylated form. In the proposed 
approach, this was performed by modulating/limiting phosphorylatable sites; in addition to this, also 
further molecular features of Fingolimod were modified in order to elucidate the structural features 
required for the compounds to be active. 
A second aim of this project has been the production of the recombinant forms of the proteins of interest: 
SET and PP2A (being more specific, the catalytic subunit of PP2A, which is the one that was demonstred 
to interact with SET71). This was pursued through a placement at Diamond Light Source and the Research 
Complex at Harwell, Oxfordshire (UK) thanks to the supervision of Dr. M. Mazzorana, Prof. T.S. 
Sorensen and Prof. R. Owens. In this way, the newly synthesized compounds could be directly tested on 
the recombinant proteins, leading to the development of biochemical assays for inhibitors of SET-PP2AC 
interaction. After an optimization phase, experiments were performed to evaluate and quantitate both the 
binding and the kinetic processes underlying the interactions between the considered proteins and the 
obtained small molecules, through techniques such as HRMS and NMR. All the structure/function data 
will allow the design of an effective structure-activity relationship and an aware application of in silico 
tools for better understanding the interactions occurring between the proteins and the active compounds. 
In perspective, this approach will allow the design of Fingolimod derivatives optimized for the treatment 
of neoplastic malignancies and with reduced side effects on the immune system. 
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2. RATIONALE AND RESULTS 
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2.1 RATIONALE OF THE SYNTHETIC PATHWAYS 
 
The following synthetic schemes are meant to provide the synthesis of compounds inspired by FTY720: 
most of the times the para-disubstituted aromatic ring is maintained, but with structural characteristics 
which could modulate/limit the affinity for S1PRs (for example, the length of the “tail”) and enhance the 
affinity towards PP2A/SET. In the explorative approach that has been decided to pursue, this meant 
starting from reactants readily available in commerce, for example phenol, p-hydroxybenzaldehyde and 
more, in order to create a small library of compounds that could provide the widest possible range of 
structural features. This kind of approach aims, after adequate biochemical and biophysical evaluations, 
to provide information in terms of structure-activity relationship for a deeper understanding of the 
structural features underling the potential interaction between PP2A/SET and the molecules themselves.  
 
 
PATHWAY 1.1: 
OH
(  )n
Br
O
(  )n
Cl
O
Br
O Br
O
(  )n
HN
O
O (  )n
N
Cl
O
O
(  )n
O
 
 
The first synthetic pathway comes from the idea of creating a set of molecules with two main 
characteristics: a modulated “tail” length and a “head” in some way comparable to Fingolimod one, since 
the aromatic scaffold is functionalized with a linker which displays (in all of the cases but one) a 
16 
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morpholine or a piperidine ring. The latter mentioned compounds were used because Fingolimod has a 
primary amine and two hydroxyl groups in its “head”; keeping this in mind, morpholine was chosen 
because it owns both a nitrogen atom and an oxygen one, but comprised in a cycle. This means that the 
oxygen atom lacks of the capability of being phosphorylated by SKs, which is responsible for the 
activation of S1PRs pathway that is needed to be avoided. Because of this the importance of the oxygen 
presence could be better elucidated, evaluating it just for its physical-chemical characteristics and not for 
being a phosphorylation substrate. This is the reason why also piperidine was used, since it is extremely 
similar to morpholine but lacking the oxygen atom. As a sort of negative control, also a compound 
lacking rings on the “head” was synthesized. 
 
Williamson reaction 
The first reaction shown here is a classical SN2 Williamson etherification (through the procedure reported 
by Gamliel72) on the hydroxyl group of the phenol (1 equivalent), which is deprotonated by a base (in this 
case potassium carbonate, 2 equivalents) and in this way it can attack the haloalkane (0.9 equivalent) with 
the following mechanism: 
OH
Base
O
Br (  )n
O (  )n
 
This reaction has been performed with a series of halo-alkenes for mimicking the “tail” of Fingolimod but 
varying its length. 
 
Friedel-Crafts acylation 
The second step of the path is represented by a Friedel-Crafts acylation through the procedure reported 
by Kiuchi73, which inserts a linker in the para position of the molecule through a electrophilic aromatic 
addition. The reaction is carried out at 0°C in dichloroethane (DCE) in the presence of a Lewis acid, i.e. 
aluminum trichloride, in stoichiometric ratio (1.5 equivalents). The following scheme represents the 
16 
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mechanism of activation of 3-bromopropyonil chloride (1 equivalent) in these conditions, in order to 
create an acylium cation thanks the formation of a complex between AlCl3 and the acyl chloride: 
 
Br Cl
O Al
ClCl
Cl
Br Cl
O Al
ClCl
Cl
Br
O
Br
O
Al
ClCl
Cl
Cl
 
This step has also been carried out with acetyl chloride. The carbocation is stabilized by resonance74 and 
can react easily with the aromatic system of the alkylated phenol (1 equivalent); actually, the presence of 
the ether activates the ring on ortho and para positions, but the acylation occurs preferentially in para. 
This probably happens because the alkyl chain of the ether provides a hindrance which makes the reaction 
more difficult to occur in ortho. Since this reaction introduces an acceptor group, multiple substitutions 
are unlikely to occur75. 
 
O (  )n O (  )n
O
O (  )n
H
O
Br
O (  )n
O BrBr
 
 
The presence of the bromine atom permits in this case a further substitution on it, in order to insert either 
morpholine or piperidine; of course this cannot be done with the derivative obtained with acetyl chloride. 
 
 
δ+ 
δ- 
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Halide exchange and nucleophilic substitution: Finkelstein procedure 
 
The nucleophilic substitution occurs through the Finkelstein procedure76, which showed to be extremely 
efficient for the insertion of the heterocycles of interest. Basically, the final aim here is to substitute the 
bromine atom of the “head” linker with a nucleophile but this, due to the Finkelstein protocol, occurs in 
two steps: indeed, first of all the bromine atom is substituted with a iodine atom, which is more reactive 
and represents an extremely good leaving group; the iodine atom itself is then easily substituted with the 
nucleophile of interest (in this case, either morpholine or piperidine, 1.5 equivalents with respect of 1 
equivalent of acylated substrate). The halogen exchange is permitted by the addition to the reaction 
mixture of potassium iodide (1.5 equivalents), while the addition of calcium carbonate (1.5 equivalents) 
buffers the acid which is produced as a byproduct. 
 
O Br KI O
I
H
H
Br
O
H
H
I
 
 
As shown by the mechanism, the reaction occurs with an inversion of the configuration on the involved 
carbon atom, and it is a SN2. The reaction can be considered to be driven by the different solubility of the 
involved salts, since the byproduct KBr is poorly soluble. Apart from this, I- is a good leaving group for 
two main reasons: the strength of the C-X bond and the stability on solution of X-, once the C-X bond is 
broken. Both the characteristics can be seen in the following table77, since it reports the values of the C-X 
bond strengths (kJ/mol) and the pKa of the HX acids, which is inversely proportional to the degree of 
dissociation of the acid itself (and so to the stability of X- in solution). 
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Table 2. Comparison among halides as leaving groups77. 
 
Compared to the other halogens, iodine has the lower bond energy and the lower pKa, and so I- can be 
considered to be the best leaving group. 
After the halide exchange, the nucleophilic substitution can easily occur: 
O I
NH
O N
 
 
In the following tables, the obtained compounds are reported. 
Compound structure 
and number 
IUPAC name 
O
O
 
1-(4-
butoxyphenyl)et
hanone 
O
O N
 
1-(4-
(hexyloxy)phen
yl)-3-(piperidin-
1-yl)propan-1-
one 
Compound structure 
and number 
IUPAC name 
O
O N
 
1-(4-
(heptyloxy)phen
yl)-3-(piperidin-
1-yl)propan-1-
one 
 
O
O N
 
1-(4-
(octyloxy)pheny
l)-3-(piperidin-
1-yl)propan-1-
one 
 
25 
30 
31 
32 
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Compound structure 
and number 
IUPAC name 
O
O N
 
1-(4-
(nonyloxy)phen
yl)-3-(piperidin-
1-yl)propan-1-
one 
O
O N
O
 
1-(4-
(hexyloxy)phen
yl)-3-
morpholinoprop
an-1-one 
O
O N
O
 
1-(4-
(heptyloxy)phen
yl)-3-
morpholinoprop
an-1-one 
  
 
Table 3. Compounds obtained from pathway 1.1. 
 
Characterization: a focus 
One of the compounds synthesized through this pathway (31) was taken as an example for further 
characterizations, mainly performed by NMR; being more specific, 2D heterocorrelated NMRs as HSQC 
(Heteronuclear Single Quantum Coherence, for detecting 1J) and HMBC (Heteronuclear Multiple Bond 
Coherence, for detecting 2J and 3J) are provided here. 
O
O N
 
Compound structure  
and number 
IUPAC name 
O
O N
O
 
3-morpholino-1-
(4-
(octyloxy)pheny
l)propan-1-one 
 
O
O N
O
 
3-morpholino-1-
(4-
(nonyloxy)phen
yl)propan-1-one 
31 
33 
34 
35 
36 
37 
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Figure 9. HSQC spectrum of 31 (a) and a zoom on the aromatic part (b). 
From the zooming on the aromatic part of HSQC (Figure 9b), it is possible to see that the 13C at δ 129.7 
ppm is directly bonded to the proton at δ 7.95 ppm (2H, ArH), while the carbon at δ 114.2 ppm is linked 
to the proton signal at δ 6.94 ppm (2H, ArH). 
                                      
                            (a)                                                                                                        (b) 
Figure 10. HMBC spectrum of 31 (a) and a zoom of it (b). 
From the zooming on the HMBC spectrum (Figure 10b) it is possible to find out the coupling between the 
13C at δ 197.5 ppm and the proton signal at δ 7.95 ppm (2H, ArH). As it can be seen from the zooming on 
the combined HSQC (blue)-HMBC (red) spectra (Figure 11), the carbon signal at 197.5 ppm just gives an 
(a) (b) 
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HMBC signal but not an HSQC one; because of this, and of its chemical shift too, it is possible to assign 
the 13C signal at 197.5 to the carbonyl carbon. 
 
Figure 11. Combined HSQC (blue)-HMBC (red) spectra. 
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PATHWAY 1.2: 
 
SH
(  )n
Br
S (  )n
Cl
O
Br
O Br
S (  )n
HN
O
S
(  )n
N
 
 
This pathway originates from the first presented one but with a substantial variation: instead of the 
phenol, here thiophenol is used. Both the elements belong to the VI group but to two subsequent periods, 
so they have similar chemical characteristics but different atomic radius and, connected to this, 
electronegativity. This specific change could tune the eventual affinity of the molecule for the substrate in 
a more fine way, providing more clues about the interactions they can have. 
 
Thiol alkylation 
The first step is again an alkylation on the heteroatom (in this case, sulfur) through a procedure quite 
similar to the previously seen Williamson reaction: the SN2 reaction between thiophenol (1 equivalent) 
and the chosen bromo-alkane (1 equivalent) is carried out in the presence of potassium hydroxyde (1 
equivalent) as a base, and ethanol as a solvent78. As shown, the reaction mechanism is totally identical to 
the previous one: the base deprotonates the thiol from its proton, and in this way the S- atom can attack 
the bromoalkane of interest. 
 
SH
Base
S
Br
S
( )n
( )n
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The synthetic steps which follow are performed in the same manner as previously reported: a Friedel-
Crafts acylation is carried out with 3-bromo propyonil chloride, followed by a nucleophilic substitution 
with morpholine or piperidine through the Finkelstein procedure. 
 
The following table shows the obtained compounds: 
 
Compound structure 
and number 
IUPAC name 
S
O N
 
1-(4-
(pentylthio)phenyl)-3-
(piperidin-1-yl)propan-
1-one 
S
O N
 
1-(4-
(hexylthio)phenyl)-3-
(piperidin-1-yl)propan-
1-one 
S
O N
 
1-(4-
(heptylthio)phenyl)-3-
(piperidin-1-yl)propan-
1-one 
 
Compound structure 
and number 
IUPAC name 
S
O N
O
 
3-morpholino-1-(4-
(pentylthio)phenyl)prop
an-1-one 
S
O N
O
 
1-(4-
(hexylthio)phenyl)-3-
morpholinopropan-1-
one 
S
O N
O
 
1-(4-
(heptylthio)phenyl)-3-
morpholinopropan-1-
one 
Table 4. Compounds obtained from the pathway 1.2. 
 
One of the advantages of this pathway is the possibility to insert further modifications: on compound 51, 
in fact, an oxidation on the S atom was performed in order to produce a sulfoxide from the thioether 
group. 
46 
47 
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51 
61 
 
Cl
O
O
O
H
S
Ar
R
S
Ar
R
HO
Cl
O
O
Cl
OH
O
S
Ar
R
O
S
Ar
R
O
 
The oxidation of the thioether (1 equivalent) is performed through the use of m-CPBA (meta-
chloroperbenzoic acid, 1 equivalent) in DCM. 
This promptness of the sulfur atom in being further modified makes this pathway extremely suitable for 
the explorative approach which is pursued in this work. 
 
Compound structure 
and number 
IUPAC name 
S
O N
O
 
1-(4-
(heptylsulfinyl)phenyl)-3-
morpholinopropan-1-one 
 
Table 4. Compound obtained from the prosecution of pathway 1.2. 
 
Characterization: a focus 
 In the following image, the 1H-NMR of the intermediates and one of the final compounds (49) are 
reported (400 MHz, CDCl3) 
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Figure 12. 1H-NMR of compounds 40, 43 and 49. 
Between the first two spectra, the change in the aromatic system is pretty clear: from a five-proton 
system, which is present in compound 40, it was possible to obtain an AA’XX’ system for compound 43 
thanks to the Friedel-Crafts acylation, which clearly shows that the reaction occurs in the para position.  
The main differences between the second and the third spectrum, instead, are the presence of the 
morpholine protons in compound 49 (δ 3.6 and 2.4 ppm, 4 H each) and the down-shift of the signals of 
the linker between the aromatic system and the morpholine itself. In fact, from two triplets at δ 3.6 and 
3.4 ppm (2 H each) two triplets at δ 3.0 and 2.8 ppm were obtained. 
 
S
S
O Br
S
O N
O
40 
43 
49 
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PATHWAY 2.1:  
 
R1
O
H2N
R R1 N
R
MeOH
R1 NH
R
NaBH4
 
 
Reductive amination 
This pathway was the most extensively used one, because it consists of an efficient and easy way to 
produce imines and amines; since Fingolimod owns a primary amine on the “head”, the insertion of a 
nitrogen atom as an imine or an amine could help in detecting its role concerning the activity. This 
synthetic pathway, starting from a carbonyl group and a primary amine (1 equivalent each), leads to the 
production of a Schiff base through the attack of the electron-rich nitrogen atom towards the carbonyl 
carbon and its subsequent dehydration; the imine is then reduced to a secondary amine using a hydride (in 
this case sodium boron hydride, 2 equivalents).  
 
R1
O
H2N
R
R1 N
OH
R
H
H2O
R1 N
R
 
After the attack of the nitrogen atom on the electron-poor carbon, the obtained N-substituted hemiaminal 
loses water to give a Schiff base. This reaction is possible both with aldehydes and with ketones, even if 
the latter react slowlier76, and is carried out in methanol at 60°C. The addition of sodium boron hydride at 
0°C provides the reduction of the double bond and the obtainment of the secondary amine: 
R1 N
R
H H
B
H
H
H R1 NH
R
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The reduction proceeds thanks to the transfer of a hydrogen atom of NaBH4, with its electronic doublet, to 
the substrate that gets reduced. The reduction of the imine takes advantage of the fact that the imine is 
partly protonated as an iminium ion, that can be rapidly reduced to the corresponding amine77. The 
resulting BH3 species is technically able to transfer other hydrogen atoms and electrons, and so to reduce 
more imines. 
In some cases the isolation of the imine was possible, while sometimes it was not. The reasons behind this 
probably reside in the stability of the imine itself77 and in the presence of undesired water in the reaction 
environment that also could decrease the quantity of final amine. 
Several carbonyl substrates have been considered for this approach, for gaining as many pieces of 
structural information as possible: benzaldehyde, 2-naphthaldehyde, 2,4,6-trimethoxybenzaldehyde, N-
benzyl piperidone. In addition to this, also p-hydroxybenzaldehyde and 3,5-dimethoxybenzaldehyde were 
used, but in this case the hydroxyl group/groups were previously alkylated through the already reported 
Williamson reaction, using bromoalkanes of various lengths. This was meant in order to obtain a variation 
on the “tails” of the molecules, which could be combined to the insertion of the imine/amine on the 
“head” of the molecule. 
The considered primary amines are even more, and provide the insertion from none to two hydroxyl 
groups on the “head” of the molecule; the choice included also phosphorylatable substrates, which is 
supposed to be an unwanted phenomenon, but in this way the library which has been synthesized can be 
considered to be more complete and all the possibilities about structure-activity relationships can be 
explored. 
In the following tables, the compounds which were obtained following this synthetic pathway (both 
imines and secondary amines) are reported: 
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Compound structure 
and number 
IUPAC name 
N O
O
 
N-benzylidene-
2,2-
diethoxyethanam
ine 
N
H
O
O
 
N-benzyl-2,2-
diethoxyethanam
ine 
N
O
O
 
2,2-diethoxy-N-
((naphthalen-3-
yl)methylene) 
ethanamine 
N
H
O
O
 
2,2-diethoxy-N-
((naphthalen-3-
yl)methyl)ethana
mine 
N N
O  
N-benzylidene-
3-
morpholinopropa
n-1-amine 
N
H
N
O
 
N-benzyl-3-
morpholinopropa
n-1-amine 
 
Compound structure 
and number 
IUPAC name 
N
N
O
 
3-morpholino-N-
((naphthalen-3-
yl)methylene)pro
pan-1-amine 
NH
N
O
 
3-morpholino-N-
((naphthalen-3-
yl)methyl)propan-
1-amine 
 
N
OH
 
4-
(benzylideneamin
o)cyclohexanol 
N
H
OH
 
4-
(benzylamino)cyc
lohexanol 
N
OH
 
4-((naphthalen-3-
yl)methyleneamin
o)cyclohexanol 
N
H
OH
 
4-((naphthalen-3-
yl)methylamino)c
yclohexanol 
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Compound structure 
and number 
IUPAC name 
N NH
N
O
 
1-benzyl-N-(3-
morpholinopropyl
)piperidin-4-
amine 
N NH
O
O
 
1-benzyl-N-(2,2-
diethoxyethyl)pip
eridin-4-amine 
O
OO
H
N
 
N-(2,4,6-
trimethoxybenzyl
)prop-2-en-1-
amine 
O
OO
H
N
O
O
 
N-(2,4,6-
trimethoxybenzyl
)-2,2-diethoxy 
ethanamine 
O
H
N
 
N-(4-
ethoxybenzyl)pro
pan-1-amine 
O
H
N
OH
OH
 
2-(4-
butoxybenzylami
no)propane-1,3-
diol 
 
Compound structure 
and number 
IUPAC name 
O
H
N
OH
OH
 
2-(4-
pentyloxybenzyla
mino)propane-
1,3-diol 
O
H
N
OH
OH
 
2-(4-
(hexyloxy)benzyl
amino)propane-
1,3-diol 
O
H
N
OH
OH
 
2-(4-
(heptyloxy)benzyl
amino)propane-
1,3-diol 
O
H
N
OH
OH
 
2-(4-
(octyloxy)benzyla
mino)propane-
1,3-diol 
H
N
OH
O  
2-(4-
butoxybenzylami
no)ethanol 
H
N
OH
O  
2-(4-
(pentyloxy)benzyl
amino)ethanol 
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73 
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86 
87 
88 
89 
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91 
92 
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Compound structure 
and number 
IUPAC name 
H
N
OH
O  
2-(4-
(hexyloxy)benzylami
no)ethanol 
H
N
O
O
OH
 
2-(2-(4-
(pentyloxy)benzylami
no)ethoxy)ethanol 
H
N
O
O
OH
 
2-(2-(4-
(hexyloxy)benzylami
no)ethoxy)ethanol 
H
N
O
O
OH
 
2-(2-(4-
(heptyloxy)benzylami
no)ethoxy) 
ethanol 
O
H
N
O
O
 
N-(4-butoxybenzyl)-
2,2-
diethoxyethanamine 
O
H
N
O
O
 
N-(4-
(pentyloxy)benzyl)-
2,2-
diethoxyethanamine 
 
Compound structure 
and number 
IUPAC name 
O
H
N
O
O
 
N-(4-
(hexyloxy)benzy
l)-2,2-
diethoxyethana
mine 
O
H
N
O
O
 
N-(4-
(heptyloxy)benz
yl)--2,2-
diethoxyethana
mine 
H
N
O  
N-(4-
butoxybenzyl)pr
opan-1-amine 
H
N
O
N
O
 
N-(4-
(pentyloxy) 
benzyl)-3-
morpholino 
propan-1-amine 
H
N
O  
N-(4-
(hexyloxy)benzy
l)prop-2-en-1-
amine 
H
N
O  
N-(4-
butoxybenzyl)-
2-phenyl 
ethanamine 
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Compound structure 
and number 
IUPAC name 
NH
OO
(  )3(  )3  
N-(3,5-
dibutoxybenzyl)
-2-
phenylethanami
ne 
H
N
O  
N-(4-
(heptyloxy)benz
yl)propan-1-
amine 
 
Compound structure 
and number 
IUPAC name 
H
N
N
O  
N-(4-
(heptyloxy)benz
yl)-2-
(pyrrolidin-1-
yl)ethanamine 
H
N
OO(  )6 (  )6
  
N-(3,5-
bis(heptyloxy)be
nzyl)butan-1-
amine 
Table 5. Compounds obtained from the pathway 2.1. 
 
Characterization: a focus  
Some of the molecules belonging to this group were characterized in deeper detail, as can be seen for 
compound 97: 
O
H
N
O
OH
 
 
This compound was characterized not only by HRMS and 1D-NMR (1H and 13C), but also through 
bidimensional homocorrelated NMR spectra as CoSY (Correlation Spectroscopy) and NOESY (Nuclear 
Overhauser Effect Spectroscopy). This was meant in order to better elucidate the attribution of the 1H 
signals. 
In the CoSY experiment, the scalar coupling of protons is shown through cross-peaks on a 2D surface. 
The following image represents a zoom on the aliphatic part of the spectrum 
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Figure 13. CoSY spectrum of compound 97. 
 
This portion of the spectrum makes possible to identify the scalar coupling between the signals at δ 3.72 
ppm and the ones at δ 3.58 ppm, and between the signals at δ 3.62 ppm and δ 2.83 ppm. Since all of them 
are triplets and integrate for 2 H, they can be considered to be two distinct groups of CH2-CH2 protons. 
The only credible attribution that can be made is that these protons belong to the aminoethoxyethanol 
portion of the molecule. 
For getting a clearer idea about the attributions, a NOESY experiment was performed; in this case the 
homonuclear bidimensional spectrum takes into account the space proximity of the considered groups of 
protons, instead of their couplings through bonds. In the following image, a zoom on the aliphatic portion 
of the spectrum is reported. 
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Figure 14. Zoom#1 of the NOESY spectrum of compound 97. 
Here the cross-peaks show space closeness between the protons responsible for the signal at δ 3.76 ppm 
(s, 2H) with the proton at δ 3.36 ppm (bs, 1H), and also between the same signal at δ 3.76 ppm and the 
group at δ 2.83 ppm (t, 2H), which was present also in the previously shown portion of CoSY and was 
said to belong to the aminoethoxyethanol “head”. Because of the integrals, the molteplicity and the cross-
peaks, the signal at δ 3.76 ppm can be considered to belong to the protons in the benzylic position, the 
one at δ 3.36 ppm to the amine and the one at δ 2.83 ppm to the portion of aminoethoxyethanol which is 
closer to the nitrogen atom. 
 
Figure 15. Zoom#2 of the NOESY spectrum of compound 97. 
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The second NOESY zoom shows that the aromatic protons responsible for the signals at δ 6.85 ppm 
(AA’, 2H) are close to the protons at δ 3.95 ppm (t, 2H) while the aromatic protons at δ 7.23 ppm (XX’, 
2H) are close to the ones at δ 3.76 ppm, previously attributed to the benzylic group. The attribution of the 
aromatic protons can be explained considering the mesomeric and the inductive effects, keeping in mind 
that: 
- mesomeric (or resonance) effects are defined as the redistribution of electrons which takes place 
in unsaturated (and preferably conjugated) systems via their π-orbitals; the delocalization of 
electrons through resonance is the most powerful factor that affects the stability of molecules. 
Mesomeric effects are permanent polarizations in the ground state of the molecule, and in neutral 
compounds there will always be a +M group (the one that donates electrons) and –M group (the 
one that accepts them)79; 
- inductive effects are defined as the polarization of the electron density of a σ-bond caused by the 
electronegativity of a nearby atom; it is a polarization effect that proceeds from atom to atom 
along a chain, and that decreases as it proceeds away from the atom/group which produces it. In 
this sense, the groups of a molecule can be classified as +I (electron donating) and –I (electron 
attracting)79. 
In the molecule taken into account both the inductive and the mesomeric effects are present, because of 
the presence of electronegativity differences among close atoms and of the high possibility of 
delocalization π of electrons, respectively. However, inductive effects would deshield more the part of the 
aromatic system which is closer to the ether group, because of the electronegativity of the O atom, which 
is definetly higher than the one of the C atom in para; this would lead the aromatic protons in ortho to O 
to be present at higher ppm. On the other hand, mesomeric effects lead to the opposite result, because of 
the way π electrons can delocalize in the system, involving both the aromatic system and the lone pair of 
the nitrogen atom. Anyway, it is known by the literature that mesomeric effects are usually stronger than 
inductive effects and are more effective over longer distances79, so it is reasonable to see that the aromatic 
protons in meta to the O atom can be found at higher ppm than the ones in ortho. 
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Taken together, all of this information can lead to the following attribution of the signals for compound 
97: 
H
N
O
OH
d 2.83
d 3.62 d 3.72+3.58
d 3.36
O
d 6.85
d 3.95
d 7.23
d 3.76
d 0.91  
 
Another of the compounds synthesized with this approach is 71: 
 
N NH
N O
 
 
This compound was obtained by a reductive amination between 1-benzyl-4-piperidone and propylamino 
morpholine; it was chosen as an example compound for better elucidating structural and conformational 
characteristics because it owns structural features (e.g. propyl linker, morpholine, phenyl group …) which 
are detected also in other of the synthesized molecules, so it can be considered to be representative for 
almost all the structural features taken into account. The characterization of 71 was perfomed by NMR, 
and in particular 1H, 13C, CoSY and NOESY. 
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Figure 16. CoSY spectrum of compound 71. 
 
 
The experiment of Correlation Spectroscopy shows several cross-peaks (very crowded in the aliphatic 
part), relative to the scalar coupling of the protons belonging to the molecule; being more specific, the 
following signals are detected (values in δ, ppm): 
- 2.89 – 2.04 
- 2.81 – 1.81 
- 2.61 – 1.55 
- 2.61 – 1.95 
- 2.45 – 1.81 
- 2.45 – 3.71 
- 2.04 – 1.55. 
 
NOESY (Nuclear Overhauser Effect Spectroscopy) gave the spectrum which is shown in the following 
figure: 
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Figure 17. NOESY spectrum of compound 71. 
 
 
The following considerations can be made: 
- The singlet at δ 3.51 ppm cross-peaks both with the methylene at δ 2.04 ppm and with the 
methylene at δ 2.89 ppm; for its molteplicity, integral and δ, the singlet can be considered to be 
the signal of the benzylic methylene. This means that the signals at δ 2.04 ppm and δ 2.89 ppm 
both belong to the piperidine ring, in the ortho positions with respect to the nitrogen atom of the 
ring itself. 
- The signal at δ 2.89 ppm, apart from the previously described cross-peak, also gives a cross-peak 
with the methylene at δ 1.95 ppm; this means that the signal at δ 1.95 ppm still belongs to the 
piperidine ring. 
- The signal at δ 2.61 ppm (1H) cross-peaks both with the signal at δ 1.95 ppm and with the one at 
δ 1.55 ppm; these protons are likely to belong to the piperidine ring, in the further position from 
the nitrogen atom. 
- The signal at δ  2.45 ppm (6H, undefined molteplicity) cross-peaks with the signals at δ 1.81 
ppm (which also gave a CoSY cross-peak) and with the signals at 2.81 ppm (both integrating for 
2H each). These considerations make possible to attribute these six protons to the methylene of 
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the propyl region of the molecule and to the two methylenes of the morpholine which are closer 
to the nitrogen atom. 
- The signal at δ 2.45 ppm also cross-peaks with the one at δ 2.61 ppm, which was previously 
hypotesized to belong to the piperidine. 
 
Because of this, the signals can be attributed as follows (the arrows represent the NOESY detectable 
cross-peaks): 
 
 
 
With the aim of enhancing the characterization on the synthesized compounds, and gaining structural 
pieces of information about the possible conformation of the molecule and the reliability of the 
predictions that can be made about it, a further study was performed; getting reliable predicted 
conformations may be relevant because they could be later combined to the pieces of information gained 
from the structural study of the target, aim which is pursued in this project as well. In this case, the 
evaluation was made on the proton-proton distances; in fact, for some functional groups, these lengths 
were measured thanks to UCSF Chimera80 software in the here reported model, that was minimized in the 
MMFF94 force field through Avogadro81 software.  
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Figure 18. minimized conformation of 71. 
 
The calculated distances were then compared to the quantitative analysis of the NOESY spectrum signals, 
according to the formula82: 
 
rij = rref ∙6√( Iref /Iij ) 
 
where  
- rij: distance among two considered groups of protons; 
- rref: reference distance; 
- Iref: reference cross-peak integral; 
- Iij: integral of the signal corresponding to the considered protons. 
The reference protons need to be chosen: in this case, it was arbitrarily decided to consider the cross-peak 
between the ones at δ 3.51 ppm (benzylic position) and the aromatic ones in ortho position with respect to 
the benzylic protons themselves (the considered protons are shown in green in figure 19).  
 
 
Figure 19. Reference protons for compound 71. 
 
Actually, it is needed to consider the average of the measure of the distances between the two groups of 
protons, which computationally gives a theorical value of 3.1 Å (rref); the value of the corresponding 
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integral in the spectrum is 76.25 (Iref). The distances between proton groups were measured in the model 
using the tools that come with UCSF Chimera80 software; the integrals for the signals of interest, instead, 
were calculated by TopSpin (Bruker corporation), and are reported in table 6: 
 
 
 
Table 6: TopSpin calculated integrals. 
 
The proton-proton (non-bonding) interactions were measured in silico with Chimera and compared to the 
values coming from the previously reported formula (inserting the integrated areas of the cross-peaks of 
interest). 
Many evaluations can be made about these values, which are reported in the following table. For the 
considered bonds, the values found in silico and the ones measured by the equation seem to be quite 
parallel; so, even if this is only one example and the results can still vary, it is probably worthy to 
consider this kind of approach for further analysis and characterizations. 
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Coupling signals (ppm) Area 
Calcd. from 
NOESY length (Å) 
In silico calcd. lenght 
(Å) 
2.04 - (7.4-7.2) 7.45 4.6 4.7 
2.89 – (7.4-7.2) 19.45 3.8 3.7 
3.51 – 2.89 61.48 2.8 2.7 
3.51 – 2.04 41.41 3.0 3.2 
2.89 – 1.95 192.04 2.7 2.6 
2.89 – 1.55 176.08 2.6 2.6 
1.95 – 2.61 161.77 2.7 2.7 
2.61 – 2.45 140.89 2.8 2.8 
2.45 – 2.81 57.36 3.3 3.4 
 
Table 7. In silico and calculated values for the considered groups of protons. 
 
The reported values also confirm some of the attributions that were already assumed: first of all, that the 
protons at δ 1.95 ppm have a distance to the ones at δ 2.89 ppm which is compatible with the attribution 
which has already been made, i.e. two of the methylenes belonging to piperidine (in figure 20, the protons 
of interest are orange). 
 
 
 
Figure 20. Coupling proton group #1. 
 
In addition to this, it was possible to confirm the attribution of the signals at δ 2.45 ppm (6 H); the 
measured distances between it and the signals at δ 2.61 ppm (2.8 Å) and at δ 2.81 ppm (3.3 Å) is 
compatible with the attribution which has been previously made. Keeping in mind that the signal at δ 2.61 
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ppm was attributed to the only methylidene signal, and that the one at δ  2.81 ppm to the methylene 
belonging to the propyl chain in the closer position to the morpholine group, in fact, we can confirm that 
it is likely that the signal at δ 2.45 ppm comprises the methylenes of the morpholine which are closer to 
the nitrogen atom (cross-peak with the protons at 2.81 ppm), and also the methylene of the propyl chain 
bonded to the non-endocyclic nitrogen atom (cross-peak with the protons at 2.61 ppm) (in figure 21, the 
protons of interest are orange). 
 
 
Figure 21. Coupling proton group #2. 
 
A further step on the study of this compound was made through the use of docking tools: basically, the 
pursued attempt was to compare the computed structure with two other, but this time coming from 
molecular docking. Giving credit to the hypothesis that Fingolimod binds to SET38, here the attempt was 
to figure out if it is reasonable to think that also the synthesized analogs can bind SET, and how they 
change their conformation after doing that. For pursuing this aim, compound 71 was docked to the 
monomer SET form (coming from PDB ID 2E50, modified through USCF Chimera80 in order to remove 
water and ions) thanks to AutoDock83, and some proton distances were measured on the docked 
compound; the lower energy docking outcome is shown in the next figures. The choice of docking the 
substrate on the monomer first comes both for the sake of simplicity, and for the fact that little is known 
about the interaction between Fingolimod (or its analogs) and SET, so it is reasonable to exploit both the 
docking with the monomer and the dimer form of SET. The grid box is placed, in both the cases, on the 
whole protein. The reported aa residues have a distance inferior than 5 Å from the compound. 
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(a)                                                                   (b) 
Figure 22. SET monomer/71 docking (whole, a; zoom, b).  
Explicating the hydrogen atoms and isolating the molecule from the protein, but maintaining its 
conformation, the following result is obtained: 
 
Figure 23. Compound 71 isolated from figure 22. 
Since the very first glance, many differences are detectable in the disposition of the atoms in the space, 
when compared to the structure minimized through MMFF94 (figure 18). Then, the docking with the 
whole SET (i.e. the dimer form) was performed; reported aa residues have a distance inferior than 5 Å 
from the compound. 
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(a)                                                                                      (b) 
Figure 24. SET dimer/71 docking (whole, a; zoom, b).  
 
The docking site is different than before, since the molecule is placed between the two monomers that 
compose SET instead of involving the sharp bend of the monomer. As before, the molecule was isolated 
from the protein: 
 
Figure 25. Compound 71 isolated from figure 24. 
 
In both the models, the distances between some proton groups has been measured; this was made through 
UCSF Chimera, considering the average of the H-H distances for the atoms composing the considered 
groups themselves. The obtained values were then compared to the previously obtained ones. The 
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following table shows the outcome of these calculations, and it permits to make a few considerations 
about them. 
Coupling 
signals (ppm) 
Calcd. from 
NOESY length 
(Å) 
In silico calcd. 
lenght (Å) 
In silico calcd. 
lenght after 
docking (Å) with 
monomer 
In silico calcd. 
lenght after 
docking (Å) with 
dimer 
2.04 - (7.4-7.2) 4.6 4.7 6.5 6.5 
2.89 – (7.4-7.2) 3.8 3.7 5.2 5.3 
3.51 – 2.89 2.8 2.7 3.1 3.1 
3.51 – 2.04 3.0 3.2 3.6 3.6 
2.89 – 1.95 2.7 2.6 2.6 2.5 
2.89 – 1.55 2.6 2.6 4.3 4.3 
1.95 – 2.61 2.7 2.7 2.5 2.5 
2.61 – 2.45 2.8 2.8 3.8 3.2 
2.45 – 2.81 3.3 3.4 2.3 2.8 
 
Table 8. Comparison among in silico distances in compound 71 groups of protons (MMFF94, docking with SET monomer, docking 
with SET dimer). 
 
The distance between the reference protons is not changing in all of the three considered cases (it is 
computed to be 3.1 Å in all the simulations); however, the other distances seem to differ quite a lot 
between the MMFF94-minimized structure and the docked ones. Only a couple of values seem to 
correspond in the three columns, especially concerning the values corresponding to 2.89-1.95 and 1.95-
2.61 ppm cross-peaks, all belonging to the piperidine ring. The last two columns, i.e. the distances 
calculated for the two docked structures, are instead extremely similar one to each other, especially in the 
area that comprises the aromatic and the piperidine ring; the propyl linker part shows more differences. 
Moreover, the calculated binding energies are exactly the same (-5.7 kcal/mol)83. Even if it is too early to 
make considerations about these dockings, also because of the kind of resulting interactions (all 
hydrophobic), it is worthy to consider this kind of approach for further evaluations. The limited 
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conformational changes in the two output docks, at least concerning the considered distances, is an aspect 
that should be evaluated in the future for its role and reliability. 
These data need to be completed with experimental studies before considering them to be trustworthy; the 
most rational thing to do, once the protein is obtained in a sufficient amount, would probably be an NMR 
study of the hypothetical interaction between the compound and SET, in order to investigate whether this 
prediction in the variation of distances, i.e. this dramatic change in the structure, is affordable or not. The 
eventual confirmation of these data would be extremely helpful for improving the rationale of the design 
of further molecules. 
In the following image, the three conformations of compound 71 are superimposed: in grey, the 
MMFF94-minimized structure; in orange, the compound docked to SET in its monomer form; in dark 
red, compound 71 docked to the dimer form. 
 
 
Figure 26. Superimposed 71 structures. 
 
The grey one was not expected to share structural features with the other two, since the distances which 
were measured are pretty different, as already commented; in addition to this, from a very qualitative 
point of view, it is possible to see that the orange and the dark red structure develop in the same direction 
in a more similar manner than the grey one. However, they do not overlap precisely in the expected areas, 
even if they have comparable distances among H groups. 
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Figure 27. Superimposed 71 structures, excluding the MMFF94 obtained one. 
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PATHWAY 3: 
 
OHO
OH
O
1. SOCl2
2.
O
O
HN
N
N
 
This pathway, which involves phenyl malonic acid, leads to the obtainment of compounds which seem to 
be slightly detached from Fingolimod structure. Since the main aim of the performed explorative 
approach presented in this thesis is to provide a library of FTY720 analogs with modulated structural 
features, the insertion of variables – even if extensive - is reasoned and performed in order to improve the 
knowledge about the actual groups of interest or the molecules to be active. Here, the effect of the total 
absence of the aliphatic “tail” in the molecule, while maintaining the aromatic ring which characterizes 
Fingolimod and most of the analogs reported in this thesis, was the subject of evaluation. In addition to 
this, the carboxyl acid residues are reacted with morpholine or piperidine for the same reasons explained 
for pathway 1.1: morpholine owns a non-phosphorylatable oxygen atom, which could help in elucidating 
the role (or the lack of it) of this atom per se and not because it is prompt to phosphorylation. Piperidine 
is used in the same way as a sort of negative control of this eventual effect. 
First of all, the acid needs to be activated to the correspondent acyl chloride through the use of a large 
eccess of thionyl chloride, which also acts as a solvent for the reaction. The activation is carried on at 
60°C and it arrives to completeness in around 1 h. The formation of the product is monitored by TLC, 
dropping a small amount of the reaction crude in 2 mL of EtOH; in this way the ester of the acid is 
formed, and it is easier to see it on a TLC plate (hexane/ethyl acetate 4:1) because of its higher Rf when 
compared to the acyl chloride as it is. 
OH
O
Cl
S
Cl
O
R O
S
Cl
OO
HCl
R O
S
Cl
OO + HCl
 
R O
S
Cl
OO + HCl
R O
S
Cl
OO
H
Cl
R O
S
Cl
OO
H
Cl
R Cl
O
+ HCl + SO2
 
110 
86 
 
The reaction brings, at the beginning, to the formation of an acyl chloro sulphite: this converts the 
hydroxyl group, a poor leaving group, into a chloro sulphite group, a more stable anion77. After that, a 
chlorine atom (resulted as a byproduct) attacks the carbonyl carbon for giving an intermediate of reaction 
which rearranges and gives the acid chloride, sulphur dioxide and hydrochloric acid77. 
The solvent is then removed through a nitrogen flux and the crude can be used without further 
purifications. At this point, the acyl chloride can be easily attacked by the nitrogen atom of the 
morpholine (2 equivalents) or of the piperidine (2 equivalents). 
R Cl
O
X
H
N
R N
O
X
 
The reaction is carried out in toluene in the presence of triethylamine (2 equivalents) in order to buffer the 
hydrochloric acid which is produced during the reaction. 
 
The obtained compounds are shown in the following table: 
 
Compound structure 
and number 
IUPAC name 
O
N
O
O
N
O  
2-benzyl-1,3-
dimorpholinopropan
e-1,3-dione 
O
N
O
N
 
2-benzyl-1,3-
di(piperidin-1-
yl)propane-1,3-
dione 
 
Table 9. Compounds obtained with the synthetis pathway 3. 
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PATHWAY 4: 
R
H
HO
O
H2N NaOH
O
R1
OH
HO
O
R NH2
R1
H2O/MeOH
 
This reaction was used to insert amino acidic “heads” on the substrates of interest. Maintaining a scaffold 
which is pretty similar to the already seen ones, and always inspired by Fingolimod, a modified 
Knoevenagel reaction was performed following the procedure reported by Portelli 84; in practical terms, 
this means that the reaction stops at the nucleophilic attack instead of prosecuting until the dehydration of 
the product, as the original Knoevenagel should provide77. Basically, the first step occurs in an aqueous 
solution of sodium hydroxide in order to deprotonate the α-carbon of the aminoacid of interest (and, of 
course, its carboxylic group which however is not involved in the reaction). 
R
H
HO
O
H2N NaOH
R
O
O
H2N
 
In this way, the carbanion which is originated can attack an electron-poor aldehydic carbon. 
NH2
O
O
R
O
R1
O
O
O
R NH2
R1  
The subsequent addition of hydrochloric acid allows the re-protonation of the hydroxyl groups. It is not 
probable that the newly inserted hydroxyl groups could be a substrate for SKs, even if placed in a similar 
position of Fingolimod: in fact, the carboxylic acid is likely to be deprotonated at physiological pH, so the 
addition of a phosphate group (which carries another negative charge) is not probable. 
The first aldehyde taken into account in this pathway was p-anisaldehyde, because the optimisation of the 
reaction requested a simple scaffold to start from. Since the main issue was to differentiate the 
phosphorylatability and the polarity of the compounds, the amino acids which have been chosen were 
glycine, tyrosine and serine; another point which was considered was the content of both heteroatoms and 
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aliphatic/aromatic portions, and these three amino acids are sufficiently different in all of these 
characteristics. This reaction was also performed on 2,4,6-trimethoxybenzaldehyde and on previously 
alkylated (for the procedure, see pathway 1.1) p-hydroxybenzaldehye, using glycine as an amino acid. 
The following table shows the obtained compounds: 
Compound structure 
and number 
IUPAC name 
O
NH2
HO OH
O
 
2-amino-3-
hydroxy-3-(4-
methoxyphenyl) 
propanoic acid 
O
HO
H2N
OH
O
OH
 
2-amino-3-
hydroxy-2-
(hydroxymethyl)-3-
(4-methoxyphenyl) 
propanoic acid 
O
HO
H2N
OH
O
OH
 
2-(4-
hydroxybenzyl)-2-
amino-3-hydroxy-
3-(4-
methoxyphenyl) 
propanoic acid 
O
HO
OO
H2N
OH
O
 
2-amino-3-
hydroxy-3-(2,4,6-
trimethoxyphenyl) 
propanoic acid 
 
Compound structure 
and number 
IUPAC name 
HO
NH2
O
OH
O  
2-amino-3-(4-
(hexyloxy)phen
yl)-3-hydroxy 
propanoic acid 
HO
NH2
O
OH
O  
2-amino-3-(4-
(heptyloxy)phen
yl)-3-hydroxy 
propanoic acid 
HO
NH2
O
OH
O  
2-amino-3-
hydroxy-3-(4-
(octyloxy)phenyl)
propanoic acid 
Table 10. Compounds obtained with pathway 4. 
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PATHWAY 5: 
 
OH
OH POCl3
O
P
O
Cl
O
N
H
O
N
O
O
P
O
O
 
 
This last pathway provides the synthesis of a cyclic phosphodiester, which is subsequently reacted with 
one of the products which were already obtained with a previous synthetic scheme (pathway 2.1). This 
compound can be considered to be a model for further derivatives. In this case, the decision of inserting a 
phosphorus atom was taken, even if the main aim of these synthetic schemes is to have compounds which 
are not likely to be phosphorylated. The insertion of this group by purpose is performed because in this 
way the role of a phosphorus atom could be evaluated per se, avoiding the negative charge. Basically, not 
having the negative charge of the phosphate could be a pro because both PP2AC and SET have an acidic 
pI (calculated around 5 and 4, respectively85), which is not likely to provide a good interaction with a 
negatively charged molecule (as Fingolimod-P is); to prove this hypothesis, it is worthy to consider the 
presence of a phosphorus atom lacking the negative charge and to evaluate its activity. 
2,2-dimethyl-1,3-propandiol (1 equivalent) is reacted with phosphorus (V) oxychloride (1 equivalent) in 
Et2O as described by Huttunen86 to obtain the cyclic phosphodiester through the following mechanism: 
 
OH
OH
P
ClCl
Cl
O
O
P
O
Cl
O
OH
O
P
Cl
O
Cl
 
The hydroxyl groups can, one after the other, attack the phosphorus atom and lead to the exit of Cl- ions. 
The presence of triethylamine (2 equivalents) in the reaction mixture buffers the pH, which could 
decrease because of the production of hydrochloric acid.  
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The remaining chlorine atom of the phosphodiester (2 equivalents) can be easily substituted by a 
secondary amine as the one which is present on compound 86 (1 equivalent), which was synthesized 
following the synthetic pathway 2.2. 
 
O
P
OCl
O
NH
O
N
O
P
O
O
O
 
Once again, Cl- acts as a leaving group; the reaction is carried out in toluene, and the addition of calcium 
carbonate (2 equivalents) buffers the acid which is obtained as a byproduct. 
 
Compound structure 
and number 
IUPAC name 
N
O
P
O
O
O
 
2-((4-
ethoxybenzyl)(propyl)amino)-
5,5-dimethyl-1,3,2-
dioxaphosphinane 2-oxide 
 
Table 11. Compound obtained with pathway 5. 
126 
91 
 
2.2 RATIONALE OF THE RECOMBINANT PROTEIN PRODUCTION 
 
This part of the project, performed at the laboratories of Diamond Light Source and the Research 
Complex at Harwell, Didcot, Oxfordshire (UK), under the supervision of Dr. Marco Mazzorana aimed at 
the production of recombinant proteins to be used for biochemical and biophysical assays as well as for 
structural characterization of the PP2A-SET interaction. Well-estabilished molecular biology 
protocols87,88 were optimized for this specific case to obtain large quantities of purified proteins, 
especially needed for christallographic experiments. 
 
2.2.1 High throughput cloning of PP2AC and SET 
The first step for obtaining the recombinant forms of the proteins consisted in the amplification of cDNA 
encoding for SET or PP2AC through PCR (Polimerase Chain Reaction). The genes were inserted in 
pOPIN expression vectors available from OPPF-UK (Oxford protein production facility)89. This choice 
allows to perform all the phases of cloning, expression and purification tests with a high throughput 
format using robotic instrumentation and support. In addition, the selected vectors used for 
overexpression in E.coli, is also suitable for expression in insect cells with the baculovirus technique as 
well as for transfection in cultured human cells. Overexpression in bacteria or insect cells is required for 
structural investigation such as chrystallography, and the possibility of transfection of human cells with 
the same vectors opens the possibility of using the same constructs to gain a deeper understanding of the 
physiological role of the proteins as well as for in vitro PP2A activation studies. Most of the chosen 
expression tags can also be easily and precisely cleaved during the purification steps by treatment with a 
His6-tagged human rhinovirus 3C protease, which is easy to produce and to remove once it is no more 
needed. The cloning strategy for SET, starting from the vector provided by the group of Prof. Masami 
Horikoshi, maintained the additional His6 tag and thrombin cleavage site at the N-terminus of the protein 
sequence. As for PP2AC, the cDNA sequence was designed applying a codon-optimization algorithm to 
avoid the usage of rare codons and the company Genscript synthesized the whole sequence ex novo 
within a carrier vector we used as a template.The chosen vectors provide the coding for the POI with six 
different tags, resulting in 12 constructs as shown below: 
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Construct A5 - pOPIN-F-PP2AC (His6-3C-PP2AC,1-245) 
Construct B5 - pOPIN-J-PP2AC (His6-GST-3C-PP2AC,1-245) 
Construct C5 - pOPIN-M-PP2AC (His6-MBP-3C-PP2AC,1-245) 
Construct D5 - pOPIN-S3C-PP2AC (His6-SUMO-3C-PP2AC,1-245) 
Construct E5 - pOPIN-E-PP2AC (PP2AC,1-245-His6) 
Construct F5 - pOPIN-eGFP-PP2AC (PP2AC,1-245-3C-eGFP-His6) 
Construct A6 - pOPIN-F-SET (His6-3C-His6-Thrombin-SET1-225) 
Construct B6 - pOPIN-J-SET (His6-GST-3C-His6-Thrombin-SET1-225) 
Construct C6 - pOPIN-M-SET (His6-MBP-3C-His6-Thrombin-SET1-225) 
Construct D6 - pOPIN-S3C-SET (His6-SUMO-3C-His6-Thrombin-SET1-225) 
Construct E6 - pOPIN-E-SET (SET1-225-His6) 
Construct F6 - pOPIN-eGFP-SET (SET1-225-eGFP-3C-His6) 
The choice of vectors allowed placing a hexa-histidine tag both at the N-terminus (pOPINF, -J, -M and 
S3C) and at the C-terminus for purification on immobilized metal affinity chromatography (IMAC). In 
addition to this, solubilizing tags such as glutathione S-transferase (GST), maltose binding protein (MBP) 
and SUMO (Small Ubiquitin-like Modifier) were added to improve expression and solubility, while eGFP 
(endothelial Green Fluorescent Protein) was designed to provide a fluorescent probe for in vivo 
experiments. The cDNA coding for PP2AC and SET was amplified by PCR and integrated in the host 
vectors (previously linearized with KpnI and HindIII restriction enzymes) using the InFusion technology 
(Clontech Laboratories, Inc.). The cloning mixtures were then used to transform One Shot OmnimaxII 
supercompetent E.coli cells (Invitrogen), a high competency strain which can yield above 109 colonies 
per µg of plasmid. Omnimax also contain a deletion for the endogenous -galactosidase gene (lacZ), 
allowing for blue/white screening of colonies; in the absence of the inserted gene, pOPIN plasmids 
complement the lacZ gene, allowing the bacteria to degrade X-gal to a dark blue product and resulting in . 
blue colonies when bacteria are cultured on solid media selective for the vector (presence of carbenicillin) 
and X-gal. If the gene of interest has been inserted in the vector, this cannot complement lacZ and the 
colonies will remain white. In this way colonies can be isolated, amplified by growing the bacteria in 
liquid medium (usually LB or PB broths), and the plasmid can be purified on ion exchange magnetic 
DNA mini-prep columns using the Bio-Robot 8000 (Qiagen) of OPPF-UK equipped with magnetic beads 
(Agencourt AMPure XP, Beckman Coulter). 
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The presence of the desired construct can be verified through a hybrid PCR, which uses a forward primer 
specific for the vector (pOPIN-Forward) and a reverse primer specific of the cloning. Qualitative 
assessment is then possible by running the PCR products on 1% agarose-TAE gel electrophoresis to show 
the presence of an amplification product of the expected size (given by the sum of sizes of the tag and of 
the gene of interest). As shown by the following gel (Figure 28), all clonings gave satisfying results and 
the purified plasmids were sequenced to confirm that the insert was in a frame with the expression vector 
and did not contain any undesired mutations. 
 
 
Figure 28. HTP mini-prep verification through agarose electrophoresis. 
Stocks of the positive clones were stored in 100 μL aliquots at -80°C as glycerol stocks (30%w/v glycerol 
final) to conveniently archive a stable source of plasmid for future needs. 
  
2.2.2 Recombinant protein expression 
As mentioned above, the chosen vectors allow the expression of recombinant protein in the most 
commonly used bacterial system, E. coli. Once a suitable expression strain is identified from small-scale 
cultures, the production of the protein can be scaled up to litres of cultures, usually yielding several 
milligrams of protein. Some targets, however, might not get expressed in prokaryotic cells or need post-
translational modifications which are only available in higher complexity systems. The vectors of the 
pOPIN suite have been chosen to expand the possibility of expression systems to insect and human cells 
in culture. This choice has revealed to be particularly important for PP2AC, which has been shown to 
express using the baculovirus technology in Hi-5 cells90. 
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The purified plasmids containing the genes of interest were then used to transform two strains of E. coli, 
optimized for the expression of proteins: Rosetta2 (DE3), especially suitable for the expression of human 
proteins, and Lemo21 (DE3), a BL21 (DE3) analogue providing fine tuning of expression and 
recommended for proteins showing toxic effects in overexpression. Colonies obtained were grown in 
high-throughput format and the protein expression was either induced by addition of IPTG (in PB media) 
or auto-induced (AI medium) overnight. These cells wereused for small-scale IMAC purification on Ni-
NTA magnetic agarose beads (Qiagen) through the Bio-Robot 8000; once again, a library of glycerol 
stocks was produced. 
The presence of the proteins in the purified soluble fraction of bacterial lysates was assessed by SDS-
PAGE, which showed that two of the constructs for SET were obtainable in good quantities: C6 (pOPIN-
M construct, carrying the solubilizing His6-MBP tag upstream of the protein sequence) and D6 (pOPIN-
S3C construct, with a solubilizing His6 SUMO tag at the N-terminus). The results were satisfying both for 
Lemo21 and for Rosetta2 cells, and both for the cells grown in PB and AI media. In the case of construct 
C6, which is supposed to have a MW of about 70 kDa (SET+MBP), the gel shows a single band just 
above 66 kDa; D6 shows a band between 45 and 55 kDa, confirming the presence of the construct should 
have a MW around 43 kDa (SET+SUMO). The electrophoretic mobility of this last construct is decreased 
due to the high content of acidic residuesof both SET and SUMO (pI~4), resulting in a higher apparent 
MW for D6. This characteristic is not so evident for C6.  
For what concerning the expression of PP2AC, no samples gave satisfying results in E. coli: this is not 
totally a surprise, since the structures reported in literature for PP2AC 91,92 have been obtained from 
samples expressed by baculovirus. In addition to this, many of them are co-crystallized at least with a 
regulatory subunit of the B family (e.g. PDB ID 2NPP, 3C5W, 3DW8, 3FGA and more) which is likely 
to provide some degree of stability to the whole structure. The choice of pOPIN vectors shows here its 
rationale, of opening to further screening of the construct in insect cells, which will be described in more 
detail later. 
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Figure 29. HTP by Ni2+-NTA of the obtained proteins (Rosetta2, AI medium). 
 
2.2.3 Scale up of expression 
These small scale results, verified by SDS-PAGE, lead to the selection of the samples for the scaling-up; 
in the preliminary phase, few mL of cell culture are lysed and protein purified by affinity only. Only the 
products showing high concentration, the correct MW and the absence of degradation are considered for 
scale-up usually at the 1÷10 L culture scale. After evaluating these factors, Rosetta2 cells transformed 
with clones C6 and D6 were considered for the scale-up, since they displayed the best overall expression 
levels. The corresponding samples from glycerol stocks were cultured overnight in medium scale to 
provide a pre-culture suitable as a starter for the expression of 12 x 1 L of autoinduction medium93. Once 
large-scale cultures were harvested, cells were stored at -80°C until the day of purification and 
overexpression of the desired was verified via SDS-PAGE on the total cell content, compared to that of 
cells not harbouring the plasmid for the protein of interest.  
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2.2.4 Purification strategy 
The purification protocol applied here can be considered a general method for protein purification, and it 
involves three main steps: 
1. IMAC purification: this exploits the capacity of polyhistidine tags to coordinate divalent cations. 
Usually the protein carrying a His6-tag is bound to a polysaccharide matrix functionalized with 
nitrilotriacetic acid and chelating Ni2+. Elution is usually performed by competition with imidazole in 
high concentrations. 
2. Tag cleavage and removal: the His6-tag used to purify the sample, sometimes also supplemented by a 
bulky to solubilize the protein of interest, needs to be removed. The constructs have been designed to 
integrate a cleavage site for thrombin or for the rhinovirus 3C protease. These enzymes recognize 
specific sequences within the protein and cleave precisely at that level. A mild overnight treatment of 
the fusion protein is sufficient to convert this into the untagged protein of interest, separated from the 
tag. This can be removed by a further reverse-affinity step or exploiting the difference in size with the 
protein of interest.  
3. Size-exclusion (or gel filtration) chromatography: partially purified protein mixtures can be 
conveniently separated in their key components due to their differences in size. The retention is longer 
for the smaller molecules, which elute slower, than for the bigger ones, which remain in the column 
for shorter times. Given the difference in size between SET or PP2AC and the tags provided by the 
cloning vector, a convenient separation strategy would be that of gelfiltration. This also allows to 
remove uncleaved proteins, whose MW results from the sum of that of the protein of interest and of 
the tag, as well as to exchange the buffer to the one selected for protein storage. 
Proteins are thus concentrated to 10÷100 mg/mL, divided in small volume aliquots (25 µL), flash frozen 
in liquid nitrogen and stored at -80°C. 
 
2.2.5 Purification of Sumo-tagged SET (D6 deriving samples)  
The purification protocol for His6-SUMO tagged SET from Rosetta2 cells was estabilished in three major 
steps: 
- Affinity chromatography on HisTrap column (GE Healthcare); 
- Dialysis and tag cleavage (3C protease treatment); 
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- Size exclusion chromatography.  
The affinity chromatography purification exploited the hexa-histidine stretch placed at the N-terminus of 
the SUMO tag itself, conferring to the protein affinity for immobilized Ni2+. The purificationccolumn is a 
prepacked matrix of Ni2+-immobilized Sepharose, which binds the His-tagged proteins selectively, 
allowing non-tagged proteins to be washed off. The His6-tagged proteinis conveniently detachted by 
addingto the buffer a sufficient amount of imidazole to compete for the Ni2+coordination sites (250 mM). 
During the chromatographic steps, performed on an automatic FPLC system (GE healthcare) the presence 
of protein was indicated by the level of absorbance at 280 nm as shown in Fig. 30. In the case of the 
purification reported, washes were performed by stepwise increases of imidazole concentration in the 
buffer and elution of the protein was obtained at 250 mM imidazole.  
 
 
 
Figure 30. Ni2+-NTA purification of D6 samples. In blue, the absorbance; dotted in green, the percentage of NPI-250. 
 
The promising fractions were then analyzed by SDS-PAGE as reported in Fig. 31. A protein displaying 
the expected MW for the protein of interest is clearly present throughout the elution peak. The same 
protein also elutes in the wash step, probably because the capacity of the column was not sufficient to 
retain all molecules of SET present in the lysate.  
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Figure 31. Purification result and cleavage attempt. 
 
The fractions from the peak were treated overnight with 3C protease at 4°C to remove the tag. This 
resulted in the cleavage of the protein into smaller ones which in SDS-PAGE displayed a lower MW and 
correspond respectively to SET (28 kDa, apparent MW 35 kDa due to the acidic pI) and SUMO (15 kDa), 
(as shown in Fig. 31 – lane “B4 + 3C protease”).  
Tag cleavage was performed while dialyzing the protein against a buffer without imidazole, in order to 
reduce the concentration of the eluting agent which often decrease protein stability in the long term. 
The last purification step consisted in a size-exclusion chromatography on a crosslinked dextran matrix. 
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Figure 32. Gel filtration result. 
 
SDS-PAGE clearly shows that the protein had been purified (D7 to D1 in Fig. 32), and SUMO was 
efficiently separated (E10 in Fig. 32). Higher molecular weight bands were visible in the gels for the less 
pure fractions, discarded as not sufficiently pure although the bands are possibly due to the spontaneous 
formation of SET multimers. The retention volume of SET was used to estimate the molecular weight 
from the gelfiltration column calibration profile and strongly suggests that the protein in fractions D7-D1 
is in a dimeric state. This is confirmed by previous literature94 that describes SET as a protein which 
exists in solution, and crystallizes (PDB ID: 2E50), as a dimer. The central fractions of the peak were 
estimated to be >95% pure from band densitometry and the total concentration of SET was measured by 
its absorbance at 280 nm by NanoDrop in 0.35 mg/mL (12 μM). This corresponds to 2.5 mg of clean SET 
in the 7 mL of purified sample, which was concentrated to approx. 10 mg/ml, aliquotedto 25 µL and 
stored at -80°C. 
To assess the real MW of the protein, the stored sample was subjected to HRMS: being more specific, 
SET was concentrated at 25 μM in a solution of ammonium acetate 150 mM. In this case, the mass 
spectrum was run using positive ionization in denaturant conditions (acetonitrile/0.1% aqueous formic 
acid, 1:1 ratio). The obtained spectrum was automatically deconvoluted and shows that the main signal is 
the one corresponding to SET (28599 Da). 
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Figure 33. Deconvoluted mass spectrum for D6-derived SET. 
 
2.2.6 Purification of MBP-tagged SET (C6 deriving samples) 
The purification of protein expressed by the C6 clones Rosetta2 cells, was initially performed as 
described for the SUMO-tagged version of the protein. Despite the large amounts of initial material (band 
densitometry of total lysate expression gels shows C6 expressed at least 3 times more protein than D6), 
the same purity was hardly achieved. This is particularly clear from the gel filtration step: after tag 
cleavage, both the chromatograms and the SDS-PAGE analysis show co-elution of SET with MBP. The 
reason for this is clear if we consider again the spontaneous dimerization of SET, whose dimer has 
comparable MW to that of the MBP tag. 
As shown in Fig. 34, SET elutes earlier than MBP. This supports the idea of its dimeric state: given that 
SET dimer should have a MW of around 56 kDa (2x28 kDa), this elutes earlier than MBP, which has a 
MW of 42 kDa. To confirm that SET behaves in solution as a dimer, analytical gelfiltration on a column 
calibrated with MW standards and coupled with a MALS detector, showed that the peak of a purified 
protein corresponds to an object of approximately 55 kDa. 
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Figure 34. Gel filtration result on C6 samples. 
The sample purified following the strategy designed for SUMO-tagged SET remains heavily 
contaminated with what is believed to be proteins aspecifically bound to the HisTrap column. Because of 
this, purifications were repeated in different conditions to try improving the purity of the final sample but 
with no success. Increasing of the salt concentration in the affinity or gel filtration buffers to contrast 
electrostatic interactions between proteins and resin, as well as a second affinity column for MBP did not 
produce better quality samples. Also also a Co2+ affinity chromatography was attemped, exploiting the 
lower affinity of Co2+ for His-tags (when compared to Ni2+) in the attempt of getting rid of aspecifically 
binding proteins, but also this approach was not successful. 
The final breakthrough was achieved by two modifications to the protocol: 
- Increasing the starting material to limit aspecific binding at early stage; 
- Tag cleavage with thrombin, followed by reverse affinity purification. 
Since SET has been reported to crystallize from solutions 70 mg/mL, the aim of obtaining at least 100 mg 
was pursued, so 12 x 1L cultures of Rosetta2 in autoinduction media were settled up and purified. This 
required scaling up the amount of resin used: 5 mL columns still showed lots of His6-MBP-SET in the 
flow through, and for this reason the flow through was loaded repeatedly on re-equilibrated 5 mL HisTrap 
columns and eluted with imidazole until the SDS-PAGE analysis showed no more protein in the unbound 
fraction. This procedure was completed with 8 passages and the total volume of eluted protein was 
approximately 300 mL with an average concentration estimated in 5 mg/mL (1.5 g protein overall). 
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In order to remove the tag efficiently, the procedure was modified and rhinovirus 3C protease cleavage 
was modified to thrombin treatment. In this way, the construct His6-MBP-3C-His6-thrombin-SET1-225 
could effectively be separated from both polyhistidine tags, eventually removed by means of reverse 
affinity, passing the proteolysed mixture on the same HisTrap affinity resin used at the beginning of the 
purification. For this step, however, the competing imidazole in the elution buffer needs to be removed 
from the protein solution to allow His-tagged constructs to bind the resin. 
Given the large amount of eluted protein, the most efficient way was to dyalise the fractions eluted from 
HisTrap against a buffer containing no imidazole, while performing the cleavage with thrombin. The 
sample was pooled and dialysed twice overnight against 7 volumes of buffer to reduce the imidazole 
concentration to approx. 5 mM (7x7 folds dilution from initial 250 mM). As shown in Fig. 35a, the 
cleavage with thrombin was monitored by SDS-PAGE and required a very large amount of enzymes 
(over 200 units added also at the end of the dyalisis process). Finally, the completely proteolysed sample 
was passed on a 40 mL HisTrap column refluxing for 24 hours to bind all the tagged proteins (Fig. 35b). 
          
(a)                                        (b) 
Figure 35. SDS-PAGE analysis of the cleavage of the obtained construct with thrombin at different concentrations (a), and reverse 
affinity outcome (b). 
 
The sample obtained through this procedure was much purer than in the previous attempts of purification 
and required only a final polishing step by gelfiltration to remove small amounts of impurities including 
thrombin, which not being His6-tagged cannot be eliminated through reverse affinity chromatography. 
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Once again, the large amount of sample could not be loaded in the size-exclusion column as such, but 
needed to be concentrated at least 10 times. Given the limited capacity of the column used (max 5 mL of 
protein solution and less than 100 mg), the sample was split in 6 aliquots each one purified in successive 
gel filtration runs. The purity of the sample, quantified by SDS-PAGE band densitometry is >90% (Fig. 
36) and perfectly comparable to the previous report by Muto and co-workers95. 
The purified sample was pooled and concentrated to approximatively 4 mL and the concentration of the 
protein was estimated in 84 mg/mL from measurements of absorbance at 280 nm. The sample, divided in 
42 x 100 μL aliquots was frozen in liquid nitrogen and stored at -80°C for structural and functional 
analysis. 
 
 
(a) 
 
(b) 
Figure 36. SDS-PAGE of gel filtration fractions (a) and quantitative evaluation of the resulting bands (b). 
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2.3 RESULTS AND DISCUSSION 
 
2.3.1 Biochemical assays on the synthesized compounds and perspectives 
 
During these years a library of compounds was synthesized and characterized. The molecules have been 
designed keeping in mind Fingolimod structure, with the aim to isolate its pro-apoptotic and potentially 
anti-tumor effect from the immunosuppressive one. This meant maintaining most of the times the 
aromatic di-substituted ring, modulating structural characteristics as the lenght of the “tail” (or even its 
presence/absence), or the polarity, hindrance and, above all, phosphorylatability of the “head”. The 
variations taken into account brought to the creation of a panel of molecules, sometimes quite dissimilar 
one to the other, for obtaining from them the most in terms of structure-activity relashionships (SAR). 
Many of the compounds were assayed at the Department of Molecular Medicine, University of Padova, in 
the laboratory of Prof. Brunati. The most promising results were obtained with the compound 100, 
published as MP07-66 (N-(4-(hexyloxy)benzyl)-2,2-diethoxyethanamine)70: 
O
N
H
O
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PP2A/SET complex was isolated from B cells from 42 untreated CLL patients and 6 normal volunteers, 
through anti-PP2A polyclonal antibody precipitation. The complex was then treated with increasing 
concentrations of different compounds, and the dissociation between PP2A and SET was evaluated 
through immunoprecipitation. As can be seen (figure 37), this compound can lead to the disruption of the 
complex. 
 
Figure 37. Evaluation of the disruption of PP2A/SET complex. 
MP07-66 
105 
 
The following step was the evaluation of the restoration of PP2A activity after the disruption of the 
complex. For doing this, the PP2A/SET complex treated with the compounds was evaluated for the 
capability of dephosphorylating the anti-apoptotic enzyme p-Akt, one of the main substrates of PP2A; 
once dephosphorylated, the enzyme is inactive and cannot perform its anti-apoptotic effect. As shown by 
densitometry on Western blot (figure 38), the increasing of the concentration of compound MP07-66 
leads to the dephosphorylation of Akt and this can be considered an indirect proof of the reactivation of 
PP2A. 
 
Figure 38. Evaluation of the reactivation of PP2A through Western blot. 
 
Finally, the factual effect on the whole cell was tested in order to see if its capability to die is restored 
after the treatment with the compound of interest. So it is, since the percentage of apoptotic cells increases 
with the increasing of the concentration of MP07-66 (figure 39). All of this makes possible to say that this 
compound can destroy the complex between PP2A and its inhibitor SET, and this fact provokes the 
reactivation of PP2A and ends with the death of the cell. 
 
 
Figure 39. Percentage of apoptotic cells vs MP07-66 concentration. 
 
In order to integrate the pieces of information obtained through these assays, the co-crystallization 
between the compound and the target would be a real improvement; basically, the main hypothesis about 
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the interaction between Fingolimod and PP2A/SET complex is that Fingolimod acts on SET and binds 
it38, but it still has to be confirmed. In addition to this, the analogs described in this thesis could act in a 
different manner than the molecule they are inspired to. Obtaining the POIs in a sufficient amount to try 
to co-crystallize them with the small molecules, could help in elucidating this point. 
The obtainment of the actual structures could also have another consequence, i.e. approaching molecular 
modeling tools for the design of future compounds. The lack of structural data about PP2A/SET complex 
and the way it potentially interacts with other substrates, indeed, renders the molecular docking quite 
difficult to perform, and in these conditions its reliability could be a matter of discussion. In the 
beginning, the dock between SET (PDB ID: 2E50) and MP07-66 was performed through the use of 
AutoDock83 and elaborated with UCSF Chimera80. SET protein structure is registered as a dimer on PDB, 
but for the sake of simplicity at the very beginning the monomeric form of SET was considered. The grid 
box was placed on the whole monomer, since the docking site is not known yet. 
 
 
(a)                                                              (b) 
 
Figure 40. SET monomer/MP07-66 docking (whole, a; zoom, b).  
As shown in the images above, the molecule seems to allocate in the sharp-bend of the protein; the 
labeled aa residues are the ones that have a distance <5Å from MP07-66 (Phe63, Arg66, Leu69, Ile70, Lys72, 
Phe76, Leu161, Pro174, Asn175, Pro176, Leu177, Tyr180, Leu181). Many of these 13 residues are hydrophobic, 
with only two charged aa (Arg, Lys) and two polar aa (Asn, Tyr). 
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However, SET protein is registered on PDB as a dimer, so the docking was then performed on the whole 
reported structure (placing again the grid on the whole macromolecular structure). The docking output 
with lower energy is shown in the next figure.  
 
 
 
Figure 41. SET dimer/MP07-66 docking (whole, a; zoom, b).  
 
Differently than before, and as shown by the reported dock, the compound seems to interact with both of 
the subunits taken into account, on the interface between one and the other. The labeled aa residues are 
the ones that have a distance <5Å from MP07-66, and they result to be present on both the monomers that 
compose SET (Thr84, Asn88, Tyr220, Leu221, Val222 on one of the subunits; Glu98, Glu99, Asp100 on the 
other). This situation is much different from the previous one, also because of the polarity of the involved 
residues: here only two residues are hydrophobic out of 8 (Leu, Val), while the most of them is polar 
(Thr, Asn, Tyr). On one of the two subunits there are even only negatively charged residues (Glu, Asp). 
At this point, only experimental data could say which the most likely situation between the two is. 
 
In addition to this discrepancy, another relevant concern about these dockings is that the obtained outputs 
might represent non-specific interactions: given that MP07-66 is extremely lypophilic (ClogP: 4.7096), the 
main interactions it can give are supposed to be non-polar, and indeed the docking reveals the presence of 
no H bonds. Lacking this kind of interactions makes the predictions difficult to evaluate for their 
(a) (b) 
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reliability; because of this, defining the actual structure through experimental techniques as X-ray 
crystallography is once again needed. Structural details would be of a great help for fully understanding 
the mechanism of action of the compound itself, revealing the involved interactors on both MP07-66 and 
the protein. As already said for compound 71, another possibility to better elucidate the interactions 
between the small molecule and the POI could be NMR spectroscopy; this technique offers several 
chances (all very well reviewed97) in terms of detecting and quantifying the interaction between a small 
molecule and a protein. This kind of approach, once optimized, permits to identify binding events either 
by evaluating the signals of the ligand or of the POI. The experiments more often performed in this kind 
of situation usually involve chemical-shift changes due to the interaction between the protein and the 
ligand, but this is just one of the options. The important point is to consider parameters (as the already 
mentioned chemical-shift changes, but also, for instance, changes of NOEs) that are obtainable with high 
sensitivity and in an easy way 97.  A few examples of the possible experiments, together with the main 
characteristics and comments about, are reported in the following table. 
 
 
 
Table 12. Main NMR techniques for detecting ligand-protein binding (SAR: structure-activity relationships; STD: saturation-
transfer-difference; NOE: nuclear Overhauser effect; Water- LOGSY: water-ligand observation with gradient spectroscopy)97. 
 
109 
 
2.3.2 Molecular biology achievements 
 
The part of the work performed at the laboratories of Diamond Light Source and Research Complex at 
Harwell aimed at the production of large amounts of SET and PP2AC for structural and functional 
characterization. The high-throughput facilities of OPPF-UK were made available to clone and express in 
small scale a large number of constructs designed to express the protein in multiple expression systems.  
An initial screening of conditions identified a good number of vectors as suitable for the expression of 
recombinant SET in E. coli. Two vectors expressing MBP and SUMO at the N-terminus of the protein 
SET1-225, previously reported by Muto and co-workers95, were successfully scaled up for large scale 
production. Initially from 2 x 1 L of culture of E. coli harboring the construct D6, the fusion protein His6-
SUMO-3C-His6-Thrombin-SET1-225 was expressed and 2.5 mg of purified SET were obtained after a 
three-step purification process. Despite the high purity of the protein, the amounts are largely insufficient 
for structural studies since previous reports described the conditions for crystallization of SET starting 
from a 70 mg/mL of the protein. 
It has to be noted that the construct used for this thesis work is the one used in the initial work from Muto 
and co-workers, rather than the one associated to the PDB entry of SET (PDB ID: 2E50). In fact, both 
works are based on N-terminally truncated forms of SET (aminoacids 1-225), but the last includes three 
point mutations to methionine to allow experimental phasing of the protein with the Se-Met method. 
Once a suitable model is available on the PDB, the structure solution can directly start from that and the 
three substitutions are no longer required. For this reason we decided to use the wild-type gene, which 
produces a protein whose structure is more similar to the naturally occurring one, thus avoiding artifacts 
that might pollute further structural and biochemical assays. 
Large amounts of pure SET1-225 were obtained from the construct C6, which expressed much more protein 
fused to a maltose-binding protein solubilizing agent (His6-MBP-3C-His6-Thrombin-SET1-225). After a 
redefinition of the purification strategy, the yields were increased by starting from a larger pool of cells. 
This implied the use of much more affinity resin and the volumes of sample produced were particularly 
difficult to work with. Given the large amount of protein eluted from the affinity resin, both proteolysis 
required large amounts of protease and repeated runs of size-exclusion chromatography. This lengthy 
process has been well tolerated by the protein, which did not show any propensity to degradation or 
precipitation. Analytical gel filtration tests coupled with MALS confirmed the protein is in its dimeric 
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form and MS analysis identified the correct MW for the protein, pure to >90% as from densitometric 
analysis of the SDS-PAGE. The overall yield was extremely satisfying: from 12 x 1 L cultures, 
approximately 340 mg of protein were produced. 
Crystallization experiments are currently undergoing in the laboratories of Diamond Light Source. 
 
Concerning PP2AC, E. coli did not produce any of the protein in small-scale tests and the production was 
not scaled up. However, as for the production of the holoenzyme using Hi-5 insect cells, preliminary 
results show that both constructs A5 (His6-3C-PP2AC,1-245) and E5 (PP2AC,1-245-His6) could produce large 
amounts of the protein in soluble form. The absence of degradation bands is also an excellent 
confirmation that the protein can be obtained separately from the other components of the holoenzyme. 
Based on the promising preliminary expression tests, the expression of construct A5 (preferred to E5 for 
the presence of a cleavable tag) is currently being expressed and purified in large scale in collaboration 
with Dr. Joanne Nettleship (OPPF-UK) and Dr. Marco Mazzorana (Diamond Light Source). The first 
small-scale purification test is very promising and indicates a good amount of soluble protein was 
expressed in a 2 L culture, as shown in figure 42.  
 
Figure 42. A6, D6, A5 and D5 construct expression in insect cells (3 μL virus/3 mL culture). 
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Purification of the protein will be performed and the sample will be used to try the reconstitution of the 
complex in vitro, followed by structural investigation, mainly through crystallography and small-angle X-
ray scattering. This technique, despite the lower resolution, does not need the protein complex in a 
crystallized form and will be integrated with high-resolution X-ray crystallography data to describe 
atomic details. This is of fundamental importance to generate new compounds with increased potency and 
specificity towards this peculiar target. 
With the quantity of SET so far obtained, HRMS experiments will also be performed to estimate the 
extent of binding between SET and the compounds. This is done by evaluating the shift of the mass peak 
corresponding to the protein itself when bonded to the analyzed compound. The optimization of the 
experiment (currently in progress) is, however, a lengthy process requiring tuning of the conditions for 
which the protein remains in its native conformation (i.e. not denaturated). For the data to be reliable and 
comparable to in vitro and in vivo behavior of SET, one must avoid denaturation, which would expose to 
the surface (and to the interaction with the ligand) residues that probably have nothing to deal with the 
binding studied. Avoiding denaturation, which would also probably inactivate the physiological function 
of SET, is not trivial: the best conditions for the protein to fly in the detector are often denaturing. At 
present, tuning experiments are carried out using SET by itself without any potential ligand, acquiring 
spectra in negative mode due to the low pI of the protein. 
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3. MATERIALS AND METHODS 
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3.1 ABBREVIATIONS 
- Å: Angstrom/angstroms 
- aa: Aminoacid/aminoacids/aminoacidic 
- ACN: acetonitrile 
- Akt: Protein kinase B 
- AI: Autoinduction medium 
- AML: Acute myeloid leukemia 
- Asp: Aspartate 
- B-CLL: B-cell chronic lymphocytic leukemia 
- bs: Broad singlet 
- °C: Celsius degrees 
- Calcd: Calculated 
- cAMP: Cyclic adenosin mono phosphate 
- CDCl3: Deuterated chloroform 
- CIP2A: Cancerous inhibitor of PP2A 
- CML: Chronic myeloid leukemia 
- Concd: Concentrated 
- CoSY: Correlation spectroscopy 
- CV: Column volume 
- δ: Delta, ppm 
- d: Doublet 
- D2O: Deuterated water 
- dd: Double doublet 
- Da: Dalton 
- DCE: 1,2-Dichloroethane 
- DCM: Dichloromethane 
- DMSO: Dimethylsulfoxide 
- DUSP: Dual specificity phosphatase 
- EB: Elution buffer 
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- EDTA: Ethylendiamino tetraacetic acid 
- ESI: Electrospray ionization 
- Et2O: Diethylether 
- EtOH: Ethanol 
- Exper: Experimental 
- FCP: TFIIF-associating C-terminal domain phosphatase 
- FDA: Food and drug administration 
- FPLC: Fast protein liquid chromatography 
- g: Gram/grams 
- g: Gravity acceleration 
- GPCR: G-protein coupled receptor 
- h: Hour/hours 
- HAD: Haloacid dehalogenase 
- HEAT: Huntingtin/elongation/A subunit/TOR 
- His: Histidine 
- HMBC: Heteronuclear multiple bond correlation 
- HRMS: High resolution mass spectrometry 
- HSC: Hematopoietic stem cells 
- HSQC: Heteronuclear single quantum coherence 
- HTP: High throughput purification 
- I2PP2A: PP2A inhibitor 2 
- IMAC: Immobilized metal ion affinity chromatography 
- IPTG: Isopropyl β-D-1-thiogalactopyranoside 
- Jak2: Janus kinase 2 
- k: Kilo 
- KPSI: Kilopounds per square inch 
- L: Liters 
- LB: Lysogeny broth 
- LCMT1: Leu-carboxyl methyltransferase 
- Leu: Leucine 
117 
 
- µ: Micro 
- m: Milli 
- M: Molarity 
- MALS: multi-angle light scattering 
- MBP: Maltose binding protein 
- MCP: Multi channel pipette 
- MeOH: Methanol 
- MES: 2-(N-morpholino)ethanesulfonic acid 
- Met: Methionin 
- m-CPBA: meta-Chloroperbenzoic acid 
- MeOD: Deuterated methanol 
- MeOH: Methanol 
- mg: Milligrams 
- MHz: Megahertz 
- mL: Milliliter/milliliters 
- mmol: Millimole/millimoles 
- mol: Mole/moles 
- MS: Multiple sclerosis 
- MW: Molecular weight 
- MWM: Molecular weight marker 
- Ni-NTA: Ni2+-nitrilotriacetate 
- nM: Nanomolar 
- NMR: Nuclear magnetic resonance 
- NOESY: Nuclear Overhauser effect spectroscopy 
- NPI: Sodium chloride, phosphate, imidazole 
- OA: Okadaic acid 
- OD: Optical density 
- o/n: Overnight 
- OPPF-UK: Oxford protein production facility-UK 
- PAGE: Polyacrylamide gel electrophoresis 
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- PB: Power broth 
- PCR: Polymerase chain reaction 
- pI: Isoelectric point 
- PI3K: Phosphoinositide 3-kinase 
- PK: Protein kinase 
- PMSF: Phenyl methyl sulfonyl fluoride 
- PP: Protein phosphatase 
- PPM: Mg2+/Mn2+ dependent protein phosphatase 
- ppm: Parts per million 
- PPP: Phosphoprotein phosphatase 
- POI: Protein of interest 
- pOPIN: Plasmids for OPPF In-Fusion 
- PP2A: Protein phosphatase 2A 
- PTP: PhosphoTyr phosphatase 
- Rf: Retention factor 
- rpm: Roots per minute 
- rt: Room temperature 
- s: Singlet 
- S1P: Sphingosine-1-phosphate 
- S1PR: Sphingosine-1-phosphate receptor 
- SCP: Small C-terminal domain phosphatase 
- SDS: Sodium dodecyl sulfate 
- SET: Suvar3-9, enhancer of zeste, trithorax 
- SHP1: Src-homology 1 domain phosphatase 
- SK: Sphingosine kinase 
- SN2: Bimolecular nucleophilic substitution 
- SUMO: Small ubiquitin-related modifier 
- SV40: Simian vacuolating virus 40 
- t: Triplet 
- TAF-Iβ: Template-activating factor-Iβ 
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- TB: Terrific broth 
- TBE: Tris borate EDTA 
- TEA: Triethylamine 
- TGF: Transforming growth factor 
- TLC: Thin layer chromatography 
- TOF: Time of flight 
- TOR: Target of rapamycin 
- Tris: Tris(hydroxymethyl)aminomethane 
- Trp: Tryptophan 
- Wnt: Wingless-type MMTV integration site 
- X-gal: 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside. 
120 
 
3.2 CONSUMABLES 
Chemicals 
All the chemicals were purchased by Agentcourt, Alfa-Aesar, Fluka, Sigma-Aldrich, Thermoscientific, 
Novagen, Qiagen or Invitrogen and used without further purifications. 
Solvents 
All the solvents were purchased by Sigma-Aldrich, Carlo Erba and VWR. 
Deuterated solvents 
All the deuterated solvents were purchased by Sigma-Aldrich and EurisoTop. 
TLC plates 
Analytical TLC was performed on 60F245 precoated silica gel plates (Merck); spots were visualized with 
UV light at 254 nm. 
Columns for Flash chromatography 
The utilized columns were SNAP cartridges 10g and 25g by Biotage. 
Vectors 
The pET-14b template vector containing the full-length SET has been kindly sent us from the research 
group of Prof. Masami Horikoshi (Institute of Molecular and Cellular Biosciences, University of Tokyo, 
Japan). The cDNA encoded by the vector translates in the following aa sequence: 
MGSSHHHHHHSSGLVPRGSHMSAQAAKVSKKELNSNHDGADETSEKEQQEAIEHIDEVQNEIDR
LNEQASEEILKVEQKYNKLRQPFFQKRSELIAKIPNFWVTTFVNHPQVSALLGEEDEEALHYLTR
VEVTEFEDIKSGYRIDFYFDENPYFENKVLSKEFHLNESGDPSSKSTEIKWKSGKDLTKRSSQTQN
KASRKRQHEEPESFFTWFTDHSDAGADELGEVIKDDIWPNPLQYYLVPDMDDEEGEGEEDDDD
DEEEEGLEDIDEEGDEDEGEEDEDDDEGEEGEEDEGEDD. 
The PP2AC coding plasmid pUC57 was purchased by GenScript Gene Synthesis service. The codon 
optimized vector was desigigned to express the protein sequence: 
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MDEKVFTKELDQWIEQLNECKQLSESQVKSLCEKAKEILTKESNVQEVRCPVTVCGDVHGQFHD
LMELFRIGGKSPDTNYLFMGDYVDRGYYSVETVTLLVALKVRYRERITILRGNHESRQITQVYGF
YDECLRKYGNANVWKYFTDLFDYLPLTALVDGQIFCLHGGLSPSIDTLDHIRALDRLQEVPHEGP
MCDLLWSDPDDRGGWGISPRGAGYTFGQDISETFNHANGLTLVSRAHQLVMEGYNWCHDRNV
VTIFSAPNYCYRCGNQAAIMELDDTLKYSFLQFDPAPRENLYFQGWSHPQFEK. 
 
Both these plasmids were treated in order to insert the coding sequences in six of the pOPIN (plasmids for 
OPPF In-Fusion) expression suite vectors89, which were kindly provided by OPPF-UK (Oxford Protein 
Production Facility); in particular, the following pOPINs were used: 
pOPIN-F: His6-3C-POI 
pOPIN-J: His6-GST-3C-POI 
pOPIN-M: His6-MBP-3C-POI 
pOPIN-S3C: His6-SUMO-3C-POI 
pOPIN-E: POI-KHis6 
pOPIN-EGFP: POI-3C-eGFP-KHis6 
(where POI is the protein of interest). 
Gels for electrophoresis 
Gels for DNA revealing were prepared in situ dissolving electrophoresis-grade agarose to 1.6% in a TAE 
buffer; for SDS-PAGE, precast Nu-PAGE 4-12% BIS-TRIS GEL (Novex by Life technologies) were 
used. 
Cells 
Competent E.coli were provided by OPPF-UK in three main strains: OmniMaxII (Invitrogen) as cloning 
strain, Lemo21 (DE3) and Rosetta2 (DE3) as expression strains. 
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Buffers and additives 
5052 50x: glycerol 2.7 M, glucose 140 mM, α-lactose 2.9 M. 
DNA loading buffer: 0.25%w/v bromophenol blue in 30%v/v glycerol. 
Dyalisis buffer: NaH2PO4 pH 8.0 50 mM, NaCl 300 mM, β-mercaptoethanol 7 mM. 
NEBuffer 3 10x: NaCl 1 M, tris-HCl 500mM, MgCl2 100 mM, DTT 10 mM, pH 7.9 at 25°C. 
NPI-10: NaH2PO4 pH 8.0 50 mM, NaCl 300 mM, imidazole 10 mM, tween 20 1%, β-mercaptoethanol 7 
mM. 
NPI-20: NaH2PO4 pH 8.0 50 mM, NaCl 300 mM, imidazole 20 mM, tween 20 0.05%, β-mercaptoethanol 
7 mM. 
NPI-250: NaH2PO4 pH 8.0 50 mM, NaCl 300 mM, imidazole 250 mM, tween 20 0.05%, β-
mercaptoethanol 7 mM. 
NPS 20x: (NH)4SO4 0.5 M, KH2PO41 M, Na2HPO41 M, pH 6.75 at 20°C. 
SET gel filtration buffer: Tris pH 8.0 20 mM, NaCl 100 mM, β-mercaptoethanol 10 mM. 
TAE: Tris 40mM, EDTA 1mM, pH 8.3 
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3.3 INSTRUMENTS 
Nuclear Magnetic Resonance (NMR) 
NMR spectra were obtained with a NMR Bruker AVANCE III 400 MHz spectrometer and a NMR 
Bruker AMX 300 MHz spectrometer. 
High Resolution Mass Spectrometry (HRMS) 
Mass spectra were obtained with a Mariner ESI-TOF (Perceptive Biosystems Inc.) spectrometer, and with 
a Xevo G2-XS QTof mass spectrometer (Waters, Manchester, UK). 
Flash Chromatography 
A chromatographic Isolera One by Biotage unit has been used. 
High throughput purification  
A Bio-Robot 8000 (Qiagen) was used, equipped with QIA soft 4.2 software. 
Fast Protein Liquid Chromatography (FPLC) 
An AKTA Purifier System was utilized for performing FPLC purifications; the instrument was controlled 
by the System Control AKTA Purifier software and data were analyzed by the Unicorn Manager 5.31 
software. The system was equipped with HisTrap FF (GE Healthcare) for IMAC purifications and a 
HiLoad 16/600 Superdex 200 prep grade (GE Healthcare) for gel filtration. 
Gel electrophoresis devices 
X cell sure lock system (Novex by Life technologies) and a Fisher scientific power station were used; gels 
were revealed with Instant Blue (Expedeon) and acquired with a GelDoc EZ Imager (Biorad). 
UV spectrophotometric analysis 
A NanoDrop 2000c spectrophotometer (Thermoscientific) was used, equipped with NanoDrop software. 
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3.4 SYNTHETIC SCHEMES 
 
PATHWAY 1.1: 
 
OH
(  )n
Br
O
(  )n
Cl
O
Br
O Br
O (  )n
HN
O
O
(  )n
N
Cl
O
O (  )n
O
16
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Synthesis of compound 18 (butoxybenzene) 
 
OH
Br
K2CO3
ACN
O
16 17
18
 
Phenol (16, 1.000 g, 10.64 mmol) was dissolved in 20 mL of acetonitrile in the presence of potassium 
carbonate (2.936 g, 21.28 mmol); the mixture was kept under magnetic stirring at rt for 1 h. Then, 1-
bromobutane (17, 1.307 g, 1.029 mL, 9.54 mmol) was added and the reaction was heated at 60°C for 24 h 
and monitored by TLC (hexane/ethyl acetate 4:1). 
After that, the reaction was filtered to remove the salts, and evaporated; the residue was dissolved in 
diethyl ether (30 mL) and washed with an aqueous  solution of sodium hydroxyde 10% (30 mL, 3 times) 
and brine (20 mL). The organic phase was dried with magnesium sulfate and evaporated to give a 
colorless oil as a product. 
Yield: 52%. 
With the same procedure, the synthesis of more ethers was performed using other bromoalkanes, i.e. 1-
bromohexane, 1-bromoheptane, 1-bromooctane, 1-bromononane. For all of these reactions, the obtained 
yields were between 50% and 60%. 
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Compound 18 – butoxybenzene 
 
O  
C10H14O 
MW: 150.2176 
1H-NMR (400MHz, CDCl3) δ: 7.32 (2H, m, ArH), 6.96 (3H, m, ArH), 4.00 (2H, m, OCH2), 1.82 (2H, m, 
CH2), 1.55 (2H, m, CH2), 1.03 (3H, t, CH3). 
HRMS (ESI): calcd. (M+H)+ 151.1045, exper. 151.1268. 
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Compound 19 – hexyloxybenzene 
 
O  
C12H18O 
MW: 178.2707 
1H-NMR (400MHz, CDCl3) δ: 7.30 (m, 2H, ArH), 6.93 (m, 3H, ArH), 3.98 (t, 2H, OCH2), 1.81 (m, 2H, 
CH2), 1.48 (m, 2H, CH2), 1.37 (m, 4H, 2x CH2), 0.93 (t, 3H, CH3). 
HRMS (ESI): calcd. (M+H)+ 179.1358, exper. 179.1549. 
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Compound 20 – heptyloxybenzene 
 
O  
C13H20O 
  
MW: 192.2973 
1H-NMR (400MHz, CDCl3) δ: 7.34 (m, 2H, ArH), 6.98 (m, 3H, ArH), 4.02 (t, 2H, OCH2), 1.86 (m, 2H, 
CH2), 1.58-1.35 (m, 8H, 4x CH2), 0.99 (t, 3H, CH3). 
HRMS (ESI): calcd. (M+H)+ 193.1514, exper. 193.1540. 
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Compound 21 – octyloxybenzene 
 
O  
C14H22O  
MW: 206.3239 
1H-NMR (400MHz, CDCl3) δ: 7.25 (2H, ArH), 6.89 (3H, ArH), 3.93 (t, 2H, OCH2), 1.76 (m, 4H, 2x 
CH2), 1.5-1-2 (m, 8H, 4x CH2), 0.88 (t, 3H, CH3). 
HRMS (ESI): calcd. (M+H)+ 207.1671, exper. 207.3490. 
 
 
132 
 
Compound 22 – nonyloxybenzene 
 
O  
C15H24O 
MW: 220.3505 
1H-NMR (400MHz, CDCl3) δ: 7.31 (m, 2H, ArH), 6.95 (m, 3H, ArH), 3.99 (t, 2H, OCH2), 3.44 (t, 2H, 
CH2), 1.80 (m, 2H, CH2), 1.82 (m, 2H, CH2), 1.6-1.4 (m, 4H, 2x CH2), 1.0-0.9 (m, 7H, 2x CH2, CH3). 
HRMS (ESI): calcd. (M+H)+ 221.1827, exper. 221.1815. 
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Synthesis of compound 24 (3-bromo-1-(4-(hexyloxy)phenyl)propan-1-one) 
 
O
Cl Br
O
AlCl3
DCE
O
O Br
19
23
24
 
Aluminum trichloride (450 mg, 3.36 mmol) in DCE (10 mL) was placed under magnetic stirring in an ice 
bath. Another solution was prepared with compound 19 (299 mg, 1.68 mmol) and 3-bromopropyonil 
chloride (23, 289 mg, 169 μL, 1.68 mmol) in DCE (5 mL); this second solution was slowly dropped in the 
first one, and the reaction was allowed to stir at rt for 3h (time by which the reaction, starting from a 
bright yellow color, becomes of a brownish orange). After the completion of the reaction, verified by 
TLC (hexane/ethyl acetate 4:1) the reaction mixture was poured in water (100 mL) and added with 20 mL 
of diethyl ether. The phases were then separated through a separation funnel, the organic phase was dried 
with MgSO4 and the solvent was evaporated to give a yellow oil as a product. 
Yield: 90%. 
The same reaction was repeated on compounds 20, 21 and 22, while on compound 18 the acylation was 
performed with acetyl chloride instead of 3-bromopropyonil chloride. For all of these reactions, the yields 
are between 80 and 90%. 
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Compound 25 - 1-(4-butoxyphenyl)ethanone 
 
O
O
 
C12H16O2  
MW: 192.2542 
1H-NMR (300MHz, CDCl3) δ: 7.94 (2H, AA'), 6.93 (2H, XX'), 4.04 (2H, t, OCH2), 2.57 (3H, s, COCH3), 
1.81 (2H, m, CH2), 1.52 (2H, m, CH2), 1.00 (3H, t, CH3). 
13C-NMR (75MHz, CDCl3) δ: 196.9, 163.2, 130.6, 130.1, 114.1, 67.9, 31.1, 26.3, 19.3, 13.8. 
HRMS (ESI): calcd. (M+H)+ 193.1150, exper. 193.1258. 
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Compound 24 - 3-bromo-1-(4-(hexyloxy)phenyl)propan-1-one 
 
O
O Br
 
C15H21BrO2  
MW: 313.2300 
1H-NMR (400MHz, CDCl3) δ: 7.95 (2H, AA’), 6.96 (2H, XX’), 4.05 (t, 2H, CH2, J=6.7 Hz), 3.76 (t, 2H, 
OCH2), 3.54 (t, 2H, CH2, J=6.7 Hz), 1.9-1.8 (m, 2H, CH2), 1.5-1.4 (m, 2H, CH2), 1.38 (m, 4H, 2x CH2), 
0.93 (t, 3H, CH3). 
HRMS (ESI): calcd. (M+H)+ 313.0725, exper. 313.1027 (C15H2179BrO2); calcd. (M+H)+ 315.0725, exper. 
315.1041 (C15H2181BrO2). 
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Compound 26 - 3-bromo-1-(4-(heptyloxy)phenyl)propan-1-one 
 
O
O Br
 
C16H23BrO2 
MW: 327.2566 
1H-NMR (400 MHz, CDCl3) δ: 7.94 (2H, AA’), 6.95 (2H, XX’), 4.04 (2H, t, J=6.8Hz, OCH2), 3.76 (2H, 
t, J=6.8Hz, CH2), 3.54 (2H, t, J=6.8Hz, COCH2), 1.83 (2H, m, CH2), 1.48 (2H, m, CH2), 1.4-1.3 (6H, m, 
3xCH2), 0.92 (3H, t, J=6.8Hz, CH3). 
HRMS (ESI): calcd. (M+H)+ 327.0881, exper. 327.1252 (C15H2179BrO2); calcd. (M+H)+ 329.0881, exper. 
329.1207 (C15H2181BrO2). 
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Compound 27 - 3-bromo-1-(4-(octyloxy)phenyl)propan-1-one 
 
O
O Br
 
C17H25BrO2 
MW: 341.2832 
1H-NMR (400MHz, MeOD) δ: 7.99 (2H, AA’), 7.03 (2H, XX’), 4.09 (t, 2H, CH2Br), 3.76 (t, 2H, CH2), 
3.60 (t, 2H, CH2), 1.82 (m, 2H, CH2), 1.51 (m, 2H, CH2), 1.5-1.3 (m, 8H, 4x CH2), 0.93 (t, 3H, CH3). 
HRMS (ESI): calcd. (M+H)+ 341.1038, exper. 341.1236 (C15H2179BrO2); calcd. (M+H)+ 343.1038, exper. 
343.3102 (C15H2181BrO2). 
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Compound 28 - 3-bromo-1-(4-(nonyloxy)phenyl)propan-1-one 
 
O
O Br
 
C18H27BrO2 
 MW: 355.3098 
1H-NMR (400MHz, CDCl3) δ: 7.95 (2H, AA’), 6.95 (2H, XX’), 4.04 (t, 2H, CH2), 3.76 (t, 2H, OCH2), 
3.54 (t, 2H, CH2), 3.43 (m, 2H, CH2) 1.85 (m, 4H, 2x CH2), 1.46 (m, 6H, 3x CH2), 0.90 (m, 5H, CH2-
CH3). 
HRMS (ESI): calcd. (M+H)+ 355.1194, exper. 355.1243 (C15H2179BrO2); calcd. (M+H)+ 357.1174, exper. 
357.0838 (C15H2181BrO2). 
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Synthesis of compound 30 (1-(4-(hexyloxy)phenyl)-3-(piperidin-1-yl)propan-1-one) 
O
O Br
H
N KI, CaCO3
toluene
O
O N
24
29
30
 
 
In a 100 mL round bottom flask containing 15 mL of toluene, were placed compound 24 (100 mg, 0.32 
mmol), piperidine (29, 40 mg, 46 μL, 0.48 mmol), potassium iodide (79 mg, 0.48 mmol) and calcium 
carbonate (48 mg, 0.48 mmol). The reaction was stirred o/n heating it at 110°C; the completion of the 
reaction was verified by TLC (hexane/ethyl acetate 4:1).  
The mixture was then cooled to rt and filtered, and the solid residue was washed with toluene; the filtrate 
was then evaporated to remove the solvent. The residue was dissolved in DCM (20 mL) and washed in a 
separation funnel with sodium hydroxyde 10% in water (20 mL, 3 times); the collected organic phase was 
dried with magnesium sulfate and the solvent was removed. The resulting product was a brownish oil. 
Yield: 85%. 
The same reaction was repeated also on compounds 26, 27 and 28 in the same way. In addition to this, 
compounds 24, 26, 27 and 28 were also reacted with morpholine instead of piperidine. All the yields were 
between 75 and 85%. 
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Compound 30 - 1-(4-(hexyloxy)phenyl)-3-(piperidin-1-yl)propan-1-one 
 
O
O N
 
C20H31NO2 
 MW: 317.4656 
1H-NMR (400MHz, CDCl3) δ: 7.80 (2H, AA’), 6.94 (2H, XX’), 4.04 (t, 2H, CH2), 3.18 (t, 2H, O CH2), 
2.82 (t, 2H, CH2), 1.82 (m, 2H, CH2), 1.63 (m, 8H, 4x CH2), 1.49 (m, 4H, 2x CH2), 1.37 (m, 4H 2x CH2), 
0.93 (t, 3H, CH3). 
13C-NMR (100MHz, CDCl3) δ: 195.5, 161.8, 129.0, 128.5, 112.9, 75.9, 66.9, 53.3, 52.8, 30.3, 27.8, 24.6, 
24.7, 21.3, 12.8.  
HRMS (ESI): calcd. (M+H)+ 318.2355, exper. 318.2690. 
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Compound 31 - 1-(4-(heptyloxy)phenyl)-3-(piperidin-1-yl)propan-1-one 
 
O
O N
 
C21H33NO2 
MW: 331.4922 
1H-NMR (400 MHz, CDCl3) δ: 7.95 (2H, AA’), 6.93 (2H, XX’), 4.04 (t, 2H, OCH2), 2.80 (m, 2H, CH2), 
2.47 (m, 4H, 2x CH2N), 1.82 (m, 2H, CH2), 1.62 (m, 4H, 2x CH2), 1.47 (m, 4H, 2x CH2), 1.4-1.2 (m, 8H, 
4x CH2), 0.92 (t, 3H, CH3). 
 
13C-NMR (100MHz, CDCl3) δ: 198.0, 163.1, 130.3, 129.8, 114.2, 68.2, 54.6, 54.2, 36.1, 31.7, 29.1, 29.0, 
26.0, 25.9, 24.3, 22.6, 14.1. 
 
HRMS (ESI): calcd. (M+H)+ 332.2511, exper. 332.2903. 
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Compound 32 - 1-(4-(octyloxy)phenyl)-3-(piperidin-1-yl)propan-1-one 
 
O
O N
 
C22H35NO2 
MW: 345.5188 
1H-NMR (400MHz, CDCl3) δ: 7.85 (2H, AA’), 6.84 (2H, XX’), 3.92 (t, 2H, OCH2), 3.62 (t, 2H, CH2), 
3.04 (t, 2H, CH2), 2.73 (m, 2H, CH2), 2.42 (m, 4H, 2x CH2), 2.23 (m, 2H, CH2), 1.72 (m, 2H, CH2), 1.37 
(m, 2H, CH2), 1.3-1.1 (m, 10H, 5xCH2), 0.79 (m, 5H, CH2CH3). 
13C-NMR (100MHz, CDCl3) δ: 195.6, 159.5, 134.6, 130.9, 66.7, 59.6, 51.4, 40.2, 33.1, 30.7, 26.5, 25.2, 
22.6, 14.0, 10.8. 
HRMS (ESI): calcd. (M+H)+ 346.2668, exper. 346.4092. 
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Compound 33 - 1-(4-(nonyloxy)phenyl)-3-(piperidin-1-yl)propan-1-one 
 
O
O N
 
C23H37NO2 
MW: 359.5454 
1H-NMR (400MHz, CDCl3) δ: 7.95 (2H, AA’), 6.93 (2H, XX’), 4.04 (t, 2H, OCH2), 3.16 (t, 2H, CH2), 
2.80 (t, 2H, CH2), 2.5-2.4 (m, 4H, 2x NCH2), 1.82 (m, 4H, 2x CH2), 1.7-1.6 (m, 6H, 3x CH2), 1.48 (m, 
4H, 2x CH2), 0.91 (m, 5H, CH2CH3). 
13C-NMR (100MHz, CDCl3) δ: 198.0, 161.2, 135.2, 133.7, 120.4, 70.5, 51.4, 49.9, 35.3, 33.6, 29.4, 28.9, 
26.2, 24.1, 22.6, 14.0. 
HRMS (ESI): calcd. (M+H)+ 360.2824, exper. 360.2878. 
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Compound 34 - 1-(4-(hexyloxy)phenyl)-3-morpholinopropan-1-one 
 
O
O N
O
 
C19H29NO3 
MW: 319.4385 
1H-NMR (400MHz, CDCl3) δ: 7.95 (2H, AA’), 6.95 (2H, XX’), 4.04 (t, 2H, OCH2), 3.74 (m, 4H, 2x 
CH2), 3.15 (t, 2H, CH2, J=7.7 Hz), 2.84 (t, 2H, CH2, J=7.7 Hz), 2.53 (m, 4H, 2x CH2), 1.83 (m, 2H, CH2), 
1.49 (m, 2H, CH2), 4.38 (m, 4H, 2x CH2), 0.93 (t, 3H, CH3). 
13C-NMR (100MHz, CDCl3) δ: 196.5, 162.2, 129.3, 113.2, 76.2, 67.3, 65.9, 52.8, 52.7, 34.5, 30.5, 28.0, 
24.6, 21.6, 13.0. 
HRMS (ESI): calcd. (M+H)+ 320.2147, exper. 320.2304. 
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Compound 35 - 1-(4-(heptyloxy)phenyl)-3-morpholinopropan-1-one 
 
O
O N
O
 
C20H31NO3 
MW: 333.4650 
1H-NMR (400 MHz, CDCl3)  δ 7.95 (2H, AA’), 6.94 (2H, XX’), 4.04 (t, 2H, OCH2) , 3.74 (m, 4H, 
2xCH2), 3.16 (t, 2H, CH2), 2.85 (t, 2H, CH2), 2.54 (m, 4H, 2x CH2N), 1.83 (m, 2H, CH2), 1.48 (m, 2H, 
CH2), 1.4-1.3 (m, 6H, 3x CH2), 0.92 (t, 3H, CH3) . 
 
13C-NMR (100 MHz, CDCl3) δ: 197.5, 163.2, 130.3, 129.7, 114.2, 68.3, 67.0, 53.8, 53.7, 35.6, 31.7, 29.1, 
29.0, 25.9, 22.6, 14.1. 
 
HRMS (ESI): calcd. (M+H)+ 334.2304, exper. 334.2690. 
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Compound 36 - 3-morpholino-1-(4-(octyloxy)phenyl)propan-1-one 
 
O
O N
O
 
C21H33NO3 
MW: 347.4916 
1H-NMR (400MHz, CDCl3) δ: 7.86 (2H, AA’), 6.84 (2H, XX’), 3.93 (t, 2H, OCH2), 3.64 (t, 2H, CH2), 
3.06 (t, 2H, CH2), 2.74 (t, 2H, CH2), 2.43 (m, 2H, CH2), 1.72 (m, 4H, 2xCH2), 1.38 (m, 2H, CH2), 1.3-1.1 
(m, 8H, 4xCH2), 0.82 (m, 5H, CH2CH3). 
13C-NMR (100MHz, CDCl3) δ: 197.5, 160.5, 135.5, 130.3, 114.6, 68.3, 66.3, 54.0, 49.9, 36.5, 33.4, 29.7, 
26.2, 22.6, 12.8. 
HRMS (ESI): calcd. (M+H)+ 348.2460, exper. 348.4092. 
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Compound 37 - 3-morpholino-1-(4-(nonyloxy)phenyl)propan-1-one 
 
O
O N
O
 
C22H35NO3 
 
MW: 361.5182 
 
1H-NMR (400MHz, CDCl3) δ: 7.81 (2H, AA’), 6.80 (2H, XX’), 3.90 (t, 2H, OCH2), 3.60 (m, 4H, 
2xCH2), 3.01 (t, 2H, CH2), 2,70 (t, 2H, CH2), 2.39 (m, 4H, 2xCH2), 1.68 (m, 2H, CH2), 1.4-1.1 (m, 10H, 
5xCH2), 0.8-0.7 (m, 5H, CH2CH3). 
13C-NMR (100MHz, CDCl3) δ: 197.6, 160.5, 134.9, 130.3, 114.6, 68.2, 66.3, 54.0, 49.6, 32.4, 29.3, 26.4, 
22.6. 
HRMS (ESI): calcd. (M+H)+ 362.2617, exper. 362.2598. 
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PATHWAY 1.2: 
 
SH
(  )n
Br
S
(  )n
Cl
O
Br
O Br
S (  )n
HN
O
S
(  )n
N
38
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Synthesis of compound 40 (pentyl(phenyl)sulfane) 
 
SH
Br
KOH
EtOH
S
38
39 40
 
In a 100 mL round-bottom flask were placed thiophenol (38, 1.000 g, 0.932 mL, 9.07 mmol) and 
potassium hydroxide (509 mg, 9.07 mmol) in 20 mL of ethanol; in the stirring solution, 1-bromopentane 
was added dropwise (39, 1.369 g, 1.125 mL, 9.07 mmol). The solution was stirred at rt for 5 h, 
monitoring it by TLC (hexane/ethyl acetate 4:1); then, the mixture was filtered and the solvent was 
removed from the filtrate to give a yellow very dense oil. 
Yield: 85%. 
With the same procedure, the synthesis of other thioethers was performed using 1-bromohexane and 1-
bromoheptane. In these cases, the yields were 81 and 75% respectively. 
 
The subsequent steps (Friedel-Crafts acylation and Finkelstein substitution) have been performed in the 
same way which was described for compounds 24 and 30. The only difference was that, at the very end, 
most of them needed to be purified (apart from 49) through flash chromatography, using DCM/MeOH 
(100:0 to 95:5) as eluents. The yields for the Friedel-Crafts acylation were between 53 and 62%, while 
the ones for the Finkelstein substitution were between 60 and 74%. 
150 
 
Compound 40 - pentyl(phenyl)sulfane 
 
S  
C11H16S 
MW: 180.3097 
1H-NMR (400 MHz, CDCl3) δ: 7.38 (2H, m, ArH), 7.23 (3H, m, ArH), 2.99 (2H, t, SCH2), 1.75 (2H, m, 
CH2), 1.46 (4H, m, 2xCH2), 1.00 (3H, m, CH3). 
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Compound 41 – hexyl(phenyl)sulfane 
 
S
 
C13H18S 
MW: 194.3363 
1H-NMR (400 MHz, CDCl3) δ: 7.5-7.3 (4H, m, ArH), 7.24 (1H, m, ArH), 3.01 (2H, t, J=7.30 Hz, SCH2), 
1.76  (2H, m, CH2), 1.53 (2H, m, CH2), 1.42 (4H, m, 2xCH2), 1.02 (3H, t, J=7.00 Hz, CH3). 
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Compound 42 - heptyl(phenyl)sulfane 
 
S  
C13H20S 
MW: 208.3629 
1H-NMR (300 MHz, CDCl3) δ: 7.4-7.3 (4H, m, ArH), 7.18 (1H, m, ArH), 2.93 (2H, t, J=7.32 Hz, SCH2), 
1.67 (2H, m, CH2), 1.5-1.2 (8H, m, CH2x4), 1.00 (3H, t, J= 6.78, CH3). 
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Compound 43 - 3-bromo-1-(4-(pentylthio)phenyl)propan-1-one 
 
S
O Br
 
C14H19BrOS 
MW: 315.2691 
1H-NMR (300 MHz, CDCl3) δ: 7.72 (2H, AA’), 7.19 (2H, XX’), 3.64 (2H, t, CH2), 3.42 (2H, t, CH2), 
2.90 (2H, t, SCH2), 1.62 (2H, m, CH2), 1.31 (4H, m, CH2x2), 0.82 (3H, t, CH3). 
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Compound 44 - 3-bromo-1-(4-(hexylthio)phenyl)propan-1-one 
 
S
O Br
 
C15H21BrOS 
MW: 329.2956 
1H-NMR (400 MHz, CDCl3) δ: 7.84 (2H, AA’), 7.30 (2H, XX’), 3.73 (2H, t, J=7.03 Hz, CH2), 3.52 (2H, 
t, J=7.03 Hz, CH2), 2.99 (2H, t, J=7.28 Hz, SCH2), 1.71 (2H, m, CH2), 1.47 (2H, m, CH2), 1.33 (4H, m, 
CH2x2), 0.91 (3H, t, CH3). 
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Compound 45 - 3-bromo-1-(4-(heptylthio)phenyl)propan-1-one 
 
 
S
O Br
 
C16H23BrOS 
MW: 343.3222 
1H-NMR (300 MHz, CDCl3) δ: 7.84 (2H, AA’), 7.31 (2H, XX’), 3.73 (2H, t, J= 6.89 Hz, CH2), 3.53 (2H, 
t, J=6.89 Hz, CH2), 2.99 (2H, t, J=7.10, SCH2), 1.68 (2H, m, CH2), 1.5-1.2 (8H, m, CH2x4), 0.88 (3H, t, 
CH3). 
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Compound 46 – 1-(4-(pentylthio)phenyl)-3-(piperidin-1-yl)propan-1-one 
 
S
O N
 
C19H29NOS 
MW: 319.5047 
1H-NMR (300 MHz, CDCl3) δ: 7.85 (AA’, 2H), 7.26 (XX’, 2H), 3.13 (2H, t, SCH2), 2.96 (2H, t, CH2), 
2.75 (2H, t, CH2), 2.91 (2H, m, CH2), 1.67 (4H, m, CH2x2), 1.58 (4H, m, CH2x2), 1.42 (4H, m, 2xCH2), 
1.32 (2H, m, CH2), 0.98 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 197.8, 145.1, 135.9, 133.0, 128.7, 69.7, 54.6, 36.5, 35.2, 33.5, 31.9, 30.1, 
29.4, 22.3. 
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Compound 47 - 1-(4-(hexylthio)phenyl)-3-(piperidin-1-yl)propan-1-one 
 
S
O N
 
C20H31NOS 
MW: 333.5312 
1H-NMR (400 MHz, CDCl3) δ: 7.86 (2H, AA’), 7.29 (2H, XX’), 3.20 (2H, t, CH2), 3.13 (4H, bt, CH2x2), 
2.99 (2H, t, SCH2), 2.85 (2H, t, CH2), 2.51 (2H, m, CH2), 1.87 (4H, m, CH2x2), 1.7-1.6 (4H, m, CH2x2), 
1.46 (2H, m, CH2), 1.31 (2H, m, CH2), 0.89 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 198.2, 145.1, 133.4, 128.8, 126.3, 54.5, 53.9, 45.1, 36.0, 33.6, 31.9, 31.3, 
29.1, 28.5, 25.7, 22.5. 
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Compound 48 - 1-(4-(heptylthio)phenyl)-3-(piperidin-1-yl)propan-1-one 
 
S
O N
 
C21H33NOS 
MW: 347.5578 
H-NMR (300 MHz, CDCl3) δ: 7.88 (AA’, 2H), 7.30 (XX’, 2H), 3.17 (2H, t, J=7.86 Hz, CH2), 3.01 (2H, t, 
S-CH2), 2.80 (2H, t, J=7.86 Hz, CH2), 2.47 (2H, t, CH2), 2.75 (4H, t, CH2x2), 2.91 (2H, m, CH2), 1.8-1.6 
(8H, m, CH2x4), 1.5-1.2 (8H, m, CH2x4), 0.89 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 197.9, 145.0, 136.0, 133.1, 128.8, 69.9, 62.3, 54.7, 36.2, 35.8, 33.5, 31.8, 
31.1, 30.2, 29.3, 28.2, 22.4. 
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Compound 49 - 3-morpholino-1-(4-(pentylthio)phenyl)propan-1-one  
 
S
O N
O
 
C18H27NO2S 
MW: 321.4775 
1H-NMR (400 MHz, CDCl3) δ: 7.83 (2H, AA’), 7.28 (2H, XX’), 3.69 (4H, t, CH2x2), 3.12 (2H, t, CH2), 
2.97 (2H, t, CH2), 2.81 (2H, t, SCH2), 2.49 (4H, m, CH2x2), 1.69 (4H, m, CH2x2), 1.37 (2H, m, CH2), 
0.90 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 197.9, 145.1, 133.5, 128.4, 126.3, 66.8, 53.7, 53.6, 35.8, 31.8, 31.0, 28.4, 
22.1, 13.8. 
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Compound 50 - 1-(4-(hexylthio)phenyl)-3-morpholinopropan-1-one 
S
O N
O
 
C19H29NO2S 
MW: 335.5041 
1H-NMR (400 MHz, CDCl3) δ: 7.84 (2H, AA’), 7.29 (2H, XX’), 3.71 (4H, t, CH2x2), 3.15 (2H, t, CH2), 
2.99 (2H, t, J=7.40 Hz, SCH2), 2.83 (2H, t, CH2), 2.50 (4H, t, CH2x2), 1.69 (2H, m, CH2), 1.44 (2H, m, 
CH2), 1.30 (4H, m, CH2x2), 0.89 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 197.9, 145.2, 137.1, 133.4, 128.8, 68.9, 53.7, 35.7, 33.6, 31.9, 31.3, 30.5, 
29.1, 28.5, 22.5. 
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Compound 51 - 1-(4-(heptylthio)phenyl)-3-morpholinopropan-1-one 
S
O N
O
 
C20H31NO2S 
MW: 349.5306 
1H-NMR (300 MHz, CDCl3) δ: 7.88 (2H, AA’), 7.30 (2H, XX’), 3.73 (4H, t, CH2x2), 3.15 (2H, t, CH2), 
3.00 (2H, t, J=7.20 Hz, SCH2), 2.84 (2H, t, CH2), 2.52 (4H, m, CH2x2), 1.69 (2H, m, CH2), 1.5-1.2 (8H, 
m, CH2x4), 0.90 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 197.7, 145.1, 136.1, 133.2, 128.9, 69.9, 54.7, 36.7, 35.4, 33.6, 31.9, 31.0, 
30.1, 29.4, 28.4, 22.5. 
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PATHWAY 1.2.1 
Synthesis of compound 52 (1-(4-(heptylsulfinyl)phenyl)-3-morpholinopropan-1-one) 
 
O N
O
S
mCPBA
DCM
O N
O
S
O
51 52  
Compound 51 (50 mg, 0.14 mmol) was dissolved in dichloromethane (10 mL) at 0°C, and a solution of 
meta-chloroperbenzoic acid (24 mg, 0.14 mmol) in 5 mL of dichloromethane was added dropwise. The 
solution was stirred at 0°C for 2 h and monitored by TLC (hexane/ethyl acetate 4:1). The reaction was 
then added with an aqueous solution of sodium hydroxyde 1N (30 mL) and extracted with DCM; the 
organic phase was washed with brine (2x20 mL) and dried over magnesium sulfate. The organic phase 
was the concentrated and purified by flash chromatography, eluting the product through a gradient of 
DCM/MeOH (from 95:5 to 90:10) to give a yellow oil. 
Yield: 30%. 
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Compound 52– 1-(4-(heptylsulfinyl)phenyl)-3-morpholinopropan-1-one 
O N
O
S
O  
C20H31NO3S 
MW: 365.5300 
1H-NMR (400 MHz, CDCl3) δ: 8.11 (2H, AA’), 7.74 (2H, XX’), 3.74 (4H, t, CH2x2), 3.24 (2H, t, CH2), 
2.9-2.8 (4H, t, CH2x2), 2.55 (4H, m, CH2x2), 1.80 (2H, m, CH2), 1.63 (2H, m, CH2), 1.5-1.2 (6H, m, 
CH2x3), 0.89 (3H, t, CH3). 
13C-NMR (75 MHz, CDCl3) δ: 198.1, 149.6, 128.8, 124.5, 66.8, 57.1, 53.7, 53.3, 36.2, 31.5, 28.8, 28.6, 
22.5, 22.0, 14.0. 
HRMS (ESI): calcd. (M+H)+ 366.2025, exper. 366.2225. 
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PATHWAY 2.1.1: 
 
H2N
R
N
R
NaBH4 NH
R
O
53
 
 
H2N
R
N
R
NaBH4 NH
R
O
54
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Synthesis of compounds 56 (N-benzylidene-2,2-diethoxyethanamine) and 57 (N-benzyl-2,2-
diethoxyethanamine) 
 
O H2N
O
O
MeOH N
O
O
NaBH4 NH
O
O
53 55
56 57
 
To a stirring solution of benzaldehyde (53, 500 mg, 0.477 mL, 4.72 mmol) in methanol (15 mL), 2,2-
diethoxyethanamine (55, 628 mg, 0.682 mL, 4.72 mmol) was added. The mixture was heated at 60°C for 
3 h, monitoring the formation of the imine by TLC (hexane/ethyl acetate 4:1). 
The solution was then divided in two halves: one of them was dried with magnesium sulfate and the 
solvent removed, in order to obtain the desired imine (56), while the second half was used for 
synthesizing the amine (57). In the latter case, the stirring solution was placed in an ice bath and carefully 
added with sodium boron hydride (269 mg, 7.08 mmol) and maintained at rt o/n. After the completion of 
the reaction, verified by TLC (hexane/ethyl acetate 4:1), the stirring solution was quenched at 0°C 
through the careful addition of a saturated aqueous solution of sodium hydroxy carbonate; the organic 
phase was then removed under reduced pressure, and the aqueous phase was extracted with 
dichloromethane (30 mL, 3 times). The combined organic phases were then washed with brine (20 mL, 
twice), dried with magnesium sulfate and the solvent was removed under reduced pressure to give a 
yellow oily product. 
Yield for the imine (56): 81%. 
Yield for the amine (57): 35%. 
The same reaction was repeated with 2-naphthaldehyde (54) instead of benzaldehyde, and also using 
different primary amines (instead of 2,2-diethoxyethanamine) as 3-morpholinopropan-1-amine or 4-
aminocyclohexanol in the same way. All the yields for the imines were between 73 and 85%, while for 
the amines were between 32 and 36%. 
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Compound 56 – N-benzylidene-2,2-diethoxyethanamine 
 
N O
O
 
C13H19NO2 
MW: 221.2955 
1H-NMR (300 MHz, CDCl3) δ: 8.21 (1H, s, CH=N), 7.66 (2H, m, ArH), 7.33 (3H, m, ArH), 4.73 (1H, t, 
J=5.40 Hz, CH), 3.71 (2H, dd, J=5.40, J=1.45, CHCH2), 3.65 (2H, m, OCH2), 3.51 (2H, m, OCH2), 1.12 
(6H, t, J=6.96 Hz, CH3x2). 
13C-NMR (75 MHz, CDCl3) δ: 163.4, 136.2, 130.7, 129.7, 129.0, 128.6, 128.2, 102.1, 64.7, 62.8, 15.4. 
HRMS (ESI): calcd. (M+H)+ 222.1416, exper. 222.1856. 
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Compound 57 - N-benzyl-2,2-diethoxyethanamine 
 
N
H
O
O
 
C13H21NO2 
  
MW: 223.3113 
1H-NMR (300 MHz, CDCl3) δ: 7.35 (4H, m, ArH), 7.24 (1H, m, ArH), 4.65 (1H, t, J=5.50 Hz, CH), 3.83 
(2H, s, ArCH2), 3.71 (2H, m, OCH2), 3.55 (2H, m, OCH2), 2.77 (2H, d, J=5.50 Hz, CHCH2), 1.23 (6H, t, 
J=7.00 Hz, CH3x2). 
13C-NMR (75 MHz, CDCl3) δ: 140.1, 128.4, 128.2, 127.0, 102.2, 64.2, 53.9, 51.6, 15.4. 
HRMS (ESI): calcd. (M+H)+ 224.1572, exper. 224.1667. 
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Compound 58 - 2,2-diethoxy-N-((naphthalen-3-yl)methylene)ethanamine 
 
N
O
O
 
C17H21NO2 
MW: 271.3541 
1H-NMR (300 MHz, CDCl3) δ: 8.47 (1H, s, CH=N), 8.1-7.9 (5H, m, ArH), 7.53 (2H, m, ArH), 4.88 (1H, 
t, J=5.41 Hz, CH), 3.87 (2H, dd, J=5.50 Hz, J=1.45 Hz, CHCH2), 3.78 (2H, m, OCH2), 3.64 (2H, m, 
OCH2), 1.24 (6H, t, J=6.91 Hz, CH3x2). 
13C-NMR (75 MHz, CDCl3) δ: 192.3, 163.6, 134.7, 133.9, 133.1, 130.1, 128.6, 127.7, 127.2, 126.5, 
123.8, 102.2, 64.8, 62.8, 15.4. 
HRMS (ESI): calcd. (M+H)+ 272.1572, exper. 272.1686. 
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Compound 59 - 2,2-diethoxy-N-((naphthalen-3-yl)methyl)ethanamine 
 
N
H
O
O
 
C17H23NO2 
MW: 273.3700 
1H-NMR (300 MHz, CDCl3) δ: 7.9-7.7 (4H, m, ArH), 7.5-7.4 (3H, m, ArH), 4.67 (1H, t, J=5.47 Hz, CH), 
4.00 (2H, s, CH2-Ar), 3.71 (2H, m, OCH2), 3.56 (2H, m, OCH2), 2.81 (2H, d, J=5.47 Hz, CHCH2), 1.23 
(6H, t, J=6.91 Hz, CH3x2). 
13C-NMR (75 MHz, CDCl3) δ: 137.7, 133.4, 132.7, 128.1, 127.7, 127.6, 126.6, 126.5, 125.9, 125.5, 
102.2, 62.4, 54.0, 51.6, 15.4. 
HRMS (ESI): calcd. (M+H)+ 274.1729, exper. 274.1623. 
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Compound 60 - N-benzylidene-3-morpholinopropan-1-amine 
 
N N
O  
C14H20N2O 
 MW: 232.3214 
1H-NMR (400 MHz, CDCl3) δ: 8.30 (1H, s, CH=N), 7.73 (2H, m, ArH), 7.42 (3H, m, ArH), 3.72 (4H, m, 
CH2x2), 3.66 (2H, t, CH2), 2.46 (6H, m, CH2x3), 1.91 (2H, m, CH2). 
13C-NMR (75 MHz, CDCl3) δ: 161.3, 136.2, 130.6, 128.6, 128.1, 67.0, 59.6, 56.7, 53.7, 27.7. 
HRMS (ESI): calcd. (M+H)+ 233.1576, exper. 233.1466. 
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Compound 61 - N-benzyl-3-morpholinopropan-1-amine 
 
N
H
N
O  
C14H22N2O 
MW: 234.3373 
1H-NMR (300 MHz, CDCl3) δ: 7.4-7.3 (5H, m, ArH), 3.78 (2H, s, CH2Ar) 3.67 (4H, t, CH2x2), 2.69 (2H, 
t, CH2), 2.4-2.3 (6H, m, CH2x3), 1.71 (2H, t, CH2). 
13C-NMR (75 MHz, CDCl3) δ: 140.0, 129.7, 128.8, 128.1, 127.3, 126.8, 66.9, 57.3, 53.7, 47.9, 26.4, 20.5. 
HRMS (ESI): calcd. (M+H)+ 235.1732, exper. 235.1632. 
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Compound 62 –3-morpholino-N-((naphthalen-3-yl)methylene)propan-1-amine 
 
N N
O  
C18H22N2O 
MW: 282.3801 
1H-NMR (400 MHz, CDCl3) δ: 8.47 (1H, s, CH=N), 8.1-7.9 (5H, m, ArH), 7.54 (2H, m, ArH), 3.8-3.7 
(6H, m, CH2x3), 2.49 (6H, m, CH2x3), 1.97 (2H, m, CH2). 
13C-NMR (100 MHz, CDCl3) δ: 161.3, 134.7, 133.9, 133.1, 129.7, 128.9, 128.4, 127.9, 127.1, 126.5, 
123.8, 67.0, 59.7, 56.7, 53.8, 27.8. 
HRMS (ESI): calcd. (M+H)+ 283.1732, exper. 283.1672. 
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Compound 63 - 3-morpholino-N-((naphthalen-3-yl)methyl)propan-1-amine 
 
N
H
N
O  
C18H24N2O 
MW: 284.3960 
1H-NMR (300 MHz, CDCl3) δ: 7.9-7.7 (4H, m, ArH), 7.5-7.4 (3H, m, ArH), 3.97 (2H, s, CH2), 3.71 (4H, 
t, CH2x2), 2.74 (2H, t, CH2), 2.43 (6H, m, CH2x3), 1.74 (2H, m, CH2). 
13C-NMR (75 MHz, CDCl3) δ: 137.9, 133.4, 132.6, 128.1, 127.7, 126.5, 126.4, 126.0, 125.6, 123.5, 
102.0, 67.0, 57.4, 54.1, 53.8, 53.5, 48.0, 26.7. 
HRMS (ESI): calcd. (M+H)+ 285.1889, exper. 285.1988. 
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Compound 64 - 4-(benzylideneamino)cyclohexanol 
 
N
OH
 
C13H17NO 
MW: 203.2802 
1H-NMR (400 MHz, CDCl3) δ: 8.36 (1H, s, CH=N), 7.74 (2H, m, ArH), 7.43 (3H, m, ArH), 3.75 (1H, m, 
CH), 3.23 (1H, m, CH), 2.09 (2H, m, CH2), 1.9-1.7 (4H, m, CH2x2), 1.54 (1H, bs, OH), 1.45 (2H, m, 
CH2). 
13C-NMR (100 MHz, CDCl3) δ: 159.4, 136.4, 130.5, 128.6, 128.1, 70.1, 68.9, 33.8, 32.2. 
HRMS (ESI): calcd. (M+H)+ 204.1310, exper. 204.1321. 
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Compound 65 - 4-(benzylamino)cyclohexanol 
 
N
H
OH
 
C13H19NO 
MW: 205.2961 
1H-NMR (400 MHz, CDCl3) δ: 7.4-7.3 (5H, m, ArH), 3.83 (2H, s, CH2Ar), 3.64 (1H, m, CH), 2.53 (1H, 
m, CH), 2.00 (4H, m, CH2x2), 1.28 (4H, m, CH2x2). 
13C-NMR (100 MHz, CDCl3) δ: 140.5, 128.5, 128.1, 126.1, 70.5, 55.4, 51.4, 33.9, 31.2. 
HRMS (ESI): calcd. (M+H)+ 206.1467, exper. 206.1362. 
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Compound 66 - 4-((naphthalen-3-yl)methyleneamino)cyclohexanol 
 
N
OH
 
C17H19NO 
MW: 253.3389 
1H-NMR (400 MHz, CDCl3) δ: 8.50 (1H, s, CH=N), 8.1-7.8 (5H, m, ArH), 7.53 (2H, m, ArH), 3.77 (1H, 
m, CH), 3.28 (1H, m, CH), 2.12 (2H, m, CH2), 1.9-1.7 (4H, m, CH2x2), 1.48 (2H, m, CH2). 
13C-NMR (100 MHz, CDCl3) δ: 159.6, 134.7, 134.1, 133.1, 129.7, 128.6, 128.4, 127.9, 127.1, 126.4, 
124.0, 70.2, 70.0, 69.1, 34.2, 33.8, 32.2. 
HRMS (ESI): calcd. (M+H)+ 254.1467, exper. 254.1565. 
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Compound 67 - 4-((naphthalen-3-yl)methylamino)cyclohexanol 
 
N
H
OH
 
C17H21NO 
MW: 255.3547 
1H-NMR (400 MHz, CDCl3) δ: 7.9-7.8 (4H, m, ArH), 7.5-7.4 (3H, m, ArH), 3.99 (2H, s, CH2Ar), 3.65 
(1H, m, CH), 2.57 (1H, m, CH), 2.1-1.9 (4H, m, CH2x2), 1.4-1.2 (4H, m, CH2x2). 
13C-NMR (100 MHz, CDCl3) δ: 138.1, 133.5, 132.6, 128.1, 127.7, 127.6, 126.5, 126.4, 126.0, 125.6, 
70.5, 55.5, 51.5, 34.0, 31.3. 
HRMS (ESI): calcd. (M+H)+ 256.1623, exper. 256.1532. 
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PATHWAY 2.1.2: 
 
H2N
R
NaBH4N O N NH
R
 
 
O
OO
O
H2N
R
NaBH4
H
N
OO
O
R
 
68 
69 
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Synthesis of compound 71 (1-benzyl-N-(3-morpholinopropyl)piperidin-4-amine) 
 
NaBH4H2N N
O MeOHN O
N NH
N O
 
 
To a stirring solution of N-benzyl piperidone (68, 500 mg, 0.490 mL, 2.65 mmol) in methanol (15 mL), 
3-morpholinopropylamine (70, 380 mg, 0.386 mL, 2.65 mmol) was added. The reaction was heated at 
60°C for 3 h, then cooled to 0°C in an ice bath and carefully added with sodium boron hydride (201 mg, 
5.30 mmol). The reaction, monitored by TLC (hexane/ethyl acetate 4:1) was allowed to stir o/n at rt, then 
quenched at 0°C through the careful addition of a saturated aqueous solution of sodium hydroxy 
carbonate; the organic phase was then removed under reduced pressure, and the aqueous phase was 
extracted with dichloromethane (30 mL, 3 times). The combined organic phases were then washed with 
brine (20 mL, twice), dried with magnesium sulfate and the solvent was removed under reduced pressure 
to give a very dense yellow liquid as a product. 
Yield: 78%. 
With the same procedure, N-benzyl piperidine was reacted also with 2,2-diethoxyethanamine, with a 
yield of 71%. 2,4,6-trimethoxybenzaldehyde was reacted with allylamine and 2,2-diethoxyethanamine, to 
give the corresponding secondary amines. Yields were 60% and 67%, respectively. 
 
68 70 71 
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Compound 71 - 1-benzyl-N-(3-morpholinopropyl)piperidin-4-amine 
 
N NH
N O
 
C18H30N2O2 
MW: 317.4689 
1H-NMR (400MHz, CDCl3) δ: 7.4-7.2 (5H, m, ArH), 3.71 (4H, t, CH2x2), 3.51 (2H, s, ArCH2), 2.96 (1H, 
m, NH), 2.89 (2H, m, CH2), 2.81 (2H, t, CH2), 2.61 (1H, m, CH), 2.5-2.4 (6H, m, CH2x3), 2.03 (2H, m, 
CH2), 1.95 (2H, m, CH2), 1.81 (2H, m, CH2), 1.55 (2H, m, CH2). 
13C-NMR (100MHz, CDCl3) d: 138.3, 129.0, 128.2, 127.0, 67.0, 62.9, 57.6, 55.0, 53.7, 53.4, 52.1, 45.3, 
31.6. 
HRMS (ESI): calcd. (M+H)+ 318.2467, exper. 318.2448. 
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Compound 72 – 1-benzyl-N-(2,2-diethoxyethyl)piperidin-4-amine 
 
N NH
O
O
 
C18H30N2O2 
MW: 306.4430 
1H-NMR (300MHz, DMSO-d6) δ: 7.29 (5H, m, ArH), 4.46 (1H, t, CH), 3.58 (2H, m, CH2), 3.46 (2H, m, 
CH2), 3.41 (2H, s, CH2Ar), 2.71 (2H, d, CH2), 2.59 (1H, m, CH), 1.92 (2H, m, CH2), 1.71 (2H, m, CH2), 
1.39 (2H, m, CH2), 1.21 (2H, m, CH2), 1.10 (6H, t, CH3x2). 
13C-NMR (100MHz, DMSO-d6) d: 138.7, 138.6, 128.6, 128.0, 126.7, 101.9, 62.3, 61.1, 51.8, 48.8, 34.4, 
32.3, 15.3. 
HRMS (ESI): calcd. (M+H)+ 307.2307, exper. 307.2553. 
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Compound 73 - N-(2,4,6-trimethoxybenzyl)prop-2-en-1-amine 
 
O
OO
H
N
 
C13H19NO3 
MW: 237.2949 
1H-NMR (300MHz, CDCl3) δ: 6.04 (2H, "s", ArH), 5.9-5.8 (1H, m, CH), 5.1-4.9 (2H, m, CHCH2), 3.7-
3.6 (11H, m, OCH3x3 + ArCH2), 3.12 (2H, m, NHCH2CH). 
 
13C-NMR (75 MHz, CDCl3) δ: 160.3, 159.3, 137.3, 115.4, 108.8, 90.3, 55.6, 55.3, 51.5, 40.7. 
 
HRMS (ESI): calcd. (M+H)+ 238.1635, exper. 238.1495. 
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Compound 74 - N-(2,4,6-trimethoxybenzyl)-2,2-diethoxyethanamine 
 
O
OO
H
N
O
O
 
 
C16H27NO5 
MW: 313.3893 
1H-NMR (400MHz, CDCl3) δ: 5.91 (2H, s, ArH), 4.40 (1H, t, CH), 3.59 (2H, s, ArCH2), 3.57 (6H, s, 
CH3x2), 3.56 (3H, s, CH3), 3.43 (2H, m, CH2), 3.29 (2H, m, CH2), 2.47 (2H, d, CH2), 0.98 (6H, t, 
CH3x2). 
13C-NMR (100MHz, CDCl3) d: 166.7, 155.8, 130.7, 102.3, 99.6, 61.9, 55.4, 50.1, 48.7, 15.2. 
HRMS (ESI): calcd. (M+H)+ 314.1889, exper. 314.2896. 
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PATHWAY 2.2: 
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Synthesis of compound 77 (4-butoxybenzaldehyde) 
 
O
Br
K2CO3
ACN
O
OH O  
 
4-hydroxybenzaldehyde (75, 1.000 g, 8.19 mmol) was dissolved in 20 mL of acetonitrile in the presence 
of potassium carbonate (2.260 g, 16.38 mmol); the mixture was kept under magnetic stirring at rt for 1 h. 
Then, 1-bromobutane (17, 1.009 g, 0.791 mL, 7.37 mmol) was added and the reaction was heated at 60°C 
for 24 h and monitored by TLC (hexane/ethyl acetate 4:1). 
After that, the reaction was filtered to remove the salts, and evaporated; the residue was dissolved in 
diethyl ether (30 mL) and washed with a solution of NaOH 10% (30 mL, 3 times) and brine (20 mL). The 
organic phase was dried with MgSO4 and evaporated to give a colorless oily product. 
Yield: 72%. 
With the same procedure, the synthesis of more ethers was performed using other aloalkanes, i.e. 1-
iodoethane, 1-bromopentane, 1-bromohexane, 1-bromoheptane and 1-bromooctane. For all of these 
reactions, the obtained yields were between 55 and 75%. 
75 
17 
77 
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Compound 78 – 4-ethoxybenzaldehyde 
 
O
O  
C9H10O2 
MW: 150.1745. 
1H-NMR (300MHz, CDCl3) δ: 9.87 (1H, s, CHO), 7.82 (2H, AA'), 6.99 (2H, XX'), 4.10 (2H, q, OCH2), 
1.44 (3H, t, CH3). 
HRMS (ESI): calcd. (M+H)+ 151.0681, exper. 151.1047.  
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Compound 77 - 4-butoxybenzaldehyde 
 
O
O  
C11H14O2 
MW: 178.2277. 
1H NMR (400MHz, CDCl3) δ: 9.89 (1H, s, CHO), 7.84 (2H, AA’), 7.01 (2H, XX’), 4.06 (2H, t, OCH2), 
1.81 (2H, m, CH2), 1.52 (2H, m, CH2), 1.00 (3H, t, CH3).  
HRMS (ESI): calcd. (M+H)+ 179.0994, exper. 179.1127. 
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Compound 79 – 4-pentyloxybenzaldehyde 
 
O
O  
C12H16O2 
MW: 192.2542 
1H NMR (400MHz, CDCl3) δ: 9.85 (1H, s, CHO), 7.79 (2H, AA’), 6.97 (2H, XX’), 4.01 (2H, t, OCH2), 
1.79 (2H, m, CH2), 1.39 (4H, m, 2xCH2), 0.92 (3H, t, CH3).  
HRMS (ESI): calcd. (M+H)+ 193.1150, exper. 193.1250. 
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Compound 80 – 4-(hexyloxy)benzaldehyde 
 
O
O  
C13H18O2 
MW: 206.2808 
1H NMR (400MHz, CDCl3) δ: 9.89 (1H, s, CHO), 7.84 (2H, AA’), 7.01 (2H, XX’), 4.02 (2H, t, OCH2), 
1.79 (2H, m, CH2), 1.46 (4H, m, 2xCH2), 1.34 (2H, m, CH2), 0.91 (3H, t, CH3).  
HRMS (ESI): calcd. (M+1)+ 207.1307, exper. 207.1439. 
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Compound 81 - 4-(heptyloxy)benzaldehyde 
 
O
O  
C14H20O2 
MW: 220.3074 
1H NMR (400MHz, CDCl3) δ: 9.86 (1H, s, CHO), 7.81 (2H, AA’), 6.97 (2H, XX’), 4.02 (2H, t, OCH2), 
1.80 (2H, m, CH2), 1.46 (2H, m, CH2), 1.39-1.27 (6H, m, 3xCH2), 0.89 (3H, t, CH3).  
HRMS (ESI): calcd. (M+1)+ 221.1463, exper. 221.1531. 
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Compound 82 – 4-(octyloxy)benzaldehyde 
 
 
O
O  
C15H22O2 
 
MW: 234.3339 
 
1H-NMR (400 MHz, CDCl3) δ: 9.90 (1H, s, CHO), 7.82 (2H, AA’), 7.03 (2H, XX’), 4.05 (2H, t, OCH2), 
1.81 (2H, m, CH2), 1.50 (4H, m, CH2x2), 1.32 (4H, m, CH2x2), 1,20 (2H, m, CH2), 0.91 (3H, t, CH3). 
 
HRMS (ESI): calcd. (M+1)+ 235.1619, exper. 235.1741. 
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Synthesis of compound 83 (3,5-dibutoxybenzaldehyde) 
 
HO OH
O
Br
K2CO3
ACN
O O
O
 
 
3,5-dihydroxybenzaldehyde (76, 100 mg, 0.72 mmol) was dissolved in 15 mL of acetonitrile in the 
presence of potassium carbonate (199 mg, 1.44 mmol); the mixture was kept under magnetic stirring at rt 
for 1 h. Then, 1-bromobutane (17, 178 mg, 0.140 mL, 1.30 mmol) was added and the reaction was heated 
at 60°C for 24 h and monitored by TLC (hexane/ethyl acetate 4:1). 
Then, the reaction was filtered and the solvent evaporated; the residue was dissolved in diethyl ether (30 
mL) and washed with a solution of NaOH 10% (30 mL, 3 times) and brine (20 mL). The organic phase 
was dried with MgSO4 and evaporated to give a colorless oil as a product. 
Yield: 34%. 
With the same procedure, the synthesis was repeated on 3,5-dihydroxybenzaldehyde with 1-
bromoheptane; in this case, the product had to be purified through flash chromatography (hexane/ethyl 
acetate 3:1; Rf=0.4). The final yield was 21%. 
76 17 83 
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Compound 83 - 3,5-dibutoxybenzaldehyde 
 
O O
O
 
C15H22O3 
MW: 250.3334 
1H NMR (400 MHz, MeOD) δ: 9.87 (1H, s, CHO), 7.02 (2H, d, ArH), 6.73 (1H, t, ArH), 4.00 (4H, t, 
OCH2x2), 1.7-1.8 (4H, m, CH2x2), 1.6-1.4 (4H, m, CH2x2); 1.00 (6H, t, CH3x2). 
HRMS (ESI): calcd. (M+H)+ 251.1569, exper. 251.1686. 
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Compound 84 - 3,5-bis(heptyloxy)benzaldehyde 
 
O O
O
 
C21H34O3 
MW: 334.4929 
1H NMR (400 MHz, MeOD) δ: 9.88 (1H, s, CHO), 7.04 (2H, d, ArH), 6.76 (1H, t, ArH), 4.04 (4H, t, 
OCH2x2), 1.8-1.7 (4H, m, CH2x2), 1.5-1.3 (16H, m, CH2x8), 0.94 (6H, t, CH3x2). 
HRMS (ESI): calcd. (M+H)+ 335.2508, exper. 335.2651. 
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Synthesis of compound 86 (N-(4-ethoxybenzyl)propan-1-amine) 
 
O
O
NH2
NaBH4
MeOH
O
H
N
 
 
To a stirring solution of compound 78 (300 mg, 2 mmol) in methanol (15 mL), propylamine (85, 118 mg, 
0.164 mL, 2 mmol) was added. The reaction was heated at 60°C for 3 h, then cooled to 0°C in an ice bath 
and carefully added with sodium boron hydride (152 mg, 4 mmol). The reaction was allowed to stir o/n at 
rt; after monitoring it by TLC (hexane/ethyl acetate 4:1), the morning after the stirring solution was 
quenched at 0°C through the careful addition of a saturated aqueous solution of sodium hydroxy 
carbonate; the organic phase was removed under reduced pressure, and the aqueous phase was extracted 
with dichloromethane (30 mL, 3 times). The combined organic phases were then washed with brine (20 
mL, twice), dried with MgSO4 and the solvent was removed under reduced pressure to give the product as 
a light yellow oil. 
Yield: 63%. 
With the same procedure also compounds 77, 79, 80, 81 and 82 were reacted with other amines, as 
ethanolamine, butylamine, serinol, 2,2-diethoxyethanamine, phenylethylamine, allylamine, 2-(pyrrolidin-
1-yl)ethanamine and 2-(2-aminoethoxy)ethanol, to give the corresponding secondary amines. Yields were 
between 60 and 83%. 
78 
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Compound 86 - N-(4-ethoxybenzyl)propan-1-amine 
 
O
H
N
 
C12H19NO 
MW: 193.2854 
1H-NMR (400MHz, DMSO-d6) δ: 7.21 (2H, AA'), 6.84 (2H, XX'), 3.99 (2H, q, OCH2), 3.60 (2H, s, 
CH2Ar), 2.43 (2H, t, NCH2CH2), 1.42 (2H, m, CH2), 1.31 (3H, t, CH3), 0.85 (3H, t, CH3). 
13C-NMR (100 MHz, MeOD) δ: 158.7, 129.8, 122.6, 110.1, 102.2, 68.0, 66.4, 56.2, 28.4, 14.0. 
HRMS (ESI): calcd. (M+H)+ 194.1467, exper. 194.1526. 
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Compound 87 - 2-(4-butoxybenzylamino)propane-1,3-diol 
 
O
H
N
OH
OH
 
C14H23NO3 
MW: 253.3373 
1H-NMR (400MHz, CDCl3) δ: 7.24 (2H, AA’), 6.87 (2H, XX’), 3.96 (2H, t, OCH2), 3.77 (2H, s, 
CH2NH), 3.73 (2H, m, CH2OH), 3.60 (2H, m, CH2OH), 2.79 (1H, m, CH), 1.78 (2H, m, CH2), 1.59 (2H, 
m, CH2), 0.99 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 158.6, 129.0, 127.8, 114.3, 66.1, 61.1, 58.3, 51.2, 31.4, 23.6, 13.8. 
HRMS (ESI): calcd. (M+H)+ 254.1678, exper. 254.1768. 
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Compound 88 - 2-(4-pentyloxybenzylamino)propane-1,3-diol 
 
O
H
N
OH
OH
 
C15H25NO3 
MW: 267.3639 
1H-NMR (400MHz, CDCl3) δ: 7.21 (2H, AA’), 6.86 (2H, XX’), 3.94 (2H, t, OCH2), 3.72 (2H, s, 
CH2NH), 3.67 (2H, m, CH2OH), 3.58 (2H, m, CH2OH), 2.72 (1H, m, CH), 1.79 (2H, m, CH2), 1.43 (4H, 
m, CH2x2), 0.96 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 158.1, 129.0, 127.9, 114.0, 66.8, 61.2, 58.4, 50.0, 31.0, 22.1, 19.0, 13.7. 
HRMS (ESI): calcd. (M+H)+ 268.1834, exper. 268.1752. 
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Compound 89 - 2-(4-(hexyloxy)benzylamino)propane-1,3-diol 
 
O
H
N
OH
OH
 
C16H27NO3 
MW: 281.3905 
1H-NMR (400MHz, CDCl3) δ: 7.23 (2H, AA’), 6.86 (2H, XX’), 3.94 (2H, t, OCH2), 3.75 (2H, s, 
CH2NH), 3.70 (2H, m, CH2OH), 3.59 (2H, m, CH2OH), 2.67 (1H, m, CH), 1.78 (2H, m, CH2), 1.47 (2H, 
m, CH2), 1.36 (4H, m, CH2x2), 0.93 (3H, t, CH3).  
13C-NMR (100 MHz, CDCl3) δ: 158.3, 129.2, 128.1, 114.2, 66.4, 61.0, 58.3, 50.1, 31.2, 26.0, 22.7, 19.0, 
13.8. 
HRMS (ESI): calcd. (M+1)+ 282.1991, exper. 282.2165. 
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Compound 90 - 2-(4-(heptyloxy)benzylamino)propane-1,3-diol 
 
O
H
N
OH
OH
 
C17H29NO3 
MW: 295.4171 
1H-NMR (400MHz, CDCl3) δ: 7.21 (2H, AA’), 6.85 (2H, XX’), 3.93 (2H, t, OCH2), 3.72 (2H, s, 
CH2NH), 3.67 (2H, m, CH2OH), 3.58 (2H, m, CH2OH), 2.71 (1H, m, CH), 1.78 (2H, m, CH2), 1.46 (2H, 
m, CH2), 1.4-1.2 (6H, m, CH2x3), 0.92 (3H, t, CH3).  
13C-NMR (100 MHz, CDCl3) δ: 158.1, 129.2, 128.3, 114.4, 66.7, 61.1, 58.1, 50.2, 31.4, 26.1, 22.9, 19.0, 
18.9, 13.7. 
HRMS (ESI): calcd. (M+1)+ 296.2147, exper. 296.2299. 
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Compound 91 - 2-(4-(octyloxy)benzylamino)propane-1,3-diol 
 
O
H
N
OH
OH
 
C18H31NO3 
MW: 309.4436 
1H-NMR (400 MHz. CDCl3) δ: 7.24 (2H, m, AA’). 6.87 (2H, m, XX’), 3.95 (2H, t, OCH2), 3.78 (2H, s, 
CH2NH), 3.74 (2H, m, CH2OH), 3.60 (2H, m, CH2OH), 2.82 (1H, m, CH), 1.80 (2H, m, CH2), 1.33 (10H, 
m, CH2x5), 0.92 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 158.2, 129.4, 128.5, 114.3, 67.7, 62.1, 58.2, 50.3, 31.3, 29.7, 26.0, 22.8, 
19.1, 19.0, 13.8. 
HRMS (ESI): calcd. (M+1)+ 310.2303, exper. 310.2431. 
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Compound 92 - 2-(4-butoxybenzylamino)ethanol 
 
H
N
OH
O  
C13H21NO2 
MW: 223.3113 
1H-NMR (400MHz, CDCl3) δ: 7.23 (2H, AA’), 6.88 (2H, XX’), 3.97 (2H, t, OCH2), 3.76 (2H, s, CH2Ar), 
3.67 (2H, t, CH2), 2.82 (2H, t, CH2), 1.78 (2H, m, CH2), 1.51 (2H, m, CH2), 0.99 (3H, t, CH3).  
13C-NMR (100 MHz, CDCl3) δ: 159.1, 131.1, 128.9, 114.0, 103.2, 77.1, 76.1, 68.2, 52.7, 28.1, 22.3, 14.0.  
HRMS (ESI): calcd. (M+H)+ 224.1572, exper. 224.1632. 
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Compound 93 - 2-(4-(pentyloxy)benzylamino)ethanol 
 
H
N
OH
O  
C14H23NO2 
MW: 237.3379 
1H-NMR (400MHz, CDCl3) δ: 7.23 (2H, AA’), 6.87 (2H, XX’), 3.95 (2H, t, OCH2), 3.75 (2H, s, CH2Ar), 
3.67 (2H, t, CH2), 2.80 (2H, t, CH2), 1.80 (2H, m, CH2), 1.43 (4H, m, CH2x2), 0.95 (3H, t, CH3).  
13C-NMR (100 MHz, CDCl3) δ: 159.3, 130.1, 127.9, 114.1, 103.3, 77.3, 77.0, 76.7, 68.0, 52.6, 28.2, 22.4, 
14.0.  
HRMS (ESI): calcd. (M+H)+ 238.1729, exper. 238.1893. 
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Compound 94 - 2-(4-(hexyloxy)benzylamino)ethanol 
 
H
N
OH
O  
C15H25NO2 
MW: 251.3645 
1H-NMR (400MHz, CDCl3) δ: 7.22 (2H, AA’), 6.86 (2H, XX’), 3.96 (2H, t, OCH2), 3.76 (2H, s, CH2Ar), 
3.68 (2H, t, CH2), 2.81 (2H, t, CH2), 1.79 (2H, m, CH2), 1.48 (2H, m, CH2), 1.36 (4H, m, CH2x2) 0.93 
(3H, t, CH3).  
13C-NMR (100 MHz, CDCl3) δ: 159.0, 130.3, 128.2, 114.3, 103.2, 77.2, 77.0, 76.6, 74.8, 68.2, 52.5, 28.1, 
22.2, 14.1.  
HRMS (ESI): calcd. (M+H)+ 252.1885, exper. 252.1985. 
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Compound 95 - 2-(2-(4-(pentyloxy)benzylamino)ethoxy)ethanol 
 
H
N
O
O
OH
 
C16H27NO3 
MW: 281.3905 
1H-NMR (400MHz, CDCl3) δ: 7.23 (2H, AA’), 6.86 (2H, XX’), 3.95 (2H, t, OCH2), 3.75 (2H, s, CH2Ar), 
3.71 (2H, t, CH2), 3.62 (2H, t, CH2), 3.58 (2H, t, CH2), 2.82 (2H, t, CH2), 1.79 (2H, m, CH2), 1.43 (4H, m, 
CH2x2), 0.95 (3H, t, CH3).  
13C-NMR (100MHz, CDCl3) d: 158.2, 130.0, 129.1, 114.1, 72.7, 69.8, 68.9, 61.7, 52.8, 48.3, 29.5, 26.3, 
22.4, 14.0. 
HRMS (ESI): calcd. (M+H)+ 282.1991, exper. 282.1897. 
 
208 
 
Compound 96 - 2-(2-(4-(hexyloxy)benzylamino)ethoxy)ethanol 
 
H
N
O
O
OH
 
C17H29NO3 
MW: 295.4171 
1H-NMR (400MHz, CDCl3) δ: 7.21 (2H, AA’), 6.84 (2H, XX’), 3.93 (2H, t, OCH2), 3.72 (2H, s, CH2Ar), 
3.68 (2H, t, CH2), 3.59 (2H, t, CH2), 3.54 (2H, t, CH2), 2.79 (2H, t, CH2), 1.77 (2H, m, CH2), 1.45 (2H, m, 
CH2), 1.34 (4H, m, CH2x2), 0.91 (3H, t, CH3).  
13C-NMR (100MHz, CDCl3) d: 158.4, 130.3, 129.2, 114.4, 72.6, 69.5, 68.1, 61.5, 52.9, 48.0, 31.6, 29.1, 
26.2, 22.2, 14.1. 
HRMS (ESI): calcd. (M+H)+ 296.2147, exper. 296.2136. 
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Compound 97 - 2-(2-(4-(heptyloxy)benzylamino)ethoxy)ethanol 
 
H
N
O
O
OH
 
C18H31NO3 
MW: 309.4436 
1H-NMR (400 MHz, CDCl3) δ: 7.23 (2H, AA’), 6.85 (2H, XX’), 3.95 (2H, t, CH2), 3.76 (2H, s, CH2Ar), 
3.72 (2H, t, OCH2), 3.63 (2H, t, OCH2), 3.58 (2H, t, OCH2), 3.36 (1H, bs, NH), 2.83 (2H, t, CH2), 1.78 
(2H, m, CH2), 1.46 (2H, m, CH2), 1.4-1.3 (6H, m, CH2x3), 0.91 (3H, t, CH3) . 
 
13C-NMR (100MHz, CDCl3) d: 158.5, 130.6, 129.6, 114.5, 72.5, 69.6, 68.0, 61.6, 52.8, 48.2, 31.8, 29.3, 
29.0, 26.0, 22.6, 14.1. 
HRMS (ESI): calcd. (M+H)+ 310.2304, exper. 310.2488. 
210 
 
Compound 98 - N-(4-butoxybenzyl)-2,2-diethoxyethanamine 
 
O
H
N
O
O
 
C17H29NO3 
MW: 295.4171 
1H-NMR (400 MHz, CDCl3) δ: 7.20 (2H, AA’), 6.83 (2H, XX’), 4.60 (1H, t, CHCH2), 3.92 (2H, t, 
OCH2), 3.72 (2H, s, CH2Ar), 3.66 (2H, m, OCH2), 3.51 (2H, m, OCH2), 2.72 (2H, d, CHCH2), 1.74 (2H, 
m, CH2) 1.48 (2H, m, CH2), 1.24 (6H, t, J=14.0 Hz, CH3x2), 0.96 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 158.3, 131.9, 129.3, 114.4, 102.1, 67.6, 62.3, 53.3, 51.4, 31.8, 19.3, 15.4, 
13.9. 
HRMS (ESI): calcd. (M+H)+ 296.2147, exper. 296.2304. 
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Compound 99 - N-(4-(pentyloxy)benzyl)-2,2-diethoxyethanamine 
 
O
H
N
O
O
 
C18H31NO3 
MW: 309.4436 
1H-NMR (400MHz, CDCl3) δ: 7.22 (2H, AA’), 6.85 (2H, XX’), 4.62 (1H, t, CHCH2), 3.94 (2H, t, OCH2), 
3.74 (2H, s, CH2Ar), 3.68 (2H, m, OCH2), 3.53 (2H, m, OCH2), 2.74 (2H, d, CHCH2), 1.78 (2H, m, CH2), 
1.42 (4H, m, CH2x2), 1.21 (6H, t, CH3x2), 0.94 (3H, t, CH3).  
13C-NMR (100 MHz, CDCl3) δ: 158.2, 131.8, 129.1, 114.2, 102.0, 67.3, 62.3, 53.1, 51.6, 31.7, 22.4, 19.0, 
15.2, 13.8. 
HRMS (ESI): calcd. (M+H)+ 310.2304, exper. 310.2430. 
212 
 
Compound 100 - N-(4-(hexyloxy)benzyl)-2,2-diethoxyethanamine 
 
O
H
N
O
O
 
C19H33NO3 
MW: 323.4702 
1H-NMR (400MHz, CDCl3) δ: 7.22 (2H, AA’), 6.86 (2H, XX’), 4.63 (1H, t, CHCH2), 3.95 (2H, t, OCH2), 
3.75 (2H, s, CH2Ar), 3.69 (2H, m, OCH2), 3.54 (2H, m, OCH2), 2.75 (2H, d, CHCH2), 1.78 (2H, m, CH2), 
1.47 (2H, m, CH2), 1.36 (4H, m, CH2x2), 1.21 (6H, t, CH3x2), 0.92 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 158.6, 131.5, 129.2, 114.3, 101.9, 67.2, 62.5, 53.4, 51.5, 31.8, 27.3, 21.4, 
19.5, 15.1, 13.9. 
HRMS (ESI): calcd. (M+H)+ 324.2460, exper. 324.2321. 
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Compound 101 - N-(4-(heptyloxy)benzyl)--2,2-diethoxyethanamine 
 
O
H
N
O
O
 
C20H35NO3 
MW: 337.4968 
1H-NMR (400 MHz, CDCl3) δ: 7.21 (2H, AA’), 6.84 (2H, XX’), 4.64 (1H, t, CHCH2), 3.96 (2H, t, 
OCH2), 3.77 (2H, s, CH2Ar), 3.66 (2H, m, OCH2), 3.51 (2H, m, OCH2), 2.74 (2H, d, CHCH2), 1.77 (2H, 
m, CH2), 1.42 (2H, m, CH2), 1.30 (6H, m, CH2x3), 1.20 (6H, t, CH3x2), 0.90 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 158.3, 131.9, 129.4, 114.4, 102.1, 68.0, 62.4, 53.2, 51.4, 31.8, 29.3, 29.1, 
26.0, 22.6, 15.4, 14.1. 
HRMS (ESI): calcd. (M+H)+ 338.2617, exper. 338.2812. 
214 
 
Compound 102 - N-(4-butoxybenzyl)propan-1-amine 
 
H
N
O  
C14H23NO 
MW: 221.3385 
1H-NMR (300MHz, MeOD): δ: 7.22 (2H, AA’), 6.83 (2H, XX’), 3.91 (2H, t, OCH2), 2.52 (2H, t, 
CH2Ar), 2.25 (2H, m, CH2), 1.54 (6H, m, CH2x3), 0.99 (6H, m, CH3x2). 
13C-NMR (100 MHz, MeOD) δ: 157.4, 127.2, 123.4, 111.9, 102.0, 69.0, 63.4, 55.2, 31.7, 29.6, 22.1, 15.0. 
HRMS (ESI): calcd. (M+H)+ 222.1780, exper. 222.1796. 
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Compound 103 – N-(4-(pentyloxy)benzyl)-3-morpholinopropan-1-amine 
 
H
N
O
N
O
 
C19H32N2O2 
MW: 320.4696 
1H-NMR (400 MHz, CDCl3) δ: 7.20 (2H, AA’), 6.83 (2H, XX’), 3.90 (2H, m, CH2), 3.68 (6H, m, 
CH2x3), 2.65 (2H, m, CH2), 2.38 (6H, m, CH2x3) 1.68 (2H, m, CH2), 1.78 (2H, m, CH2), 1.40 (4H, m, 
CH2x2); 0.92 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 158.1, 132.1, 129.1, 114.3, 67.9, 66.9, 57.3, 53.7, 53.3, 47.8, 28.9, 28.1, 
26.5, 22.4, 13.9.  
HRMS (ESI): calcd. (M+H)+ 321.2464, exper. 321.2694. 
 
216 
 
Compound 104 – N-(4-(hexyloxy)benzyl)prop-2-en-1-amine 
 
H
N
O  
C16H25NO 
MW: 247.3758 
1H-NMR (300MHz, MeOD): δ: 7.08 (AA’, 2H), 6.71 (XX’, 2H), 5.79 (1H, m, CH), 5.07 (1H, dd, CH), 
4.98 (1H, dd, CH), 3.78 (2H, t, OCH2), 3.57 (2H, s, CH2Ar), 3.12 (2H, d, CH2), 1.63 (2H, m, CH2), 1.10 
(6H, m, CH2x3), 0.30 (3H, t, CH3). 
13C-NMR (100MHz, MeOD):158.3, 136.8, 136.7, 132.0, 129.3, 114.3, 68.2, 52.7, 51.5, 31.4, 29.2, 25.9, 
22.7, 14.4. 
HRMS (ESI): calcd. (M+H)+ 248.1936, exper. 248.1943. 
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Compound 105 - N-(4-butoxybenzyl)-2-phenylethanamine 
 
H
N
O  
C19H25NO 
MW: 283.4079 
1H-NMR (400 MHz, CDCl3) δ: 7.4-7.2 (7H, m, ArH), 6.91 (2H, m, ArH), 4.00 (2H, m, CH2), 3.77 (2H, s, 
CH2Ar), 3.0-2.8 (4H, m, CH2x2), 1.81 (2H, m, CH2), 1.55 (2H, m, CH2), 1.02 (3H, t, CH3). 
13C-NMR (100 MHz, CDCl3) δ: 159.1, 143.1, 140.9, 130.7, 130.1, 127.0, 107.1, 102.4, 70.2, 55.4, 50.2, 
37.2, 30.4, 15.8, 11.1. 
HRMS (ESI): calcd. (M+H)+ 284.1936, exper. 284.2113. 
 
218 
 
Compound 106 - N-(3,5-dibutoxybenzyl)-2-phenylethanamine 
 
H
N
OO  
C23H33NO2 
MW: 355.5136 
1H-NMR (400 MHz, CDCl3) δ: 7.3-7.2 (5H, m, ArH), 6.44 (2H, d, J=2.41 Hz, ArH), 6.36 (1H, t, J=4.42 
Hz, ArH), 3.92 (4H, t, OCH2x2), 3.68 (2H, s, CH2Ar), 2.82 (4H, m, CH2x2), 1.8-1.7 (4H, m, CH2x2), 1.5-
1.4 (4H, m, CH2x2), 0.98 (6H, t, CH3x2). 
13C-NMR (100 MHz, CDCl3) δ: 160.4, 141.1, 139.5, 128.3, 128.1, 125.9, 106.4, 100.0, 67.3, 52.8, 49.6, 
35.2, 31.0, 18.8, 12.9. 
HRMS (ESI): calcd. (M+H)+ 356.2511, exper. 356.2625. 
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Compound 107 - N-(4-(heptyloxy)benzyl)propan-1-amine 
 
H
N
O  
C17H29NO 
MW: 263.4183 
1H-NMR (300MHz, MeOD): δ: 7.20 (2H, AA’), 6.83 (2H, XX’), 3.91 (2H, t, OCH2), 3.71 (2H, s, CH2), 
3.61 (2H, s, CH2Ar), 2.26 (2H, t, NCH2), 1.78 (2H, m, CH2), 1.47 (4H, m, CH2x2), 1.32 (8H, m, CH2x4), 
0.89 (6H, m, CH3x2). 
13C-NMR (100 MHz, CDCl3) δ: 158.4, 139.9, 107.7, 99.8, 69.6, 56.2, 48.8, 31.2, 30.9, 28.3, 28.0, 25.4, 
23.3, 21.3, 14.0. 
HRMS (ESI): calcd. (M+H)+ 264.2249, exper. 264.2254. 
 
220 
 
Compound 108 - N-(4-(heptyloxy)benzyl)-2-(pyrrolidin-1-yl)ethanamine 
 
H
N
N
O  
C20H34N2O 
MW: 318.4968 
1H-NMR (400 MHz, acetone-d6) δ: 7.32 (2H, AA’), 6.86 (2H, XX’), 3.97 (2H, t, OCH2), 3.72 (2H, s, 
NCH2), 2.69 (2H, m, CH2), 2.62 (2H, m, CH2), 2.5-2.4 (4H, m, CH2x2), 2.08 (2H, m, CH2), 1.8-1.7 (m, 
4H, CH2x2), 1.48 (2H, m, CH2), 1.4-1.2 (6H, m, CH2x3), 0.92 (3H, t, CH3). 
¹³C-NMR (75 MHz, CDCl3) δ: 158.2, 129.9, 129.4, 114.3, 67.9, 55.5, 54.3, 54.1, 53.2, 47.2, 31.8, 29.2, 
29.0, 23.4, 22.6, 14.1 
HRMS (ESI): calcd. (M+H)+ 319.2671, exper. 319.2770. 
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Compound 109 - N-(3,5-bis(heptyloxy)benzyl)butan-1-amine 
 
H
N
OO  
C25H45NO2 
MW: 391.6303 
1H-NMR (400 MHz, CDCl3): 6.45 (2H, d, J= 2.02 Hz, ArH), 6.34 (1H, t, J=4.43 Hz, ArH), 3.92 (4H, t, 
OCH2x2), 3.71 (2H, s, CH2Ar), 2.62 (2H, t, NCH2), 1.75 (4H, m, CH2x2), 1.5-1.3 (20H, m, CH2x10), 0.91 
(9H, m, CH3x3). 
13C-NMR (100 MHz, CDCl3) δ: 160.4, 142.9, 106.4, 99.9, 68.0, 54.2, 49.2, 32.3, 31.8, 29.3, 29.1, 26.0, 
22.6, 20.5, 14.1, 14.0. 
HRMS (ESI): calcd. (M+H)+ 392.3450, exper. 392.3650. 
222 
 
223 
 
PATHWAY 3: 
 
OHO
OH
O
1. SOCl2
2.
O
O
HN
N
N
 
 
110 
224 
 
225 
 
Synthesis of compound 112 (2-benzyl-1,3-dimorpholinopropane-1,3-dione) 
 
OHO
OH
O
1. SOCl2
2.
O
O
N
N
N
H
O O
O
TEA, toluene
 
In a round bottom flask benzylmalonic acid (110, 100 mg, 0.52 mmol) is placed together with thyonil 
chloride (3 mL); the mixture is heated at 60°C and monitored by TLC (hexane/ethyl acetate 4:1). After 1 
h, the reaction is cooled and the solvent evaporated; the obtained chloride is used for the following step 
without further purifications. 
Morpholine (111, 90 mg, 0.089 mL, 1.04 mmol) is dissolved in anhydrous toluene (10 mL), and the 
freshly prepared chloride (dissolved in toluene, 5 mL) is subsequently added. After 1 h of stirring at rt, 
triethylamine (105 mg, 0.144 mL, 1.04 mmol) is added and the mixture is heated o/n at 60°C. The 
reaction is monitored by TLC (hexane/ethyl acetate 4:1) and, once completed, is cooled to rt and added 
with DCM (20 mL). The mixture is washed with water (20 mL, 3 times), dried with magnesium sulfate 
and the solvent evaporated under reduced pressure. 
 
Yield: 53%. 
The same reaction was repeated on benzylmalonic acid using piperidine instead of morpholine; in this 
case, the yield was 28%. 
110 
111 
112 
226 
 
Compound 112 - 2-benzyl-1,3-dimorpholinopropane-1,3-dione 
O
N
O
O
N
O  
C18H24N2O4 
MW: 332.3942 
1H-NMR (400 MHz, acetone-d6) δ: 7.3-7.2 (5H, m, ArH), 4.27 (1H, t, CHCH2), 3.6-3.2 (16H, m, 
CH2x8), 3.16 (2H, d, CH2CH). 
13C-NMR (100 MHz, acetone-d6) δ: 167.8, 139.5, 129.4, 128.3, 126.5, 66.1, 47.8, 45.7, 35.8. 
HRMS (ESI): calcd. (M+H)+ 333.3924, exper. 333.2037. 
227 
 
Compound 113 - 2-benzyl-1,3-di(piperidin-1-yl)propane-1,3-dione 
O
N
O
N
 
C20H28N2O2 
MW: 328.4485 
1H-NMR (400 MHz, acetone-d6) δ: 7.3-7.2 (5H, m, ArH), 3.95 (1H, t, CHCH2), 3.7-3.6 (2H, m, CH2), 
3.5-3.3 (4H, m, CH2x2), 3.26 (2H, d, CH2CH), 3.2-3.1 (2H, m, CH2), 1.7-1.3 (12H, m, CH2x6). 
13C-NMR (100 MHz, acetone-d6) δ: 167.2, 137.3, 129.1, 125.3, 123.5, 66.3, 48.8, 45.0, 42.2, 33.9. 
HRMS (ESI): calcd. (M+H)+ 329.2151, exper. 329.2274. 
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PATHWAY 4.1: 
 
O
O
O
HO
O
OH
RH2N
HO
O
NH2
R
 
 
O
O
O
HO O
R
H2N
HO
O
NH2
R
O O
O O
OH
 
114 
69 
230 
 
231 
 
Synthesis of compound 116 (2-amino-3-hydroxy-3-(4-methoxyphenyl)propanoic acid) 
 
O
O
O
HO
HO
O
NH2
H2N
OH
ONaOH
H2O/MeOH
 
 
In a round bottom flask containing water and methanol (1.5 and 2.5 mL respectively), were placed 
glycine (115, 50 mg, 0.67 mmol) and sodium hydroxide (80 mg, 2 mmol); then, p-anisaldehyde was 
added (114, 182 mg, 0.163 mL, 1.34 mmol) and the reaction was allowed to stir o/n at rt. The solution 
was then acidified with concd. hydrochloric acid, and allowed to stir 60 more minutes. The solvent was 
evaporated with the help of subsequent additions of ethanol, then the residue was added with an aqueous 
solution of sodium hydroxide, 10%. The reaction was stirred for 2 more h, until it cooled. The suspension 
was then filtered through a Buchner funnel and the solid white residue dried in a heater for 24 h. 
Yield: 63%. 
The same reaction has been repeated on p-anisaldehyde also with serine and threonine, and on 2,4,6-
trimethoxybenzaldehyde with glycine. All the yields were between 49 and 65%. 
 
114 
115 
116 
232 
 
Compound 116 – 2-amino-3-hydroxy-3-(4-methoxyphenyl)propanoic acid 
 
O
HO
H2N
OH
O
 
C10H13NO4 
MW: 211.2145 
1H-NMR (300MHz, DMSO-d6) δ: 8.10 (1H, s, OH), 7.67 (2H, AA’), 6.97 (2H, XX’), 3.95 (2H, “d”, 
NH2), 3.87 (1H, s, OH), 3.79 (3H, s, OCH3), 3.77 (1H, d, CH), 3.66 (1H, d, CH). 
13C-NMR (100MHz, DMSO-d6) d: 161.3, 160.9, 130.1, 115.3, 114.4, 66.8, 55.6. 
HRMS (ESI): calcd. (M+H)+ 212.0845, exper. 212.0763. 
 
 
233 
 
Compound 117 - 2-amino-3-hydroxy-2-(hydroxymethyl)-3-(4-methoxyphenyl)propanoic acid 
 
O
HO
H2N
OH
O
OH
 
C11H15NO5 
MW: 241.2405 
1H-NMR (300MHz, DMSO-d6) δ: 8.10 (1H, s, OH), 7.67 (2H, AA’), 6.98 (2H, XX’), 5.79 (bs, OH), 3.80 
(3H, s, CH3), 3.73 (1H, “t”, CHH), 3.60 (1H, “t”, CHH), 3.49 (1H, “s”, CH). 
13C-NMR (100MHz, DMSO-d6) d:206.9, 174.9, 161.3, 129.8, 114.3, 75.8, 64.8, 55.8, 31.2. 
HRMS (ESI): calcd. (M+H)+ 242.0950, exper. 242.1135. 
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Compound 118 - 2-(4-hydroxybenzyl)-2-amino-3-hydroxy-3-(4-methoxyphenyl)propanoic acid 
 
O
HO
H2N
OH
O
OH
 
C17H19NO5 
MW: 317.3365 
1H-NMR (300MHz, DMSO-d6) δ: 7.83 (1H, s, OH), 7.60 (2H, AA’), 6.94 (2H, XX’), 6.69 (2H, AA’), 
6.28 (2H, XX’), 3.78 (3H, s, OCH3), 3.66 (1H, dd, CH, J=4.5 Hz, J=4.5 Hz), 3.01 (dd, 1H, CHH, J=13.0 
Hz, J=4.5 Hz), 2.69 (dd, 1H, CHH, J=13.0 Hz, J=4.5 Hz). 
13C-NMR (100MHz, DMSO-d6) d: 174.9, 160.7, 158.4, 155.1, 130.1, 129.3, 114.6, 113.8, 79.2, 56.0, 
55.2, 18.5. 
HRMS (ESI): calcd. (M+H)+ 318.1263, exper. 318.1158. 
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Compound 119 - 2-amino-3-hydroxy-3-(2,4,6-trimethoxyphenyl)propanoic acid 
 
O
HO O
H2N
O O
OH
 
C12H17NO6 
MW: 271.2665 
1H-NMR (300MHz, DMSO-d6) δ: 8.41 (1H, s, OH), 6.30 (2H, s, ArH), 3.91 (1H, d, CH), 3.83 (9H, s, 
CH3x3), 3.18 (1H, d, CH). 
13C-NMR (100MHz, CDCl3) d: 175.2, 165.6, 108.6, 99.6, 73.6, 61.5, 55.9. 
HRMS (ESI): calcd. (M+H)+ 272.1056, exper. 272.3012. 
236 
 
PATHWAY 4.2: 
 
OH
O
(  )n
Br
O (  )n
O
O (  )n
HO OH
O
HO
O
NH2
NH2
 
 
The synthesis of these compounds is accordant to the procedures already described. The procedure 
explained for compound 77 (Williamson reaction) was performed to obtain compounds 80, 81 and 82, the 
characterization of which have already been reported in this thesis. The procedure described for 
compound 116 (Knoevenagel reaction modified by Portelli) was applied to obtain compounds 120, 121 
and 122. 
Yields: between 50 and 55%. 
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Compound 120 - 2-amino-3-(4-(hexyloxy)phenyl)-3-hydroxypropanoic acid 
 
HO
NH2
O
OH
O  
C15H23NO4 
MW: 281.3474 
1H-NMR (400MHz, D2O) δ: 7.81 (2H, AA’), 6.98 (2H, XX’), 4.10 (2H, t, OCH2), 3.57 (1H, d, CH), 2.19 
(1H, d, CH), 1.74 (2H, m, CH2), 1.41 (2H, m, CH2), 1.3-1.2 (m, 4H, CH2x2), 0.83 (3H, t, CH3). 
13C-NMR (100MHz, D2O) d: 158.5, 131.0, 130.6, 55.6, 31.2, 29.3, 29.0, 26.0, 22.6, 14.1. 
HRMS (ESI): calcd. (M+H)+ 282.1627, exper. 282.2008. 
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Compound 121 - 2-amino-3-(4-(heptyloxy)phenyl)-3-hydroxypropanoic acid 
 
HO
NH2
O
OH
O  
C16H25NO4 
MW: 295.3740 
1H-NMR (400MHz, D2O) δ: 7.79 (2H, AA’), 6.97 (2H, XX’), 4.08 (2H, t, OCH2), 3.87 (1H, d, CH), 3.62 
(1H, d, CH), 1.74 (2H, m, CH2), 1.4-0.9 (6H, m, CH2x3), 0.81 (5H, m, CH2CH3). 
13C-NMR (100MHz, D2O) d: 158.7, 130.8, 130.4, 55.6, 35.5, 31.2, 29.3, 29.0, 26.8, 24.6, 18.1. 
HRMS (ESI): calcd. (M+H)+ 296.3740, exper. 296.3539. 
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Compound 122 - 2-amino-3-hydroxy-3-(4-(octyloxy)phenyl)propanoic acid 
 
HO
NH2
O
OH
O  
C17H27NO4 
MW: 309.4006 
1H-NMR (400MHz, D2O+NaOH) δ: 7.77 (2H, AA’), 6.95 (2H, XX’), 4.06 (2H, t, OCH2), 3.52 (1H, d, 
CH), 3.08 (1H, d, CH), 2.11 (2H, m, CH2), 1.70 (2H, m, CH2), 1.4-1.2 (8H, m, CH2x4), 1.09 (3H, t, CH3). 
13C-NMR (100MHz, D2O) d: 155.4, 127.9, 120.4, 48.3, 35.5, 31.2, 29.3, 29.0, 26.8, 24.6, 18.1, 14.1. 
HRMS (ESI): calcd. (M+H)+ 310.1940, exper. 310.1926. 
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PATHWAY 5: 
 
 
OH
OH POCl3
O
P
O
Cl
O
N
H
O
N
O
O
P
O
O
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Synthesis of compound 125 (2-chloro-5,5-dimethyl-1,3,2-dioxaphosphinane 2-oxide) 
 
OH
OH
P
ClCl
Cl
O
TEA
Et2O
O
P
O
Cl
O  
 
Phosphorus (V) oxychloride (124, 1650 mg, 1.000 mL, 11 mmol) was dissolved in cold diethylether (5 
mL), and added dropwise to a stirring solution of 2,2-dimethyl-1,3-propandiol (123, 1150 mg, 11 mmol) 
in diethylether (5 mL) and triethylamine (2226 mg, 3.050 mL, 22 mmol) at 0°C under nitrogen 
atmosphere. The solution was stirred for 1 h, then filtered; the solid was discarded, and the filtrate was 
evaporated under reduced pressure to obtain the product as a white solid. 
Yield: 86%. 
 
123 124 125 
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Compound 125 - 2-chloro-5,5-dimethyl-1,3,2-dioxaphosphinane 2-oxide 
 
O
P
O
Cl
O  
C5H10ClO3P 
MW: 184.5579 
1H-NMR (400MHz, CDCl3) δ: 4.22 (2H, d, J=11.1, OCH2,), 3.98 (2H, dd, J=11.1, OCH2), 1.28 (3H, s, 
CH3), 0.89 (3H, s, CH3). 
HRMS (ESI): calcd. (M+H)+ 185.0056, exper. 185.0131 (C5H1135ClO3P); calcd. (M+H)+ 187.0027, exper. 
187.0098 (C5H1137ClO3P). 
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Synthesis of compound 126 (2-((4-ethoxybenzyl)(propyl)amino)-5,5-dimethyl-1,3,2-
dioxaphosphinane 2-oxide) 
 
O
P
O
Cl
O
NH
O
CaCO3
toluene
N
O
P
O
O
O
 
 
In a round bottom flask all the reactants were placed: compound 125 (300 mg, 1.62 mmol), compound 86 
(145 mg, 0.81 mmol), calcium carbonate (162 mg, 1.62 mmol) in toluene (20 mL). The mixture was 
allowed to stir at 110°C o/n; the completion of the reaction was verified through TLC (hexane/ethyl 
acetate 4:1). 
The mixture was allowed to cool to rt, then it was filtered and the precipitate was washed with toluene. 
The filtrate was evaporated to remove the solvent, and the residue was dissolved with DCM and washed 
with sodium hydroxyde 10% (20 mL, 3 times) in a separation funnel. The organic phase was dried with 
magnesium sulfate and evaporated to give the product as a colorless oil. 
Yield: 78%.  
 
86 
125 126 
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Compound 126 – 2-((4-ethoxybenzyl)(propyl)amino)-5,5-dimethyl-1,3,2-dioxaphosphinane 2-oxide 
N
O
P
O
O
O
 
C17H28NO4P 
MW: 341.3823 
1H-NMR (400MHz, CDCl3) δ: 7.24 (2H, AA'), 6.86 (2H, XX'), 4.49 (2H, d, CH2), 4.00 (4H, m, CH2x2), 
3.74 (2H, s, CH2Ar), 2.60 (2H, t, NCH2), 1.54 (2H, m, CH2), 1.41 (3H, t, CH3), 1.33 (3H, s, CH3), 0.92 
(3H, t, CH3), 0.91 (3H, s, CH3). 
13C-NMR (100MHz, CDCl3) d: 158.3, 158.0, 129.4, 129.3, 114.4, 79.1, 63.4, 32.2, 21.9, 19.9, 14.9, 11.8. 
HRMS (ESI): calcd. (M+H)+ 342.1756, exper. 342.1854. 
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3.5 VECTOR CONSTRUCTION AND AMPLIFICATION 
 
The design of constructs was performed inserting the template sequences for SET and PP2AC in the 
Opiner tool from OPPF-UK website98. 
The following constructs were designed: 
Construct A5 - pOPIN-F-PP2AC (His6-3C-PP2AC,1-245) 
Construct B5 - pOPIN-J-PP2AC (His6-GST-3C-PP2AC,1-245) 
Construct C5 - pOPIN-M-PP2AC (His6-MBP-3C-PP2A C,1-245) 
Construct D5 - pOPIN-S3C-PP2AC (His6-SUMO-3C -PP2A C,1-245) 
Construct E5 - pOPIN-E-PP2AC (PP2AC,1-245-His6) 
Construct F5 - pOPIN-eGFP-PP2A C (PP2A C,1-245-3C-eGFP-His6) 
Construct A6 - pOPIN-F-SET (His6-3C-His6-Thrombin-SET1-225) 
Construct B6 - pOPIN-J-SET (His6-GST-3C-His6-Thrombin-SET1-225) 
Construct C6 - pOPIN-M-SET (His6-MBP-3C-His6-Thrombin-SET1-225) 
Construct D6 - pOPIN-S3C-SET (His6-SUMO-3C-His6-Thrombin-SET1-225) 
Construct E6 - pOPIN-E-SET (SET1-225-His6) 
Construct F6 - pOPIN-eGFP-SET (SET1-225-eGFP-3C-His6). 
 
On the basis of the design above, the following oligonucleotides were purchased from Sigma-Aldrich and 
dissolved to 10 µM: 
PP2A_1Fw  aagttctgtttcagggcccgATGGATGAAAAAGTCTTTACCAAAGAA 
PP2A_309Rv  atggtctagaaagctttaTTTTTCGAACTGCGGATGCGACC 
PP2A_1FwE  aggagatataccatgATGGATGAAAAAGTCTTTACCAAAGAA 
PP2A_309RvE  gtgatggtgatgtttTTTTTCGAACTGCGGATGCGACC 
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PP2A_309RvEGFP cagaacttccagtttTTTTTCGAACTGCGGATGCGACC 
SET_1Fw  aagttctgtttcagggcccgATGGGCAGCAGCCATCATCATCA 
SET_245Rv  atggtctagaaagctttaCATATCGGGAACCAAGTAGTACTG 
SET_24Fw  aggagatataccatgCAGGCGGCCAAAGTCAGTAAAAAG 
SET_245RvE  gtgatggtgatgtttCATATCGGGAACCAAGTAGTACTG 
SET_245RvEGFP cagaacttccagtttCATATCGGGAACCAAGTAGTACTG 
 
3.5.1 PCR cloning and purification 
A PCR was run to amplify the sequences of interest. This step was meant to provide DNA fragments, 
bearing ends that could be compatible with pOPIN series vectors, which could codify for SET and 
PP2AC. Each reaction was set up as follows:  
- Phusion flash master mix (Thermoscientific F-548L) 2x, 25 µL 
- Sterile water, 17 µL 
- Appropriate forward primer 10 µM, 3 µL 
- Appropriate reverse primer 10 µM, 3 µL 
- Template plasmid 10 µM, 2 µL. 
 
With the following thermal cycles: 
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The products of the PCR reactions were checked by a verification agarose gel (1.6% agarose TAE, 100V, 
30 min). 
To each reaction, 5 µL of DpnI 1x in NE Buffer were added and the plate was incubated at 37°C for 30 
min to digest the template cDNA.  
After that, the PCR products were purified by adding 90 µL of AMPure XP magnetic beads; the plate was 
then incubated for 5 min at rt, then placed onto a SPRIPlate 96R magnet for 5 min to separate the beads 
from the solution; the cleared solutions were aspired and discarded. After that, 200 µL of EtOH 70% were 
added to wash the beads, incubated for 30 sec and discarded; this passage was repeated twice. The plate, 
left to air-dry at rt for 10 min, was subsequently removed from the magnet and 30 µL of buffer (EB 10 
mM Tris pH 8.0) were added to elute the PCR products. The beads were removed by placing the plate 
again on the magnet and the sample contained in each well was collected in a clean PCR plate. 
Also in this case, in order to control the efficiency of the purification, a verification gel was run (1.6% 
agarose-TAE, 100V, 30 min). 
 
3.5.2 In-FusionTM, HTP transformation into cloning-grade E.coli and HTP mini-preps 
The obtained inserts and the pOPIN vectors (linearized with KpnI and HindIII and concentrated to 100 
ng/µL) were mixed in molar ratio 2:1 and supplemented with water to a final volume of 10 µL. These 
solutions were transferred to a dry-down In-FusionTM plate and incubated for 30 min at 42°C. The 
products were then added with 40 µL of TE buffer and 5 µL of this diluted reaction were used 
immediately to transform 50 µL OneShot OmniMaxII cells (cloning efficiency >109 cfu/µg plasmid). 
The cells were incubated in ice for 30 min, heat shocked for 30 sec at 42°C and placed back in ice for 2 
min. PB (300 µL) was then added and the cells were incubated for 1 h at 37°C. 
The transformed cells were then plated on LB agar plates added with carbenicillin 50 mg/mL (1:1000), 
20% X-Gal (1:1000), IPTG 1 M (1:1000); more specifically, each experiment was repeated twice, plating 
in one case 5 µL of cells added with 20 µL of PB, and in the other 25 µL of cells. The plates were 
incubated o/n at 37°C. 
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The day after, two colonies per well were picked and transferred into deep-well blocks containing 1.2 mL 
of PB supplemented with carbenicillin 50 mg/mL (1:1000) and chloramphenicol 35 mg/mL (1:1000). The 
plates were sealed and grown o/n at 37°C with vigorous agitation (600 rpm). 
The subsequent day, an aliquot of each o/n culture was added with the same amount of filter sterilized 
LB/30%v/v glycerol and kept at -80°C as a stock. 
The remaining samples were centrifuged at 6000 x g for 10 min and the medium was discarded. On the 
collected cells, an HTP mini plasmid preparation was performed by a Bio-Robot 8000 (Qiagen) on 
Wizard SV96 purification plates, following the instructions of the manufacturer. The presence of the 
insert in the purified vectors was verified through a PCR screening, using 0.15 µL of pOPIN forward 
primer 100 µM for each construct, added with 1.5 µL of the proper reverse primer 10 µM. Since the 
pOPIN forward primer is present in most of the pOPIN vectors, it can be used for all the constructs; its 
addition, together with the appropriate reverse primer, could reveal if the nucleic acids had been 
integrated and purified correctly. An agarose gel was run to verify the nature of the PCR products (1.6% 
agarose-TAE, 100V, 30 min). 
 
 
3.6 PROTEIN EXPRESSION 
 
3.6.1 E.coli expression strain transformation, protein expression and HTP purification 
The purified plasmids (3 µL each) were used to transform 50 µL aliquots of expression E.coli (Lemo21 
and Rosetta2); after the addition of the plasmids to the cells, they were incubated in an ice bath for 30 
min. The cells were then heat shocked for 30 sec at 42°C, then returned back to ice for 2 min. 300 µL of 
PB per each aliquot were added and the cells were incubated for 1 h at 37°C. After that, 30 µL of cells 
were plated on LB agar added with carbenicillin 50 mg/mL (1:1000) and chloramphenicol 35 mg/mL 
(1:1000), and incubated o/n at 37°C. 
The day after, one colony for each o/n culture was picked and transferred to a deep-well block containing 
0.7 mL of PB added with carbenicillin 50 mg/mL (1:1000) and chloramphenicol 35 mg/mL (1:1000), and 
incubated o/n at 37°C, 600 rpm.  
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The following day, 100 μL of each culture were added with the same amount of filter-sterilised 
LB/30%v/v glycerol and collected in a plate stored at -80°C as a glycerol stock. Another aliquot of each 
colony (150 µL for Lemo21, 250 µL for Rosetta2) was scaled up both in PB and in AI; in both the cases, 
the samples were added with carbenicillin 50 mg/mL (1:1000) and chloramphenicol 35 mg/mL (1:1000), 
and incubated at 37°C, 600 rpm until they reached an OD of 0.5 (approximately 5 h). Cells growing in AI 
medium were simply switched to 25°C, while the ones which grew in PB were turned at 20°C and added 
with IPTG 0.5 M (1:500); these conditions were maintained for the whole night after. 
An aliquot of 1 mL of each well was transferred in a 96 well deep-well block; this step was made twice. 
The cells were centrifuged at 6000 x g for 10 min, the media discarded and the plates stored at -80°C. The 
cells were then resuspended in 210 µL of NPI-10 supplemented with 1 mg/mL lysozyme and 400 
units/mL of DNAse I, and then the high throughput purification was performed thanks to the QIAGEN 
Bio Robot 8000 equipped with Ni2+-NTA beads, following the instructions of the constructor regarding 
soluble proteins. The buffers used in this case were NPI-10 (lysis buffer), NPI-20 (wash buffer) and NPI-
250 (elution buffer). For verifying the expression and the purification of each protein, 10% SDS-PAGE 
gels were performed in MES 1x buffer.  
 
3.6.2 Culture scale up 
Basing on the results of the SDS-PAGE gels, some of the cultures were scaled up. In particular, 1 µL of 
the expression plasmid was added to an aliquot of the chosen cells; here pOPIN-M and pOPIN-S3C t 
vectors containing SET gene were used (i.e. C6 and D6). The aliquots were kept in an ice bath for 30 min, 
heat-shocked at 42°C for 30 sec and placed back in ice for 2 min. 450 µL of PB were added in each tube 
and the cells were incubated for 1 h at 37°C. After that, 50 µL of culture from the bottom of the tubes 
were plated in 5 mL of medium, made up by LB agar added with carbenicillin 50 mg/mL (1:1000) and 
chloramphenicol 35 mg/mL (1:1000); the plates were incubated at 37°C o/n. 
The day after, a single colony was inoculated in 100 mL of PB, added with glucose 0.1% and with 
carbenicillin 50 mg/mL (1:1000) and chloramphenicol 35 mg/mL (1:1000); this step was made in 
duplicates. The incubation was carried on at 37°C, 225 rpm, o/n. 
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The following day, 10 mL of the o/n cultures (coming from just one of the two duplicates) were 
inoculated in 1 L of medium, either PB or AI (both added with chloramphenicol and carbenicillin, in the 
quantities which have already been described), as follows: 
- PB: the flasks were incubated at 240 rpm, 37°C until the OD reached a value around 0.5 
(approximately 5 h); then, IPTG 0.5 M (1:500) was added to promote the induction of the 
proteins and the temperature switched to 20°C for the o/n expression; 
- AI: 5052 (50x), NPS (20x), MgSO4 2 M (1000x) were added at the very beginning and the flasks 
were incubated in the same way as the PB ones (240 rpm, 37°C) until the OD reached a value 
around 0.5 (approximately 5 h), then then the temperature was decreased to 25°C o/n. 
Cells were harvested after approximately 18 h by centrifugation at 5000 rpm for 15 min; the supernatant 
was discarded, the pellet was transferred in 50 mL falcon tubes using a spatula and the tubes were stored 
at -80°C until the purification. On the average, 1 L of culture yielded 15 g of cells.  
 
3.7 PROTEIN PURIFICATION 
 
3.7.1 Cell lysis and Affinity chromatography 
The collected cells were suspended in a proper amount of NPI-10 buffer (typically 15 g of cells in 50 mL 
of buffer), and added with an aliquot of DNAse I, MgCl2 1M (5 µL for one aliquot of DNAse), one 
aliquot of cOmplete EDTA free protease inhibitor cocktail and lysozyme 100 mg/mL (1000x); the sample 
was then put in an ice bath for 10 min. The cells were then added with PMSF 1M in DMSO (1000x) and 
disrupted at 4°C, 30 KPSI. The collected sample was ultracentrifuged (vacuum, 200000 x g, 4°C, 1 h). 
The obtained supernatant was filtered under vacuum and loaded on an affinity column (HisTrap FF, GE 
Healthcare) for the first purification step, collecting the flowthrough in a bottle. For the elution, NPI-10 
and NPI-250 were used as solvents. Being more specific, the purification was run as follows: 
- 10 CV NPI-250 0% 
- 5 CV NPI-250 10% 
- 10 CV NPI-250 100%. 
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The elute was collected in 1 mL fractions; 40-µL aliquots of the fractions themselves were analyzed by a 
4-12% SDS-PAGE. 
 
3.7.2 Proteolytic cleavage and Dialysis 
The fractions obtained from the affinity chromatography, once united, were added with His-tagged 3C 
protease (~50 µL per estimated mg of protein) and dialyzed against dialysis buffer (stir o/n 4°C) through 
a dialysis tubing cellulose membrane, in order to both eliminate the imidazole and cleave the tag. The day 
after, the sample was collected in a bottle and a gel was run in order to verify if the cleavage was 
performed efficiently. Then, the sample was concentrated to 4-5 mL with MW concentration tubes (cut-
off: 10 kDa), centrifuging at 4000 x g in 10-min slots. Between one slot and the other, the sample was 
carefully resuspended. 
 
 
3.7.3 Gel filtration 
The concentrated sample was injected, through a 5 mL loop, on the gel filtration column previously 
equilibrated with 10 CV of SET gel filtration buffer. 1 mL fractions were collected in a deep well 96-well 
plate with a flow of 0.3 mL/min, and 40-µL aliquots were analyzed by 4-12% SDS-PAGE to identify the 
presence of the cleaved protein.  
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3.8 IN SILICO STUDIES 
 
3.8.1 Molecular modeling 
Compound 71 was evaluated in silico for the comparison of the predicted conformation with the 
quantitative analysis of NOESY spectrum. For the modeling part, the compound was drawn in 
Avogadro81 and minimized with a MMFF94 force field. The PDB outcome was then analized through 
UCSF Chimera80 for calculating the distances between proton groups. 
 
3.8.2 Docking 
Some of the obtained compounds (71 and 100, or MP07-66) were written as PDB files using 
ChemDraw96 and Avogadro81, and then imported on AutoDockTools 1.5.6 furnished with AutoGrid 4 and 
AutoDock 4.2.683 for docking them with SET. The POI (PDB ID: 2E50) was modified through UCSF 
Chimera80 in order to eliminate water, ions and other eventual co-crystallized ligands, and to obtain both 
its dimeric and monomeric form; protons and partial charges were added. The docking grid was placed on 
the whole macromolecule, since the docking site is not known yet. 10 genetic algorithm runs were 
performed with a population size of 15000. AutoDock gave 10 output files for each docking, and the one 
at lower energy was considered for each compound and evaluated through UCSF Chimera. 
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